MU-CONOPEPTIDES

Abstract: The present invention is to μ-conopeptides, derivatives or pharmaceutically acceptable salts thereof. The present invention is further directed to the use of this peptide, derivatives thereof and pharmaceutically acceptable salts thereof for the treatment of disorders associated with voltage-gated sodium channels. Thus, the μ-conopeptides or derivatives are useful as neuromuscular blocking agents, local anesthetic agents, analgesic agents and neuroprotective agents. The μ-conopeptides are also useful for treating neuromuscular disorders. The invention is further directed to nucleic acid sequences encoding the mu -conopeptides and encoding propeptides, as well as the propeptides.

Description: TITLE OF THE INVENTION MU-CONOPEPTIDES CROSS-REFERENCE TO RELATED APPLICATIONS [0001] The present application claims benefit under 35 USC §119(e) to U.S. provisional patent applications Serial No. 60/219,619 filed on 21 July 2000, Serial No. 60/245,157 filed on 3 November 2000, Serial No. 60/264,319 filed on 29 January 2001 and Serial No. 60/277,270 filed on 21 March 2001. Each of these applications is incorporated herein by reference. [0002] This invention was made with Government support under Grant No. PO1 GM48677 awarded by the National Institute of General Medical Sciences, National Institutes of Health, Bethesda, Maryland. The United States Government has certain rights in the invention. BACKGROUND OF THE INVENTION [0003] The present invention is to μ-conopeptides, derivatives or pharmaceutically acceptable salts thereof. The present invention is further directed to the use of this peptide, derivatives thereof and pharmaceutically acceptable salts thereof for the treatment of disorders associated with voltage-gated sodium channels. Thus, the μ-conopeptides or derivatives are useful as neuromuscular blocking agents, local anesthetic agents, analgesic agents and neuroprotective agents. The μ-conopeptides are also useful for treating neuromuscular disorders. The in ention is further directed to nucleic acid sequences encoding the μ- conopeptides and encoding propeptides, as well as the propeptides. [0004] The publications and other materials used herein to illuminate the background of the invention, and in particular, cases to provide additional details respecting the practice, are incorporated by reference, and for convenience are referenced in the following text by author and date and are listed alphabetically by author in the appended bibliography. [0005] Conus is a genus of predatory marine gastropods (snails) which envenomate their prey. Venomous cone snails use a highly developed projectile apparatus to deliver their cocktail of toxic conotoxins into their prey, hi fish-eating species such as Conus magus the cone detects the presence of the fish using chemosensors in its siphon and when close enough extends its proboscis and fires a hollow harpoon-like tooth containing venom into the fish. This immobilizes the fish and enables the cone snail to wind it into its mouth via an attached filament . . For general information on Conus and their venom see the website address http://grimwade.biochem.unimelb.edu.au/cone/referenc.html. Prey capture is accomplished through a sophisticated arsenal of peptides which target specific ion channel and receptor subtypes. Each Conus species venom appears to contain a unique set of 50-200 peptides. The composition of the venom differs greatly between species and between individual snails within each species, each optimally evolved to paralyse it's prey. The active components of the venom are small peptides toxins, typically 10-40 amino acid residues in length and are typically highly constrained peptides due to their high density of disulphide bonds. [0006] The venoms consist of a large number of different peptide components that when separated exhibit a range of biological activities: when injected into mice they elicit a range of physiological responses from shaking to depression. The paralytic components of the venom that have been the focus of recent investigation are the α-, ω- and μ-conotoxins. All of these conotoxins act by preventing neuronal communication, but each targets a different aspect ofthe process to achieve this. The α-conotoxins target nicotinic ligand gated channels, the μ- conotoxins target the voltage-gated sodium channels and the ω -conotoxins target the voltage- gated calcium channels (Olivera et al., 1985; Olivera et al., 1990). For example a linkage has been established between α-, αA- & φ-conotoxins and the nicotinic ligand-gated ion channel; ω- conotoxins and the voltage-gated calcium channel; μ-conotoxins and the voltage-gated sodium channel; δ-conotoxins and the voltage-gated sodium channel; K-conotoxins and the voltage- gated potassium channel; conantokins and the ligand-gated glutamate (NMD A) channel. [0007] However, the structure and function of only a small minority of these peptides have been determined to date. For peptides where function has been determined, three classes of targets have been elucidated: voltage-gated ion channels; ligand-gated ion channels, and G- protein-linked receptors. [0008] Conus peptides which target voltage-gated ion channels include those that delay the inactivation of sodium channels, as well as blockers specific for sodium channels, calcium channels and potassium channels. Peptides that target ligand-gated ion channels include antagonists of NMDA and serotonin receptors, as well as competitive and noncompetitive nicotinic receptor antagonists. Peptides which act on G-protein receptors include neurotensin and vasopressin receptor agonists. The unprecedented pharmaceutical selectivity of conotoxins is at least in part defined by a specific disulfide bond f ameworks combined with hypervariable amino acids within disulfide loops (for a review see Mchitosh et al., 1998). [0009] There are drugs used in the treatment of pain, which are known in the literature and to the skilled artisan. See, for example, Merck Manual, 16th Ed. (1992). However, there is a demand for more active analgesic agents with diminished side effects and toxicity and which are non-addictive. The ideal analgesic would reduce the awareness of pain, produce analgesia over a wide range of pain types, act satisfactorily whether given orally or parenterally, produce minimal or no side effects, be free from tendency to produce tolerance and drug dependence. [0010] Due to the high potency and exquisite selectivity ofthe conopeptides, several are in various stages of clinical development for treatment of human disorders. For example, two Conus peptides are being developed for the treatment of pain. The most advanced is ω-conotoxin MNIIA (ziconotide), an Ν-type calcium channel blocker (see Heading, C, 1999; U.S. Patent No. 5,859,186). ω-Conotoxin MVIIA, isolated from Conus magus, is approximately 1000 times more potent than morphine, yet does not produce the tolerance or addictive properties of opiates. ω-Conotoxin MVIIA has completed Phase III (final stages) of human clinical trials and has been approved as a therapeutic agent. ω-Conotoxin MVIIA is introduced into human patients by means of an implantable, programmable pump with a catheter threaded into the intrathecal space. Preclinical testing for use in post-surgical pain is being carried out on another Conus peptide, contulakin-G, isolated from Conus geographus (Craig et al. 1999). Contulakin-G is a 16 amino acid O-linked glycopeptide whose C-terminus resembles neurotensin. It is an agonist of neurotensin receptors, but appears significantly more potent than neurotensin in inhibiting pain in in vivo assays. [0011] In view of a large number of biologically active substances in Conus species it is desirable to further characterize them and to identify peptides capable of treating disorders involving voltage gated ion channels, such as stroke and pain. Surprisingly, and in accordance with this invention, Applicants have discovered novel conotoxins that can be useful for the treatment of disorders involving voltage gated ion channels and could address a long felt need for a safe and effective treatment. SUMMARY OF THE INVENTION [0012] The present invention is to μ-conopeptides, derivatives or pharmaceutically acceptable salts thereof. The present invention is further directed to the use of this peptide, derivatives thereof and pharmaceutically acceptable salts thereof for the treatment of disorders associated with voltage-gated sodium channels. Thus, the μ-conopeptides or derivatives are useful as neuromuscular blocking agents, local anesthetic agents, analgesic agents and neuroprotective agents. The μ-conopeptides are also useful for treating neuromuscular disorders. The invention is further directed to nucleic acid sequences encoding the μ- conopeptides and encoding propeptides, as well as the propeptides. [0013] More specifically, the present invention is directed to μ-conopeptides, having the amino acid sequences set forth in Tables 1 and 2 below. [0014] The present invention is also directed to derivatives or pharmaceutically acceptable salts of the μ-conopeptides or the derivatives. Examples of derivatives include peptides in which the Arg residues may be substituted by Lys, ornithine, homoargine, nor-Lys, N-methyl-Lys, N,N-dimethyl-Lys, N,N,N-trimethyl-Lys or any synthetic basic amino acid; the Lys residues may be substituted by Arg, ornithine, homoargine, nor-Lys, or any synthetic basic amino acid; the Tyr residues may be substituted with meta-Tyr, ortho-Tyr, nor-Tyr, mono-halo- Tyr, di-halo-Tyr, O-sulpho-Tyr, O-phospho-Tyr, nirro-Tyr or any synthetic hydroxy containing amino acid; the Ser residues may be substituted with Thr or any synthetic hydroxylated amino acid; the Thr residues may be substituted with Ser or any synthetic hydroxylated amino acid; the Phe residues may be substituted with any synthetic aromatic amino acid; the Trp residues may be substituted with Trp (D), neo-Trp, halo-Trp (D or L) or any aromatic synthetic amino acid; and the Asn, Ser, Thr or Hyp residues may be glycosylated. The halogen may be iodo, chloro, fluoro or bromo; preferably iodo for halogen substituted-Tyr and bromo for halogen-substituted Trp. The Tyr residues may also be substituted with the 3-hydroxyl or 2-hydroxyl isomers (meta- Tyr or ortho-Tyr, respectively) and corresponding O-sulpho- and O-phospho-derivatives. The acidic amino acid residues may be substituted with any synthetic acidic amino acid, e.g., tetrazolyl derivatives of Gly and Ala. The aliphatic amino acids may be substituted by synthetic derivatives bearing non-natural aliphatic branched or linear side chains C n H 2n+2 up to and including n=8. The Met residues may be substituted by norleucine (Nle). The Cys residues may be in D or L configuration and may optionally be substituted with homocysteine (D or L). [0015] Examples of synthetic aromatic amino acid include, but are not limited to, nitro- Phe, 4-substituted-Phe wherein the substituent is C r C 3 alkyl, carboxyl, hyrdroxymethyl, sulphomethyl, halo, phenyl, -CHO, -CN, -SO 3 H and -NHAc. Examples of synthetic hydroxy containing amino acid, include, but are not limited to, such as 4-hydroxymethyl-Phe, 4- hydroxyphenyl-Gly, 2,6-dimethyl-Tyr and 5-amino-Tyr. Examples of synthetic basic amino acids include, but are not limited to, N-l-(2-pyrazolinyl)-Arg, 2-(4-piρerinyl)-Gly, 2-(4- ρiperinyl)-Ala, 2-[3-(2S)pyrrolininyl)-Gly and 2-[3-(2S)pyrrolininyl)-Ala. These and other synthetic basic amino acids, synthetic hydroxy containing amino acids or synthetic aromatic amino acids are described in Building Block Index, Version 3.0 (1999 Catalog, pages 4-47 for hydroxy containing amino acids and aromatic amino acids and pages 66-87 for basic amino acids; see also http://www.amino-acids.com), incorporated herein by reference, by and available from RSP Amino Acid Analogues, Inc., Worcester, MA. Examples of synthetic acid amino acids include those derivatives bearing acidic functionality, including carboxyl, phosphate, sulfonate and synthetic tetrazolyl derivatives such as described by Ornstein et al. (1993) and in U.S. Patent No. 5,331,001, each incorporated herein by reference. [0016] Optionally, in the μ-conopeptides of the present invention, the Asn residues may be modified to contain an N-glycan and the Ser, Thr and Hyp residues may be modified to contain an O-glycan (e.g., g-N, g-S, g-T and g-Hyp). In accordance with the present invention, a glycan shall mean any N-, S- or O-linked mono-, di-, tri-, poly- or oligosaccharide that can be attached to any hydroxy, amino or thiol group of natural or modified amino acids by synthetic or enzymatic methodologies known in the art. The monosaccharides making up the glycan can include D-allose, D-altrose, D-glucose, D-mannose, D-gulose, D-idose, D-galactose, D-talose, D-galactosamine, D-glucosamine, D-N-acetyl-glucosamine (GlcNAc), D-N-acetyl- galactosamine (GalNAc), D-fucose or D-arabinose. These saccharides may be structurally modified, e.g., with one or more O-sulfate, O-phosphate, O-aceryl or acidic groups, such as sialic acid, including combinations thereof. The gylcan may also include similar polyhydroxy groups, such as D-penicillamine 2,5 and halogenated derivatives thereof or polypropylene glycol derivatives. The glycosidic linkage is beta and 1-4 or 1-3, preferably 1-3. The linkage between the glycan and the amino acid may be alpha or beta, preferably alpha and is 1-. [0017] Core O-glycans have been described by Van de Steen et al. (1998), incorporated herein by reference. Mucin type O-linked oligosaccharides are attached to Ser or Thr (or other hydroxylated residues of the present peptides) by a GalNAc residue. The monosaccharide building blocks and the linkage attached to this first GalNAc residue define the "core glycans," of which eight have been identified. The type of glycosidic linkage (orientation and connectivities) are defined for each core glycan. Suitable glycans and glycan analogs are described further in U.S. Serial No. 09/420,797 filed 19 October 1999 and in PCT Application No. PCT/US99/24380 filed 19 October 1999 (PCT Published Application No. WO 00/23092), each incorporated herein by reference. A preferred glycan is Gal(βl-»3)GalNAc(αl-»). [0018] Optionally, in the μ-conopeptides described above, pairs of Cys residues may be replaced pairwise with isoteric lactam or ester-thioether replacements, such as Ser/(Glu or Asp), Lys/(Glu or Asp), Cys/(Glu or Asp) or Cys/Ala combinations. Sequential coupling by known methods (Barnay et al., 2000; Hruby et al., 1994; Bitan et al., 1997) allows replacement of native Cys bridges with lactam bridges. Thioether analogs may be readily synthesized using halo-Ala residues commercially available from RSP Amino Acid Analogues. [0019] The present invention is further directed to derivatives of the above peptides and peptide derivatives which are acylic permutations in which the cyclic permutants retain the native bridging pattern of native toxin. See, for example, Craik et al. (2001). [0020] The present invention is further directed to a method of treating disorders associated with voltage gated ion channel disorders in a subject comprising administering to the subject an effective amount of the pharmaceutical composition comprising a therapeutically effective amount of a μ-conopeptide described herein or a pharmaceutically acceptable salt or solvate thereof. The present invention is also directed to a pharmaceutical composition comprising a therapeutically effective amount of a μ-conopeptide described herein or a pharmaceutically acceptable salt or solvate thereof and a pharmaceutically acceptable carrier. [0021] More specifically, the present invention is further directed to uses of these peptides or nucleic acids as described herein as neuromuscular blocking agents, local anesthetic agents, analgesic agents and neuroprotective agents. The μ-conopeptides are . also useful for treating neuromuscular disorders. [0022] The present invention is directed to the use of μ-conopeptides as a local anesthetic for treating pain. The μ-conopeptides have long lasting anesthetic activity and are particularly useful for spinal anesthesia, either administered acutely for post-operative pain or via an intrathecal pump for severe chronic pain situations. The μ-conopeptides are also useful as analgesics in chronic and neuropathic pain states, such as trigeminal neuralgia, diabetic neuropathy, post-herpetic neuralgia, neuroma pain and phantom limb pain. The μ-conopeptides are also useful for treating burn pain and as ocular anesthetics. [0023] The present invention is directed to the use of μ-conopeptides as neuroprotectants. The μ-conopeptides are useful for the treatment and alleviation of epilepsy and as a general anticonvulsant agent. The μ-conopeptides are also useful for treating neurodegenerative diseases, such as Arnyotropbic Lateral Sclerosis (ALS). The μ-conopeptides are further useful as cerebroprotectants, such as for reducing neurotoxic injury associated with conditions of hypoxia, anoxia or ischemia which typically follows stroke, cerebrovascular accident, brain or spinal cord trauma, myocardial infarct, physical trauma, drowning, suffocation, perinatal asphyxia, or hypoglycemic events. [0024] The present invention is directed to the use of μ-conopeptides as neuromuscular blockers and for treating neuromuscular disorders. As such, the μ-conopeptides are useful for providing relaxation of muscle, for treating benign essential blepharospasm and other forms of focal dystonia and for anti-wrinkle use. [0025] More specifically, the present invention is also directed to nucleic acids which encode μ-conopeptides ofthe present invention or which encodes precursor peptides for these μ- conopeptides, as well as the precursor peptide. The nucleic acid sequences encoding the precursor peptides of other μ-conopeptides of the present invention are set forth in Table 1. Table 1 also sets forth the amino acid sequences of these precursor peptides. [0026] The present invention is further directed to the use of selectively radioiodinated or radiotritiated μ-conopeptides for characterizing pore occlusion sites on different sodium channel subtypes or for use in screening assays. [0027] The present invention is also directed to the use of μ-conopeptides for screening small molecule libraries to identify small molecules that are selective blocking agents at specific sodium channel subtypes expressed in mammalian systems. In one embodiment, the blocking activity of a small molecule at a particular sodium channel subtype is compared to the blocking activity of a μ-conopeptide at the same sodium channel subtype. In a second embodiment, the ability of a small molecule to displace a μ-conopeptide from a sodium channel subtype is determined. In a third emdiment, the binding affinity of a small molecule for a sodium channel subtype is compared to the binding affinity of a μ-conopeptide for the same sodium channel subtype. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT [0028] The present invention is to μ-conopeptides, derivatives or pharmaceutically acceptable salts thereof. The present invention is further directed to the use of this peptide, derivatives thereof and pharmaceutically acceptable salts thereof for the treatment of disorders associated with voltage-gated sodium channels. Thus, the μ-conopeptides or derivatives are useful as neuromuscular blocking agents, local anesthetic agents, analgesic agents and neuroprotective agents. The μ-conopeptides are also useful for treating neuromuscular disorders. The invention is further directed to nucleic acid sequences encoding the μ- conopeptides and encoding propeptides, as well as the propeptides. [0029] The present invention, in another aspect, relates to a pharmaceutical composition comprising an effective amount of an μ-conopeptides, a mutein thereof, an analog thereof, an active fragment thereof or pharmaceutically acceptable salts or solvates. Such a pharmaceutical composition has the capability of acting at voltage gated ion channels, and are thus useful for treating a disorder or disease of a living animal body, including a human, which disorder or disease is responsive to the partial or complete blockade of voltage gated ion channels of the central nervous system comprising the step of administering to such a living animal body, including a human, in need thereof a therapeutically effective amount of a pharmaceutical composition ofthe present invention. [0030] The present invention is directed to the use of μ-conopeptides as neuromuscular blockers and for treating neuromuscular disorders. As such, the μ-conopeptides are useful for providing relaxation of muscle, for treating benign essential blepharospasm and other forms of focal dystonia and for anti- wrinkle use. Thus, in one aspect, the μ-conopeptides are useful as neurmuscular blocking agents in conjunction with surgery or for intubation of the trachea by conventional parenteral administration e.g., intramuscular or intravenous administration in solution. In a second aspect, the μ-conopeptides are useful as agents for treating neuromuscular disorders such as myofacial pain syndrome, chronic muscle spasm, dystonias and spasticity. [0031] The primary factor detrimental to neurons in neurological disorders associated with deficient oxygen supply or mitochondrial dysfunction is insufficient ATP production relative to their requirement. As a large part of the energy consumed by brain cells is used for maintenance of the Na + gradient across the cellular membrane, reduction of energy demand by down-modulation of voltage-gated Na(+)-channels is one strategy for neuroprotection. In addition, preservation of the inward Na + gradient may be beneficial because it is an essential driving force for vital ion exchanges and transport mechanisms such as Ca 2+ homeostasis and neurotransmitter uptake. Thus, the μ-conopeptides of the present invention are useful as neuroprotectants . [0032] Thus, the pharmaceutical compositions of the present invention are useful as neuroprotectants, especially cerebroprotectants, neuromuscular blockers, analgesics (both as a local anesthetic and for general analgesia use) or adjuvants to general anesthetics. A "neurological disorder or disease" is a disorder or disease of the nervous system including, but not limited to, global and focal ischemic and hemorrhagic stroke, head trauma, spinal cord injury, hypoxia-induced nerve cell damage as in cardiac arrest or neonatal distress or epilepsy. In addition, a "neurological disorder or disease" is a disease state and condition in which a neuroprotectant, anticonvulsant, analgesic and/or as an adjunct in general anesthesia may be indicated, useful, recommended or prescribed. [0033] More specifically, the present invention is directed to the use of these compounds for reducing neurotoxic injury associated with conditions of hypoxia, anoxia or ischemia which typically follows stroke, cerebrovascular accident, brain or spinal cord trauma, myocardial infarct, physical trauma, drowning, suffocation, perinatal asphyxia, or hypoglycemic events. The present invention is further directed to the use of these compounds for treating pain, including acute and chronic pain, such migraine, nociceptive and neuropathic pain. [0034] A "neuroprotectant" is a compound capable of preventing the neuronal death associated with a neurological disorder or disease. An "analgesic" is a compound capable of relieving pain by altering perception of nociceptive stimuli without producing anesthesia or loss of consciousness. A "muscle relaxant" is a compound that reduces muscular tension. An "adjunct in general anesthesia" is a compound useful in conjunction with anesthetic agents in producing the loss of ability to perceive pain associated with the loss of consciousness. [0035] The invention relates as well to methods useful for treatment of neurological disorders and diseases, including, but not limited to, global and focal ischemic and hemorrhagic stroke, head trauma, spinal cord injury, hypoxia-induced nerve cell damage such as in cardiac arrest or neonatal distress, epilepsy or other convulsive disorders without undesirable side effects. [0036] Thus, in one embodiment, the invention provides a method of reducing/alleviating/ decreasing the perception of pain by a subject or for inducing analgesia in a subject comprising administering to the subject an effective amount of the pharmaceutical composition comprising a therapeutically effective amount of a μ-conopeptide described herein or a pharmaceutically acceptable salt or solvate thereof. The pain may be acute, persistent, inflammatory or neuropathic pain. The μ-conopeptides are useful as an analgesia for chronic and neuropathic pain states, such as trigeminal neuralgia, diabetic neuropathy, post-herpetic neuralgia, neuroma pain, phantom limb pain. These peptides are also useful for treating burn pain and as ocular anesthetics. [0037] In a second embodiment, the invention provides a method of reducing/alleviating/ decreasing the perception of pain by a subject or for inducing analgesia, particularly local analgesia, in a subject comprising administering to the subject an effective amount of the pharmaceutical composition comprising a therapeutically effective amount of a μ-conopeptide described herein or a pharmaceutically acceptable salt or solvate thereof. These peptides are also useful for treating burn pain and as ocular anesthetics. [0038] In a third embodiment, the invention provides a method of treating stroke, head or spinal cord trauma or injury, anoxia, hypoxia-induced nerve cell damage, ischemia, migraine, psychosis, anxiety, schizophrenia, inflammation, movement disorder, epilepsy, any other convulsive disorder or in the prevention ofthe degenerative changes coimected with the same in a subject comprising administering to the subject an effective amount of the pharmaceutical composition comprising a therapeutically effective amount of a μ-conopeptide described herein or a pharmaceutically acceptable salt or solvate thereof. [0039] In a fourth embodiment, the invention provides a method for providing a neuromuscular block or for treating neuromuscular disorders, such as methods for providing relaxation of muscle, for treating benign essential blepharospasm and other forms of focal dystonia and for anti-wrinkle use. Thus, in one aspect, the μ-conopeptides are useful as neurmuscular blocking agents in conjunction with surgery or for intubation of the trachea by conventional parenteral administration e.g., intramuscular or intravenous administration in solution. In a second aspect, the μ-conopeptides are useful as agents for treating neuromuscular disorders such as myofacial pain syndrome, chronic muscle spasm, dystonias and spasticity. [0040] The present invention is also directed to the use of μ-conopeptides for screening small molecule libraries to identify small molecules that are selective blocking agents at specific sodium channel subtypes expressed in mammalian systems. In one embodiment, the blocking activity of a small molecule at a particular sodium channel subtype is compared to the blocking activity of a μ-conopeptide at the same sodium channel subtype, hi a second embodiment, the ability of a small molecule to displace a μ-conopeptide from a sodium channel subtype is determined. In a third emdiment, the binding affinity of a small molecule for a sodium channel subtype is compared to the binding affinity of a μ-conopeptide for the same sodium channel subtype. [0041] The μ-conopeptides described herein are sufficiently small to be chemically synthesized. General chemical syntheses for preparing the foregoing co-conotoxin peptides are described hereinafter. Various ones ofthe μ-conopeptides can also be obtained by isolation and purification from specific Conus species using the technique described in U.S. Patent Nos. 4,447,356 (Olivera et al., 1984); 5,514,774; 5,719,264; and 5,591,821, as well as in PCT published application WO 98/03189, the disclosures of which are incorporated herein by reference. [0042] Although the μ-conopeptides of the present invention can be obtained by purification from cone snails, because the amounts of μ-conopeptides obtainable from individual snails are very small, the desired substantially pure μ-conopeptides are best practically obtained in commercially valuable amounts by chemical synthesis using solid-phase strategy. For example, the yield from a single cone snail may be about 10 micrograms or less of μ- conopeptides peptide. By "substantially pure" is meant that the peptide is present in the substantial absence of other biological molecules of the same type; it is preferably present in an amount of at least about 85% purity and preferably at least about 95% purity. Chemical synthesis of biologically active μ-conopeptides peptides depends of course upon correct determination ofthe amino acid sequence. [0043] The μ-conopeptides can also be produced by recombinant DNA techniques well known in the art. Such techniques are described by Sambrook et al. (1989). A gene of interest (i.e., a gene that encodes a suitable μ-conopeptides) can be inserted into a cloning site of a suitable expression vector by using standard techniques. These techniques are well known to those skilled in the art. The expression vector containing the gene of interest may then be used to transfect the desired cell line. Standard transfection techniques such as calcium phosphate co-precipitation, DEAE-dextran transfection or electroporation may be utilized. A wide variety of host/expression vector combinations may be used to express a gene encoding a conotoxin peptide of interest. Such combinations are well known to a skilled artisan. The peptides produced in this manner are isolated, reduced if necessary, and oxidized to form the correct disulfide bonds. [0044] One method of forming disulfide bonds in the μ-conopeptides of the present invention is the air oxidation of the linear peptides for prolonged periods under cold room temperatures or at room temperature. This procedure results in the creation of a substantial amount of the bioactive, disulfide-linked peptides. The oxidized peptides are fractionated using reverse-phase high performance liquid chromatography (HPLC) or the like, to separate peptides having different linked configurations. Thereafter, either by comparing these fractions with the elution of the native material or by using a simple assay, the particular fraction having the correct linkage for maximum biological potency is easily determined. However, because of the dilution resulting from the presence of other fractions of less biopotency, a somewhat higher dosage may be required. [0045] The peptides are synthesized by a suitable method, such as by exclusively solid- phase techniques, by partial solid-phase techniques, by fragment condensation or by classical solution couplings. [0046] In conventional solution phase peptide synthesis, the peptide chain can be prepared by a series of coupling reactions in which constituent amino acids are added to the growing peptide chain in the desired sequence. Use of various coupling reagents, e.g., dicyclohexylcarbodiimide or diisopropylcarbonyldimidazole, various active esters, e.g., esters of N-hydroxyphthalimide or N-hydroxy-succinimide, and the various cleavage reagents, to carry out reaction in solution, with subsequent isolation and purification of intermediates, is well known classical peptide methodology. Classical solution synthesis is described in detail in the treatise, "Methoden der Organischen Chemie (Houben-Weyl): Synthese von Peptiden," (1974). Techniques of exclusively solid-phase synthesis are set forth in the textbook, "Solid-Phase Peptide Synthesis," (Stewart and Young, 1969), and are exemplified by the disclosure of U.S. Patent 4,105,603 (Vale et al., 1978). The fragment condensation method of synthesis is exemplified in U.S. Patent 3,972,859 (1976). Other available syntheses are exemplified by U.S. Patents No. 3,842,067 (1974) and 3,862,925 (1975). The synthesis of peptides containing γ- carboxyglutamic acid residues is exemplified by Rivier et al. (1987), Nishiuchi et al. (1993) and Zhou et al. (1996). [0047] Common to such chemical syntheses is the protection of the labile side chain groups of the various amino acid moieties with suitable protecting groups which will prevent a chemical reaction from occurring at that site until the group is ultimately removed. Usually also common is the protection of an α-amino group on an amino acid or a fragment while that entity reacts at the carboxyl group, followed by the selective removal ofthe α-amino protecting group to allow subsequent reaction to take place at that location. Accordingly, it is common that, as a step in such a synthesis, an intermediate compound is produced which includes each of the amino acid residues located in its desired sequence in the peptide chain with appropriate side- chain protecting groups linked to various ones ofthe residues having labile side chains. [0048] As far as the selection of a side chain amino protecting group is concerned, generally one is chosen which is not removed during deprotection ofthe α-amino groups during the synthesis. However, for some amino acids, e.g., His, protection is not generally necessary. In selecting a particular side chain protecting group to be used in the synthesis of the peptides, the following general rules are followed: (a) the protecting group preferably retains its protecting properties and is not split off under coupling conditions, (b) the protecting group should be stable under the reaction conditions selected for removing the α-amino protecting group at each step of the synthesis, and (c) the side chain protecting group must be removable, upon the completion of the synthesis containing the desired amino acid sequence, under reaction conditions that will not undesirably alter the peptide chain. [0049] It should be possible to prepare many, or even all, of these peptides using recombinant DNA technology. However, when peptides are not so prepared, they are preferably prepared using the Merrifield solid-phase synthesis, although other equivalent chemical syntheses known in the art can also be used as previously mentioned. Solid-phase synthesis is commenced from the C-terminus of the peptide by coupling a protected α-amino acid to a suitable resin. Such a starting material can be prepared by attaching an α-amino-protected amino acid by an ester linkage to a chloromethylated resin or a hydroxymethyl resin, or by an amide bond to a benzhydrylamine (BHA) resin or paramethylbenzhydrylamine (MBHA) resin. Preparation of the hydroxymethyl resin is described by Bodansky et al. (1966). Chloromethylated resins are commercially available from Bio Rad Laboratories (Richmond, CA) and from Lab. Systems, Inc. The preparation of such a resin is described by Stewart and Young (1969). BHA and MBHA resin supports are commercially available, and are generally used when the desired polypeptide being synthesized has an unsubstituted amide at the C- terminus. Thus, solid resin supports may be any of those known in the art, such as one having the formulae -O-CH 2 -resin support, -NH BHA resin support, or -NH-MBHA resin support. When the unsubstituted amide is desired, use of a BHA or MBHA resin is preferred, because cleavage directly gives the amide. In case the N-methyl amide is desired, it can be generated from an N-methyl BHA resin. Should other substituted amides be desired, the teaching of U.S. Patent No. 4,569,967 (Kornreich et al., 1986) can be used, or should still other groups than the free acid be desired at the C-terminus, it may be preferable to synthesize the peptide using classical methods as set forth in the Houben-Weyl text (1974). [0050] The C-terminal amino acid, protected by Boc or Fmoc and by a side-chain protecting group, if appropriate, can be first coupled to a chloromethylated resin according to the procedure set forth in K. Horiki et al. (1978), using KF in DMF at about 60°C for 24 hours with stirring, when a peptide having free acid at the C-terminus is to be synthesized. Following the coupling of the BOC-protected amino acid to the resin support, the α-amino protecting group is removed, as by using trifluoroacetic acid (TFA) in methylene chloride or TFA alone. The deprotection is carried out at a temperature between about 0°C and room temperature. Other standard cleaving reagents, such as HCl in dioxane, and conditions for removal of specific α- amino protecting groups may be used as described in Schroder & Lubke (1965). [0051] After removal ofthe α-amino-protecting group, the remaining α-amino- and side chain-protected amino acids are coupled step-wise in the desired order to obtain the intermediate compound defined hereinbefore, or as an alternative to adding each amino acid separately in the synthesis, some of them may be coupled to one another prior to addition to the solid phase reactor. Selection of an appropriate coupling reagent is within the skill of the art. Particularly suitable as a coupling reagent is N,N'-dicyclohexylcarbodiimide (DCC, DIC, HBTU, HATU, TBTU in the presence of HoBt or Ho At). [0052] The activating reagents used in the solid phase synthesis of the peptides are well known in the peptide art. Examples of suitable activating reagents are carbodiimides, such as N,N'-diisopropylcarbodiimide and N-ethyl-N'-(3-dimethylaminopropyl)carbodiimide. Other activating reagents and their use in peptide coupling are described by Schroder & Lubke (1965) and Kapoor (1970). [0053] Each protected amino acid or amino acid sequence is introduced into the solid- phase reactor in about a twofold or more excess, and the coupling may be carried out in a medium of dimethylformamide (DMF):CH 2 C1 2 (1 :1) or in DMF or CH 2 C1 2 alone. In cases where intermediate coupling occurs, the coupling procedure is repeated before removal ofthe α-amino protecting group prior to the coupling of the next amino acid. The success of the coupling reaction at each stage of the synthesis, if performed manually, is preferably monitored by the ninhydrin reaction, as described by Kaiser et al. (1970). Coupling reactions can be performed automatically, as on a Beckman 990 automatic synthesizer, using a program such as that reported in Rivier et al. (1978). [0054] After the desired amino acid sequence has been completed, the intermediate peptide can be removed from the resin support by treatment with a reagent, such as liquid hydrogen fluoride or TFA (if using Fmoc chemistry), which not only cleaves the peptide from the resin but also cleaves all remaining side chain protecting groups and also the -amino protecting group at the N-tenninus if it was not previously removed to obtain the peptide in the form of the free acid. If Met is present in the sequence, the Boc protecting group is preferably first removed using trifluoroacetic acid (TFA)/ethaneditbiol prior to cleaving the peptide from the resin with HF to eliminate potential S-alkylation. When using hydrogen fluoride or TFA for cleaving, one or more scavengers such as anisole, cresol, dimethyl sulfide and methylethyl sulfide are included in the reaction vessel. [0055] Cyclization of the linear peptide is preferably affected, as opposed to cyclizing the peptide while a part of the peptido-resin, to create bonds between Cys residues. To effect such a disulfide cyclizing linkage, fully protected peptide can be cleaved from a hydroxymethylated resin or a chloromethylated resin support by ammonolysis, as is well known in the art, to yield the fully protected amide intermediate, which is thereafter suitably cyclized and deprotected. Alternatively, deprotection, as well as cleavage of the peptide from the above resins or a benzhydrylamine (BHA) resin or a methylbenzhydrylamme (MBHA), can take place at 0°C with hydrofluoric acid (HF) or TFA, followed by oxidation as described above. [0056] The peptides are also synthesized using an automatic synthesizer. Amino acids are sequentially coupled to an MBHA Rink resin (typically 100 mg of resin) beginning at the C- terminus using an Advanced Chemtech 357 Automatic Peptide Synthesizer. Couplings are carried out using 1,3-diisopropylcarbodimide in N-methylpyrrolidinone (NMP) or by 2-(lH- benzotriazole-l-yl)-l,l,3,3-tetramethyluronium hexafluorophosphate (HBTU) and diethylisopro- pylethylamine (DIEA). The FMOC protecting group is removed by treatment with a 20% solution of piperidine in dimethylformamide(DMF). Resins are subsequently washed with DMF (twice), followed by methanol and NMP. [0057] Muteins, analogs or active fragments, of the foregoing conotoxin peptides are also contemplated here. See, e.g., Hammerland et al. (1992). Derivative muteins, analogs or active fragments of the conotoxin peptides may be synthesized according to known techniques, including conservative amino acid substitutions, such as outlined in U.S. Patent Nos. 5,545,723 (see particularly col. 2, line 50— col. 3, line 8); 5,534,615 (see particularly col. 19, line 45— col. 22, line 33); and 5,364,769 (see particularly col. 4, line 55— col. 7, line 26), each herein incorporated by reference. [0058] The μ-conopeptides of the present invention are also useful to reduce neurotoxic injury associated with conditions of hypoxia, anoxia or ischemia which typically follows stroke, cerebrovascular accident, brain or spinal chord trauma, myocardial infarct, physical trauma, drownings, suffocation, perinatal asphyxia, or hypoglycemic events. To reduce neurotoxic injury, an ω-conopeptide should be administered in a therapeutically effective amount to the patient within 24 hours ofthe onset ofthe hypoxic, anoxic or ischemic condition in order for the μ-conopeptide to effectively minimize the CNS damage which the patient will experience. [0059] The μ-conopeptides ofthe present invention are further useful in controlling pain, ' e.g., as analgesic agents, and the treatment of migraine, acute pain or persistent pain. They can be used prophylactically or to relieve the symptoms associated with a migraine episode, or to treat acute or persistent pain. For these uses, an μ-conopeptide is administered in a therapeutically effective amount to overcome or to ease the pain. [0060] The μ-conopeptides of the present invention are also useful as neuromuscular blockers and for treating neuromuscular disorders. They can be used for providing relaxation of muscle, for treating benign essential blepharospasm and other foims of focal dystonia and for anti-wrinkle use. Thus, in one aspect, the μ-conopeptides are used as neurmuscular blocking agents in conjunction with surgery or for intubation of the trachea by conventional parenteral administration e.g., intramuscular or intravenous administration in solution. In a second aspect, the μ-conopeptides are used as agents for treating neuromuscular disorders such as myofacial pain syndrome, chronic muscle spasm, dystonias and spasticity. For these uses, a μ-conopeptide is administered in a therapeutically effective amount to relax muscle or provide a neuromuscular block. [0061] Pharmaceutical compositions containing a compound of the present invention as the active ingredient can be prepared according to conventional pharmaceutical compounding techniques. See, for example, Remington's Pharmaceutical Sciences, 18th Ed. (1990, Mack Publishing Co., Easton, PA). Typically, an antagonistic amount of active ingredient will be admixed with a pharmaceutically acceptable carrier. The carrier may take a wide variety of forms depending on the form of preparation desired for administration, e.g., intravenous, oral, parenteral or intrathecally. For examples of delivery methods see U.S. Patent No. 5,844,077, incorporated herein by reference. [0062] "Pharmaceutical composition" means physically discrete coherent portions suitable for medical administration. "Pharmaceutical composition in dosage unit form" means physically discrete coherent units suitable for medical administration, each containing a daily dose or a multiple (up to four times) or a sub-multiple (down to a fortieth) of a daily dose ofthe active compound in association with a carrier and/or enclosed within an envelope. Whether the composition contains a daily dose, or for example, a half, a third or a quarter of a daily dose, will depend on whether the pharmaceutical composition is to be administered once or, for example, twice, three times or four times a day, respectively. [0063] The term "salt", as used herein, denotes acidic and/or basic salts, formed with inorganic or organic acids and/or bases, preferably basic salts. While pharmaceutically acceptable salts are preferred, particularly when employing the compoimds of the invention as medicaments, other salts find utility, for example, in processing these compounds, or where non-medicament-type uses are contemplated. Salts of these compounds may be prepared by art-recognized techniques. [0064] Examples of such pharmaceutically acceptable salts include, but are not limited to, inorganic and organic addition salts, such as hydrochloride, sulphates, nitrates or phosphates and acetates, trifluoroacetates, propionates, succinates, benzoates, citrates, tartrates, fumarates, maleates, methane-sulfonates, isothionates, theophylline acetates, salicylates, respectively, or the like. Lower alkyl quaternary ammonium salts and the like are suitable, as well. [0065] As used herein, the term "pharmaceutically acceptable" carrier means a non-toxic, inert solid, semi-solid liquid filler, diluent, encapsulating material, formulation auxiliary of any type, or simply a sterile aqueous medium, such as saline. Some examples of the materials that can serve as pharmaceutically acceptable carriers are sugars, such as lactose, glucose and sucrose, starches such as com starch and potato starch, cellulose and its derivatives such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; powdered tragacanth; malt, gelatin, talc; excipients such as cocoa butter and suppository waxes; oils such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, com oil and soybean oil; glycols, such as propylene glycol, polyols such as glycerin, sorbitol, mannitol and polyethylene glycol; esters such as ethyl oleate and ethyl laurate, agar; buffering agents such as magnesium hydroxide and aluminum hydroxide; alginic acid; pyrogen-free water; isotonic saline, Ringer's solution; ethyl alcohol and phosphate buffer solutions, as well as other non-toxic compatible substances used in pharmaceutical formulations. [0066] Wetting agents, emulsifiers and lubricants such as sodium lauryl sulfate and magnesium stearate, as well as coloring agents, releasing agents, coating agents, sweetening, flavoring and perfuming agents, preservatives and antioxidants can also be present in the composition, according to the judgment of the formulator. Examples of pharmaceutically acceptable antioxidants include, but are not limited to, water soluble antioxidants such as ascorbic acid, cysteine hydrochloride, sodium bisulfite, sodium metabisulfite, sodium sulfite, and the like; oil soluble antioxidants, such as ascorbyl palmitate, butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), lecithin, propyl gallate, aloha-tocopherol and the like; and the metal chelating agents such as citric acid, ethylenediamine terraacetic acid (EDTA), sorbitol, tartaric acid, phosphoric acid and the like. [0067] For oral administration, the compounds can be formulated into solid or liquid preparations such as capsules, pills, tablets, lozenges, melts, powders, suspensions or emulsions. In preparing the compositions in oral dosage form, any of the usual pharmaceutical media may be employed, such as, for example, water, glycols, oils, alcohols, flavoring agents, preservatives, coloring agents, suspending agents, and the like in the case of oral liquid preparations (such as, for example, suspensions, elixirs and solutions); or carriers such as starches, sugars, diluents, granulating agents, lubricants, binders, disintegrating agents and the like in the case of oral solid preparations (such as, for example, powders, capsules and tablets). Because of their ease in administration, tablets and capsules represent the most advantageous oral dosage unit form, in which case solid pharmaceutical carriers are obviously employed. If desired, tablets may be sugar-coated or enteric-coated by standard techniques. The active agent can be encapsulated to make it stable to passage through the gastrointestinal tract while at the same time allowing for passage across the blood brain barrier. See for example, WO 96/11698. [0068] For parenteral administration, the compound may be dissolved in a pharmaceutical carrier and administered as either a solution or a suspension. Illustrative of suitable carriers are water, saline, dextrose solutions, fructose solutions, ethanol, or oils of animal, vegetative or synthetic origin. The carrier may also contain other ingredients, for example, preservatives, suspending agents, solubilizing agents, buffers and the like. When the compounds are being administered intrathecally, they may also be dissolved in cerebrospinal fluid. [0069] A variety of administration routes are available. The particular mode selected will depend of course, upon the particular drug selected, the severity ofthe disease state being treated and the dosage required for therapeutic efficacy. The methods of this invention, generally speaking, may be practiced using any mode of administration that is medically acceptable, meaning any mode that produces effective levels of the active compounds without causing clinically unacceptable adverse effects. Such modes of administration include oral, rectal, sublingual, topical, nasal, transdermal or parenteral routes. The term "parenteral" includes subcutaneous, intravenous, epidural, irrigation, intramuscular, release pumps, or infusion. [0070] For example, administration of the active agent according to this invention may be achieved using any suitable delivery means, including: (a) pump (see, e.g., Luer & Hatton (1993), Zimm et al. (1984) and Ettinger et al. (1978)); (b), microencapsulation (see, e.g., U.S. Patent Nos. 4,352,883; 4,353,888; and 5,084,350); (c) continuous release polymer implants (see, e.g., U.S. Patent No. 4,883,666); (d) macroencapsulation (see, e.g., U.S. Patent Nos. 5,284,761, 5,158,881, 4,976,859 and 4,968,733 and published PCT patent applications WO92/19195, WO 95/05452); (e) naked or unencapsulated cell grafts to the CNS (see, e.g., U.S. Patent Nos. 5,082,670 and 5,618,531); (f) injection, either subcutaneously, intravenously, intra-arterially, intramuscularly, or to other suitable site; or (g) oral administration, in capsule, liquid, tablet, pill, or prolonged release formulation. [0071] In one embodiment of this invention, an active agent is delivered directly into the CNS, preferably to the brain ventricles, brain parenchyma, the intrathecal space or other suitable CNS location, most preferably intrathecally. [0072] Alternatively, targeting therapies may be used to deliver the active agent more specifically to certain types of cell, by the use of targeting systems such as antibodies or cell specific ligands. Targeting may be desirable for a variety of reasons, e.g. if the agent is unacceptably toxic, or if it would otherwise require too high a dosage, or if it would not otherwise be able to enter the target cells. [0073] The active agents, which are peptides, can also be administered in a cell based delivery system in which a DNA sequence encoding an active agent is introduced into cells designed for implantation in the body of the patient, especially in the spinal cord region. Suitable delivery systems are described in U.S. Patent No. 5,550,050 and published PCT Application Nos. WO 92/19195, WO 94/25503, WO 95/01203, WO 95/05452, WO 96/02286, WO 96/02646, WO 96/40871, WO 96/40959 and WO 97/12635. Suitable DNA sequences can be prepared synthetically for each active agent on the basis of the developed sequences and the known genetic code. [0074] Exemplary methods for administering such muscle relaxant compounds (e.g., so as to achieve sterile or aseptic conditions) will be apparent to the skilled artisan. Certain methods suitable for administering compounds useful according to the present invention are set forth in Goodman and Gilman's TXlie Pharmacological Basis of Tlterapeutics, 7th Ed. (1985). The administration to the patient can be intermittent; or at a gradual, continuous, constant or controlled rate. Administration can be to a warm-blooded animal (e.g. a mammal, such as a mouse, rat, cat, rabbit, dog, pig, cow or monkey); but advantageously is administered to a human being. Administration occurs after general anesthesia is administered. The frequency of administration normally is determined by an anesthesiologist, and typically varies from patient to patient. [0075] The active agent is preferably administered in an therapeutically effective amount. By a "therapeutically effective amount" or simply "effective amount" of an active compound is meant a sufficient amount of the compound to treat the desired condition at a reasonable benefit/risk ratio applicable to any medical treatment. The actual amount administered, and the rate and time-course of administration, will depend on the nature and severity of the condition being treated. Prescription of treatment, e.g. decisions on dosage, timing, etc., is within the responsibility of general practitioners or spealists, and typically takes account of the disorder to be treated, the condition ofthe individual patient, the site of delivery, the method of administration and other factors known to practitioners. Examples of techniques and protocols can be found in Remington 's Parmaceutical Sciences. [0076] Dosage may be adjusted appropriately to achieve desired drug levels, locally or systemically. Typically the active agents of the present invention exhibit their effect at a dosage range from about 0.001 mg/kg to about 250 mg/kg, preferably from about 0.01 mg/kg to about 100 mg/kg ofthe active ingredient, more preferably from a bout 0.05 mg/kg to about 75 mg/kg. A suitable dose can be administered in multiple sub-doses per day. Typically, a dose or sub- dose may contain from about 0.1 mg to about 500 mg of the active ingredient per unit dosage form. A more preferred dosage will contain from about 0.5 mg to about 100 mg of active ingredient per unit dosage form. Dosages are generally initiated at lower levels and increased until desired effects are achieved. In the event that the response in a subject is insufficient at such doses, even higher doses (or effective higher doses by a different, more localized delivery route) may be employed to the extent that patient tolerance pennits. Continuous dosing over, for example 24 hours or multiple doses per day are contemplated to achieve appropriate systemic levels of compounds. [0077] For the treatment of pain, if the route of administration is directly to the CNS, the dosage contemplated is from about 1 ng to about 100 mg per day, preferably from about 100 ng to about 10 mg per day, more preferably from about 1 μg to about 100 μg per day. If administered peripherally, the dosage contemplated is somewhat higher, from about 100 ng to about 1000 mg per day, preferably from about 10 μg to about 100 mg per day, more preferably from about 100 μg to about 10 mg per day. If the conopeptide is delivered by continuous infusion (e.g., by pump delivery, biodegradable polymer delivery or cell-based delivery), then a lower dosage is contemplated than for bolus delivery. [0078] Advantageously, the compositions are formulated as dosage units, each unit being adapted to supply a fixed dose of active ingredients. Tablets, coated tablets, capsules, ampoules and suppositories are examples of dosage forms according to the invention. [0079] It is only necessary that the active ingredient constitute an effective amount, i.e., such that a suitable effective dosage will be consistent with the dosage form employed in single or multiple unit doses. The exact individual dosages, as well as daily dosages, are determined according to standard medical principles under the direction of a physician or veterinarian for use humans or animals. [0080] The pharmaceutical compositions will generally contain from about 0.0001 to 99 wt. %, preferably about 0.001 to 50 wt. %, more preferably about 0.01 to 10 wt.% of the active ingredient by weight ofthe total composition. In addition to the active agent, the pharmaceutical compositions and medicaments can also contain other pharmaceutically active compounds. Examples of other pharmaceutically active compounds include, but are not limited to, analgesic agents, cytokines and therapeutic agents in all of the major areas of clinical medicine. When used with other pharmaceutically active compounds, the conopeptides of the present invention may be delivered in the form of drug cocktails. A cocktail is a mixture of any one of the compounds useful with this invention with another drug or agent. In this embodiment, a common administration vehicle (e.g., pill, tablet, implant, pump, injectable solution, etc.) would contain both the instant composition in combination supplementary potentiating agent. The individual drugs of the cocktail are each administered in therapeutically effective amounts. A therapeutically effective amount will be determined by the parameters described above; but, in any event, is that amount which establishes a level of the drugs in the area of body where the drugs are required for a period of time winch is effective in attaining the desired effects. [0081] The practice of the present invention employs, unless otherwise indicated, conventional techniques of chemistry, molecular biology, microbiology, recombinant DNA, genetics, immunology, cell biology, cell culture and transgenic biology, which are within the skill of the art. See, e.g., Maniatis et al, 1982; Sambrook et al, 1989; Ausubel et al, 1992; Glover, 1985; Anand, 1992; Guthrie and Fink, 1991; Harlow and Lane, 1988; Jakoby and Pastan, 1979; Nucleic Acid Hybridization (B. D. Hames & S. J. Higgins eds. 1984); Transcription And Translation (B. D. Hames & S. J. Higgins eds. 1984); Culture Of Animal Cells (R. I. Freshney, Alan R. Liss, Inc., 1987); Immobilized Cells And Enzymes (IRL Press, 1986); B. Perbal, A Practical Guide To Molecular Cloning (1984); the treatise, Methods In Enzymology (Academic Press, Inc., N.Y.); Gene Transfer Vectors For Mammalian Cells (J. H. Miller and M. P. Calos eds., 1987, Cold Spring Harbor Laboratory); Methods In Enzymology, Vols. 154 and 155 (Wu et al. eds.), Immunochemical Methods In Cell And Molecular Biology (Mayer and Walker, eds., Academic Press, London, 1987); Handbook Of Experimental Immunology, Volumes I-IV (D. M. Weir and C. C. Blackwell, eds., 1986); Riott, Essential Immunology, 6th Edition, Blackwell Scientific Publications, Oxford, 1988; Hogan et al, Manipulating the Mouse Embryo, (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY., 1986). EXAMPLES [0082] The present invention is described by reference to the following Examples, which are offered by way of illustration and are not intended to limit the invention in any manner. Standard techniques well known in the art or the techniques specifically described below were utilized. EXAMPLE 1 Isolation of μ-Conopeptides [0083] Cmde venom was extracted from venom ducts (Cruz et al, 1976), and the components were purified as previously described (Cartier et al., 1996). The crude extract from venom ducts was purified by reverse phase liquid chromatography (RPLC) using a Vydac C 18 semi-preparative column (10 x 250 mm). Further purification of bioactive peaks was done on a Vydac C 18 analytical column (4.6 x 220 mm). The effluents were monitored at 220 nm. Peaks were collected, and aliquots were assayed for activity. Throughout purification, HPLC fractions were assayed by means of intracerebral ventricular (i.c.v.) injection into mice (Clark et al., 1981). [0084] The amino acid sequence of the purified peptides were determined by standard methods. The purified peptides were reduced and alkylated prior to sequencing by automated Edman degradation on an Applied Biosystems 477A Protein Sequencer with a 120A Analyzer (DNA/Peptide Facility, University of Utah) (Martinez et al, 1995; Shon et al., 1994). [0085] In accordance with this method, the μ-conopeptides described as "isolated" in Table 1 were obtained. These μ-conopeptides, as well as the other μ-conopeptides and the μ- conopeptide precursors set forth in Table 1 are synthesized as described in U.S. Patent No. 5,670,622. EXAMPLE 2 Isolation of DNA Encoding μ-Conopeptides [0086] DNA coding for μ-conopeptides was isolated and cloned in accordance with conventional techniques using general procedures well known in the art, such as described in Olivera et al. (1996). Alternatively, cDNA libraries was prepared from Conus venom duct using conventional techniques. DNA from single clones was amplified by conventional techniques using primers which correspond approximately to the Ml 3 universal priming site and the Ml 3 reverse universal priming site. Clones having a size of approximately 300-500 nucleotides were sequenced and screened for similarity in sequence to known μ-conotoxins. The DNA sequences and encoded propeptide sequences are set forth in Table 1. DNA sequences coding for the mature toxin can also be prepared on the basis of the DNA sequences set forth in Tablel. An alignment ofthe μ-conopeptides ofthe present invention is set forth in Table 2. TABLE 1 DNA and Amino Acid Sequences of μ-Conopeptides and Precursors Name: Ar3.1 Species: arenatus Cloned: Yes DNA Sequence: CAAGAAGGATCGATAGCAGTTCATGATGTCTAAACTGGGAGTCTTCTTGACCATCTG TATGCTTCTGTTTCCCCTTACTGCTCTTCCGCTGGATGGGGATCAACCTGCAGACCG ACCTGCAGAGCGTATGCAGGACGACTTTATAACTGAGCATCATCCCCTGTTTGATCC TGTCAAACGGTGTTGCGAGAGGCCATGCAACATAGGATGCGTACCTTGTTGTTAATG ACCAGCTTTGTCATCGCGGCCTCATCAAGCGAATAAGTAAAACGATTGCAGT (SEQ ID NO:l) Translation: MMSKLGNFLTICMLLFPLTALPLDGDQP ADRP AERMQDDFITEHHPLFDPNKRCCERPC ΝIGCVPCC (SEQ ID ΝO:2) Toxin Sequence: Cys-Cys-Xaal-Arg-Xaa3-Cys-Asn-Ile-Gly-Cys-Val-Xaa3-Cys-Cys- Λ (SEQ ID NO:3) Name: Ak3.1 Species: atlanticus Cloned: Yes DNA Sequence: GGATCCATGATGTCTAAACTGGGAGTCTTGTTGACCATCTGTCTGCTTCTGTTTCCAC TTACTGCTCTTCCGCTGGATGAAGATCAACCGGTACACCGACCTGCAGAGCGTATGC AGGACATTTCATCTGATCAACATCTCTTCTTTGATCTCATCAAACGGTGCTGCGAGT TGCCATGCGGGCCAGGCTTTTGCGTCCCTTGTTGCTGACATCAATAACGTGTTGATG ACCAACTTTCTCGAG (SEQ ID NO:4) Translation: GSMMSKLGVLLTICLLLFPLTALPLDEDQPVHRPAERMQDISSDQHLFFDLIKRCCELPC GPGFCVPCC (SEQ ID NO:5) Toxin Sequence: Cys-Cys-Xaal-Leu-Xaa3-Cys-Gly-Xaa3-Gly-Phe-Cys-Val-Xaa3-Cys-Cys- A (SEQ ID NO:6) Name: A3.1 Species: aurisiacus Cloned: Yes DNA Sequence: CAAGAGGGATCGATAGCAGTTCATGATGTCTAAACTGGGAGTCTTGTTGACCATCTG TTTGCTTCTGTTTCCCCTTACTGCTCTTCCGATGGATGGAGATCAATCTGTAGACCGA CCTGAAGAGCGTATGCAGGACGACATTTCATCTGAGCAGCATCCCTTGTTTAATCAG AAAAGAATGTGTTGCGGCGAAGGCCGGAAATGCCCCAGCTATTTCAGAAACAGTCA GATTTGTCATTGTTGTTAAATGACAACGTGTCGATGACCAACTTCGTTATCACGACT AATGAATAAGTAAAACGATTGCAGT (SEQ ID NO:7) Translation: MMSKLGVLLTICLLLFPLTALPMDGDQSVDRPEERMQDDISSEQHPLFNQKRMCCGEG RKCPSYFRNSQICHCC (SEQ ED NO: 8) Toxin Sequence: Met-Cys-Cys-Gly-Xaal-Gly-Arg-Lys-Cys-Xaa3-Ser-Xaa5-Phe-Arg-Asn-Ser-Gln-Ile-Cys-His- Cys-Cys- Λ (SEQ ID NO:9) Name: A3.2 Species: aurisiacus Cloned: Yes DNA Sequence: GGATCCATGATGTCTAAACTGGGAGTCTTGTTGACCATCTGTTTGCTTCTGTTTCCCC TTACTGCTCTTCCGATCGATGGAGATCAATCTGTAGACCGACCTGCAGAGCGTATGC AGGATGACATTTCATCTGAGCAGCATCGCTTGTTCAATCAGAAAAGAAGGTGCTGC CGGTGGCCATGCCCCCGACAAATCGACGGTGAATATTGTGGCTGTTGCCTTGGATGA TAACCGTGTTGATGACCAACTTTCTCGAG (SEQ ID NO:10) Translation: GSMMSKLGVLLTICLLLFPLTALPIDGDQSVDRPAERMQDDISSEQHRLFNQKRRCCRW PCPRQIDGEYCGCCLG (SEQ ID NO.ll) Toxin Sequence: Cys-Cys-Arg-Xaa4-Xaa3-Cys-Xaa3-Arg-Gln-Ile-Asp-Gly-Xaal-Xaa5-Cys-Gly-Cys-Cys-Leu-# (SEQ ID NO: 12) Name: A3.3 Species: aurisiacus Cloned: Yes DNA Sequence: GGATCCATGATGTCTAAACTGGGAGTCTTGTTGACCATCTGTCTACTTCTGTTTCCCC TTACTGCTTTTCCGATGGATGGAGATCAACCTGCAGACCAACCTGCAGATCGTATGC AGGACGACATTTCATCTGAGCAGTATCCCTTGTTTGATAAGAGACAAAAGTGTTGCA CTGGGAAGAAGGGGTCATGCTCCGGCAAAGCATGCAAAAATCTCAAATGTTGCTCT GGACGATAACGTGTTGATGACCAACTTTCTCGAG (SEQ ID NO:13) Translation: GSMMSKLGVLLTICLLLFPLTAFPMDGDQPADQPADRMQDDISSEQYPLFDKRQKCCT GKKGSCSGKACKNLKCCSGR (SEQ ID NO: 14) Toxin Sequence: Xaa2-Lys-Cys-Cys-Thr-Gly-Lys-Lys-Gly-Ser-Cys-Ser-Gly-Lys-Ala-Cys-Lys-Asn-Leu-Lys- Cys-Cys-Ser-# (SEQ ID NO: 15) Name: A3.4 Species: aurisiacus Cloned: Yes DNA Sequence: GGATCCATGATGTCTAAACTGGGAGTCTTGCTGACCATCTGTCTGCTTCTGTTTCCAC TTACTGCTGTTCCGCTGGATGGAGATCAACCTCTAGACCGACACGCGGAGCGTATGC ATGATGGCATTTCACCTAAACGCCATCCCTGGTTTGATCCCGTCAAACGGTGTTGCA AGGTGCAATGCGAGTCTTGCACCCCTTGTTGCTAACGTGTTGATGACCAACTTTCTC GAG (SEQ ID NO: 16) Translation: GSMMS__ΩLGVLLTICLLLFPLTAVPLDGDQPLDI^AERMHDGISPKRHPWFDPVKRCCK VQCESCTPCC (SEQ ID NO:17) Toxin Sequence: Cys-Cys-Lys-Val-Gln-Cys-Xaal-Ser-Cys-Thr-Xaa3-Cys-Cys- Λ (SEQ ID NO:18) Name: Bn3.1 Species: bandanus Cloned: Yes DNA Sequence: GGATCCATGATGTCTAAACTGGGAGTCTTGTTGACCATCTGTATGCTTCTGTTTCCCC TCACTGCTCTTCCGATGGATGGAGATCAACCTGCAGACCGACCTGCAGAGCGTAGT CAGGACGTTTCATCTGAACAGCATCCCTTGTTTGATCCCGTCAAACGGTGTTGCAAC TGGCCATGCTCCATGGGATGCATCCCTTGTTGCTACTATTAATAACGTGTTGATGAC CAACTTTCTCGAG (SEQ ID NO: 19) Translation: GSMMSKLGVLLTICMLLFPLTALPMDGDQPADRPAERSQDVSSEQHPLFDPVKRCCNW PCSMGCIPCCYY (SEQ ID NO:20) Toxin Sequence: Cys-Cys-Asn-Xaa4-Xaa3-Cys-Ser-Met-Gly-Cys-Ile-Xaa3-Cys-Cys-Xaa5-Xaa5- A (SEQ ID NO:21) Name: Bt3.1 Species: betulinus Cloned: Yes DNA Sequence: CAAGAGGGATCGATAGCAGTTCATGATGTCTAAACTGGGAGTCTTGTTGACCTTCTG TCTGCTTCTGTTTCCCCTGACTGCTCTTCCGCTGGATGAAGATCAACCTGCAGACCG ACCTGCAGAGCGTATGCAGGACATTTCATCTGAACAGCATCCCTTGTTTGATCCCGT CAAACGGTGTTGCGAATTGCCATGCCATGGATGCGTCCCTTGTTGCTGGCCTTAATA ACGTGTGGATGACCAACTGTGTTATCACGGCCACGTCAAGTGTCTAATGAATAAGT AAAATGATTGCAGT (SEQ ID NO:22) Translation: MMSKLGVLLTFCLLLFPLTALPLDEDQPADRPAERMQDISSEQHPLFDPVKRCCELPCH GCVPCCWP (SEQ ID NO:23) Toxin Sequence: Cys-Cys-Xaal-Leu-Xaa3-Cys-His-Gly-Cys-Val-Xaa3-Cys-Cys-Xaa4-Xaa3- Λ (SEQ ID NO:24) Name: Bt3.2 Species: betulinus Cloned: Yes DNA Sequence: CAAGAGGGATCGATAGCAGTTCATGATGTCTAAACTGGGAGTCTTGTTGACCTTCTG TCTGCTTCTGTTTCCCCTGACTGCTCTTCCGCTGGATGAAGATCAACCTGCAGACCG ACATGCAGAGCGTATGCAGGACATTTCACCTGAACAGCATCCCTCGTTTGATCCCGT CAAACGGTGTTGCGGGCTGCCATGCAATGGATGCGTCCCTTGTTGCTGGCCTTCATA ACGTGTGGACGACCAACTTTGTTATCACGGCCACGTCAAGTGTCTGATGAATAAGTA AAACGATTGCAGT (SEQ ID NO:25) Translation: MMSKLGVLLTFCLLLFPLTALPLDEDQPADRHAERMQDISPEQHPSFDPVKRCCGLPCN GCVPCCWPS (SEQ ID NO:26) Toxin Sequence: Cys-Cys-Gly-Leu-Xaa3-Cys-Asn-Gly-Cys-Val-Xaa3-Cys-Cys-Xaa4-Xaa3-Ser- Λ (SEQ ID NO:27) Name: Bt3.3 Species: betulinus Cloned: Yes DNA Sequence: CAAGAGGGATCGATAGCAGTTCATGATGTTTAAACTGGGAGTCTTGTTGACCATCTA TATGCTTCTGTTTCCCTTTACTGCTCTTCCGCTGGATGGAGATCAACCTGCAGACCAA CCTCTAGAGCGCATGCAGTATGACATGTTACGTGCAGTGAATCCCTGGTTTGATCCC GTCAAAAGGTGCTGCTCGAGGAACTGCGCAGTATGCATCCCTTGTTGCCCGAATTGG CCAGCTTGATTATCGCGGCCAAGAGTCTAATGAATAAGTAAAACGATTGCAGT (SEQ ID NO:28) Translation: MMP__Π,GVLLTΓYMLLFPFTALPLDGDQPADQPLERMQYDMLRAVNPWFDPVKRCCSR NCAVCIPCCPNWPA (SEQ ID NO:29) Toxin Sequence: Cys-Cys-Ser-Arg-Asn-Cys-Ala-Val-Cys-Ile-Xaa3-Cys-Cys-Xaa3-Asn-Xaa4-Xaa3-Ala- Λ (SEQ ID NO:30) Name: Bu3.1 Species: bullatus Cloned: Yes DNA Sequence: CAAGAAGGATCGATAGCAGTTCATGATGTCTAAACTGGGAGTCTTGTTGACCATCTG TCTGCTTCTGTTTCCCCTTTTTGCTCTTCCGCAGGATGGAGATCAACCTGCAGACCGA CCTGCAGAGCGTATGCAGGACGACATTTCATCTGAGCAGAATTCCTTGCTTGAGAA GAGAGTTACTGACAGGTGCTGCAAAGGGAAGAGGGAATGCGGCAGATGGTGCAGA GATCACTCGCGTTGTTGCGGTCGACGATAAGCTGTTGATGACCAGCTTTGTTATCAC GGCTACATCAAGTGTCTAGTGAATAAGTAAAATGATTGCAGT (SEQ ID NO:31) Translation: MMSKLGVLLTICLLLFPLFALPQDGDQPADRPAERMQDDISSEQNSLLEKRVTDRCCKG KRECGRWCRDHSRCCGRR (SEQ ID NO:32) Toxin Sequence: Val-Thr-Asp-Arg-Cys-Cys-Lys-Gly-Lys-Arg-Xaal-Cys-Gly-Arg-Xaa4-Cys-Arg-Asp-His-Ser- Arg-Cys-Cys-# (SEQ ID NO:33) Name: Bu3.1A Species: bullatus Cloned: Yes DNA Sequence: CAAGAGGGATCGATAGCAGTTCATGATGTCTAAACTGGGAGTCTTGTTGACCATCTG TCTGCTTCTGTTTCCCCTTTTTGCTCTTCGGCAGGATGGAGATCAACCTGCAGACCGA CCTGCAGAGCGTATGCAGGATGACATTTCATCTGAGCAGAATCCCTTGCTTGAGAA GAGAGTTGGTGACAGGTGCTGCAAAGGGAAGAGGGGGTGCGGCAGATGGTGCAGA GATCACTCACGTTGTTGCGGTCGACGATAACGTGTTGATGACCAGCTTTGTTATCAC GGCTACATCAAGTGTCTTAGTGATTAAGTAAAACGATTGCAGT (SEQ ID NO:34) Translation: MMSKLGVLLTICLLLFPLFALRQDGDQPADRPAERMQDDISSEQNPLLEKRVGDRCCK GKRGCGRWCRDHSRCCGRR (SEQ ID NO:35) Toxin Sequence: Val-Gly-Asp-Arg-Cys-Cys-Lys-Gly-Lys-Arg-Gly-Cys-Gly-Arg-Xaa4-Cys-Arg-Asp-His-Ser- Arg-Cys-Cys-# (SEQ ID NO:36) Name: Bu3.2 Species: bullatus Cloned: Yes DNA Sequence: CAAGAAGGATCGATAGCAGTTCATGATGTCTAAACTGGGAGTCTTGTTGACCATCTG TCTGCTTCTGTTTCCCCTTTTTGCTCTTCCGCAGGATGGAGATCAACCTGCAGACCGA CCTGCAGAGCGTATGCAGGACGACATTTCATCTGAGCAGAATCCCTTGCTTGAGAA GAGAGTTGGTGAAAGGTGCTGCAAAAACGGGAAGAGGGGGTGCGGCAGATGGTGC AGAGATCACTCACGTTGTTGCGGTCGACGATAACGTGTTGATGACCGAGGCTTTCGT TATCACGGCTACATCAAGTGTCTAGTGAATAAGTAAAACGATTGCAGT (SEQ ID NO:37) Translation: MMSKLGVLLTICLLLFPLFALPQDGDQPADRPAERMQDDISSEQNPLLEKRVGERCCKN GKRGCGRWCRDHSRCCGRR (SEQ ID NO:38) Toxin Sequence: Val-Gly-Xaal-Arg-Cys-Cys-Lys-Asn-Gly-Lys-Arg-Gly-Cys-Gly-Arg-Xaa4-Cys-Arg-Asp-His- Ser-Arg-Cys-Cys-# (SEQ ID NO:39) Name: Bu3.3 Species: bullatus Cloned: Yes DNA Sequence: CAAGAGGGATCGATAGCAGTTCATGATGTCTAAACTGGGAGTCTTGTTGACCATCTG TCTGCTTCTGTTTCCCCTTTTTGCTCTTCCGCAGGACGGAGATCAACCTGCAGACCG ACCTGCAGAGCGTATGCAGGACGACCTTTCATCTGAGCAGCATCCCTTGTTTGAGAA GAGAATTGTTGACAGGTGCTGCAACAAAGGGAACGGGAAGAGGGGGTGCAGCAGA TGGTGCAGAGATCACTCACGTTGTTGCGGTCGACGATGAACTGTTGATGACCGAGG CTTTGGTTATCACGGCTACATCAAGTGTCTAGTGAATAAGTAAAACGATTGCAGT (SEQ ID NO:40) Translation: MMS__^GVLLTICLLLFPLFALPQDGDQPADRPAERMQDDLSSEQHPLFEKRIVDRCCNK GNGKRGCSRWCRDHSRCCGRR (SEQ ID NO:41) Toxin Sequence: Ile-Val-Asp-Arg-Cys-Cys-Asn-Lys-Gly-Asn-Gly-Lys-Arg-Gly-Cys-Ser-Arg-Xaa4-Cys-Arg- Asp-His-Ser-Arg-Cys-Cys-# (SEQ ID NO:42) Name: Bu3.4 Species: bullatus Cloned: Yes DNA Sequence: CAAGAAGGATCGATAGCAGTTCATGATGTCTAAACTGGGAGTCTTGTTGACCATCTG TCTGCTTCTGTTTCCCCTTTTTGCTCTTCCGCAGGATGGAGATCAACCTGCAGACCGA CCTGCTGAGCGTATGCAGGACGACATTTCATCTGAGCGGAATCCCTTGTTTGAGAAG AGCGTTGGTTTATATTGCTGCCGACCCAAACCCAACGGGCAGATGATGTGCGACAG ATGGTGCGAAAAAAACTCACGTTGTTGCGGTCGACGATAATGTGTTGATGACCAGC TTTGTTATCAAGGCTACATCAAGTATCTAGTGAATAAGTAAAACGATTGCAGT (SEQ ID NO:43) Translation: MMSKLGVLLTICLLLFPLFALPQDGDQPADRPAERMQDDISSERNPLFEKSVGLYCCRP KPNGQMMCDRWCEKNSRCCGRR (SEQ ID NO:44) Toxin Sequence: Val-Gly-Leu-Xaa5-Cys-Cys-Arg-Xaa3-Lys-Xaa3-Asn-Gly-Gln-Met-Met-Cys-Asp-Arg-Xaa4- Cys-Xaal-Lys-Asn-Ser-Arg-Cys-Cys-# (SEQ ID NO:45) Name: Bu3.5 Species: bullatus Cloned: Yes DNA Sequence: CAAGAAGGATCGATAGCAGTTCATGATGTCTAAACTGGGAGTTTTGTTGACCATCTG TCTGCTTCTGTTTCCCCTTACTGCTCTTCCGATGGATGGAGATCAATCTGTAGACCGA CCTGCAGAACGTATGCAGGACGACCTTTCATCTGAGCAGCATCCCTTGTTTGTTCAG AAAAGAAGGTGTTGCGGCGAAGGCTTGACATGCCCCAGATATTGGAAAAACAGTCA GATTTGTGCTTGTTGTTAAATGACAACGTGTCGATGACCAACTTCGGTATCACGACT ACGCCAAGTGTCTAATGAATAAGTAAAACGATTGCAGT (SEQ ID NO:46) Translation: MMSKLGVLLTICLLLFPLTALPMDGDQSVDRPAERMQDDLSSEQHPLFVQKRRCCGEG LTCPRYWKNSQICACC (SEQ ID NO:47) Toxin Sequence: Arg-Cys-Cys-Gly-Xaal-Gly-Leu-Thr-Cys-Xaa3-Arg-Xaa5-Xaa4-Lys-Asn-Ser-Gln-Ile-Cys-Ala- Cys-Cys- Λ (SEQ ID NO:48) Name: Bu3.5A Species: bullatus Cloned: Yes DNA Sequence: CAAGAGGGATCGATAGCAGTTCATGATGTCTAAACTGGGAGTCTTGTTGACCATCTG TCTGCTTCTGTTTCCCCTTTTTGCTCTTCCGCAGGATGGAGATCAACCTGCAGACCGA CCTGCTGAGCGTATGCAGGACGACATTTCATCTGAGCAGGATCCCTTGTTTGTTCAG AAAAGAAGGTGTTGCGGCGAAGGCTTGACATGCCCCAGATATTGGAAAAACAGTCA GATTTGTGCTTGTTGTTAAATGACAACGTGTGATGACCAACTTCGGTATC ACGACT A CGCCAAGTGTCTAATGAATAAGTAAAACGATTGCAGT (SEQ ID NO:49) Translation: MMSKLGVLLTICLLLFPLFALPQDGDQPADRPAERMQDDISSEQDPLFVQKRRCCGEGL TCPRYWKNSQICACC (SEQ ID NO:50) Toxin Sequence: Arg-Cys-Cys-Gly-Xaal-Gly-Leu-Thr-Cys-Xaa3-Arg-Xaa5-Xaa4-Lys-Asn-Ser-Gln-Ile-Cys-Ala- Cys-Cys- Λ (SEQ ID NO:51) Name: Cp3.1 Species: capitaneus Cloned: Yes DNA Sequence: GGATCCATGATGTCTAAACTGGGAGTCTTGGTGACCATCTGCCTGCTTCTGTTTCCC CTTGCTGCTTTTCCACTGGATGGAAATCAACCTGCAGACCACCCTGCAAAGCGTACG CAAGATGACAGTTCAGCTGCCCTGATCAATACCTGGATTGATCATTCCCATTCTTGC TGCAGGGACTGCGGTGAAGATTGTGTTGGTTGTTGCCGGTAACGTGTTGATGACCAA CTTTCTCGAG (SEQ ID NO:52) Translation: GSMMSKLGVLVTICLLLFPLAAFPLDGNQPADHPAKRTQDDSSAALINTWIDHSHSCCR DCGEDCVGCCR (SEQ ID NO:53) Toxin Sequence: Ser-Cys-Cys-Arg-Asp-Cys-Gly-Xaal-Asp-Cys-Val-Gly-Cys-Cys-Arg- Λ (SEQ ID NO:54) Name: Ca3.1 Species: caracteristicus Cloned: Yes DNA Sequence: CAAGAGGGATCGATAGCAGTTCATGATGTCTAAACTGGGAGTCTTGTTGACCATCTG TCTGCTTCTGTTTCCCCTTACTGCTCTTCCAATGGATGGAGATCAACCTGCAGACCA ACCTGCAGATCGTATGCAGGACGACATTTCATCTGAGCAGTATCCCTTGTTTGATAT GAGAAAAAGGTGTTGCGGCCCCGGCGGTTCATGCCCCGTATATTTCAGAGACAATT TTATTTGTGGTTGTTGTTAAATGACAACGTGTCGATGACCAACTTCATTATCACGAC TACGCCAAGTGTCTAATGAATAAGTAAAATGATTGCAGT (SEQ ID NO:55) Translation: MMSKLGVLLTICLLLFPLTALPMDGDQPADQPADRMQDDISSEQYPLFDMRKRCCGPG GSCPVYFRDNFICGCC (SEQ ID NO:56) Toxin Sequence: Cys-Cys-Gly-Xaa3-Gly-Gly-Ser-Cys-Xaa3-Val-Xaa5-Phe-Arg-Asp-Asn-Phe-Ile-Cys-Gly-Cys- Cys- A (SEQ ID NO:57) Name: Ca3.2 Species: caracteristicus Cloned: Yes DNA Sequence: CAAGAGGGATCGATAGCAGTTCATGATGTCTAAACTGGGAGTCTTGTTGACCATCTG TCTGCTTCTGTTTCCCCTTACTGCTCTTCCGATGGATGGAGATGAACCTGCAAACCG ACCTGTCGAGCGTATGCAGGACAACATTTCATCTGAGCAGTATCCCTTGTTTGAGAA GAGACGAGATTGTTGCACTCCGCCGAAGAAATGCAAAGACCGACAATGCAAACCCC AGAGATGTTGCGCTGGACGATAACGTGTTGATGACCAACTTTATCACGGCTACGTCA AGTGTTTAGTGAATAAGTAAAATGATTGCAGT (SEQ ID NO:58) Translation: MMSKLGVLLTICLLLFPLTALPMDGDEPANRPVERMQDNISSEQYPLFEKRRDCCTPPK KCKDRQCKPQRCCAGR (SEQ ID NO:59) Toxin Sequence: Arg-Asp-Cys-Cys-Thr-Xaa3-Xaa3-Lys-Lys-Cys-Lys-Asp-Arg-Gln-Cys-Lys-Xaa3-Gln-Arg- Cys-Cys-Ala-# (SEQ ID NO:60) Name: Ca3.3 Species: caracteristicus Cloned: Yes DNA Sequence: CAAGAGGGATCGATAGCAGTTCATGATGTCTAAACTGGGAGTCTTGTTGACCATCTG TCTGCTTCTGTTTCCCCTTACTGCTCTTCCACTGGATGGAGATCAACCTGCAGATCAA TCTGCAGAGCGACCTGCAGAGCGTACGCAGGACGACATTCAGCAGCATCCGTTATA TGATCCGAAAAGAAGGTGTTGCCGTTATCCATGCCCCGACAGCTGCCACGGATCTTG CTGCTATAAGTGATAACATGTTGATGGCCAGCTTTGTTATCACGGCCACGTCAAGTG TCTTAATGAATAAGTAAAACGATTGCAGT (SEQ ID NO:61) Translation: MMSKLGVLLTICLLLFPLTALPLDGDQPADQSAERPAERTQDDIQQHPLYDPKRRCCRY PCPDSCHGSCCYK (SEQ ID NO:62) Toxin Sequence: Arg-Cys-Cys-Arg-Xaa5-Xaa3-Cys-Xaa3-Asρ-Ser-Cys-His-Gly-Ser-Cys-Cys-Xaa5-Lys- Λ (SEQ ID NO:63) Name: Ca3.4 Species: caracteristicus Cloned: Yes DNA Sequence: C AAGAGGGATCGATAGCAGTTC ATGATGTCTAAACTGGGAGCCTTGTTGACC ATCT GTCTACTTCTGTTTTCCCTTACTGCTGTTCCGCTGGATGGAGATCAACATGCAGACC AACCTGCACAGCGTCTGCAGGACCGCATTCCAACTGAAGATCATCCCTTATTTGATC CCAACAAACGGTGTTGCCCGCCGGTGGCATGCAACATGGGATGCAAGCCTTGTTGT GGATGACCAGCTTTGTTATCGCGGTCTTCATGAAGTGTCTTAATGAATAAGTAAAAT GATTGCAGT (SEQ ID NO:64) Translation: MMSKLGALLTICLLLFSLTAVPLDGDQHADQPAQRLQDRTPTEDHPLFDPNKRCCPPVA CNMGCKPCCG (SEQ ID NO:65) Toxin Sequence: Cys-Cys-Xaa3-Xaa3-Val-Ala-Cys-Asn-Met-Gly-Cys-Lys-Xaa3-Cys-Cys-# (SEQ ID NO:66) Name: Ca3.5 Species: caracteristicus Cloned: Yes DNA Sequence: CAAGAGGGATCGATAGCAGTTCATGATGTCTAAACTGGGAGCCTTGTTGACCATCT GTCTACTTCTGTTTTCCCTAACTGCTGTTCCGCTGGATGGAGATCAACATGCAGACC AACCTGCAGAGCGTCTGCATGACCGCCTTCCAACTGAAAATCATCCCTTATATGATC CCGTCAAACGGTGTTGCGATGATTCGGAATGCGACTATTCTTGCTGGCCTTGCTGTA TGTTTGGATAACCTTTGTTATCGCGGCCTCATCAAGTGTCTAATGAATAAGTAAAAC GATTGCAGT (SEQ ID NO:67) Translation: MMSKLGALLTICLLLFSLTAWLDGDQHADQPAERLHDRLPTENHPLYDPVKRCCDDSE CDYSCWPCCMFG (SEQ ID NO:68) Toxin Sequence: Cys-Cys-Asp-Asp-Ser-Xaal -Cys-Asp-Xaa5-Ser-Cys-Xaa4-Xaa3-Cys-Cys-Met-Phe-# (SEQ ID NO:69) Name: Ca3.6 Species: caracteristicus Cloned: Yes DNA Sequence: GGATCCATGATGTCTAAACTGGGAGTCTTGTTGACCATCTGTCTGCTTCTGTTTCCCC TTACTGCTGTTCCGCTGGATGGAGATCAACCTGCAGACCGACCTGCAGAGCGTAAG CAGGACGTTTCATCTGAACAGCATCCCTTCTTTGATCCCGTCAAACGGTGTTGCCGC CGGTGTTACATGGGATGCATCCCTTGTTGCTTTTAACGTGTTGATGACCAACTTTCTC GAG (SEQ ID NO:70) Translation: GSMMSKLGVLLTICLLLFPLTAVPLDGDQPADRPAERKQDVSSEQHPFFDPVKRCCR C YMGCIPCCF (SEQ ID NO:71) Toxin Sequence: Cys-Cys-Arg-Arg-Cys-Xaa5-Met-Gly-Cys-Ile-Xaa3-Cys-Cys-Phe- Λ (SEQ ID NO:72) Name: Cr3.1 Species: circumcisus Cloned: Yes DNA Sequence: CAAGAAGGATCGATAGCAGTTCATGATGTCTAAACTGGGGGTATTGTTGACCATCT GTCTGCTTCTGTTTCCCCTTACTGCTCTTCCAATGGATGGAGATCAACCTGCAGACC AACCTGCAGATCGTATGCAGGACGACATTTCATCTGAGCAGTATCCCTTGTTTGATA AGAGACGAAAGTGTTGCGGCAAAGACGGGCCATGCCCCAAATATTTCAAAGACAAT TTTATTTGTGGTTGTTGTTAAATGACAACGTGTCGATGACCAACTTCGTTATCACGAT TCGCCAAGTGTCTTAATGAATAAGTAAAATGATTGCAGT (SEQ ID NO:73) Translation: MMSKLGVLLTICLLLFPLTALPMDGDQPADQPADRMQDDISSEQYPLFDKRRKCCGKD GPCPKYFKDNFICGCC (SEQ ID NO:74) Toxin Sequence: Arg-Lys-Cys-Cys-Gly-Lys-Asp-Gly-Xaa3-Cys-Xaa3-Lys-Xaa5-Phe-Lys-Asp-Asn-Phe-Ile-Cys- Gly-Cys-Cys- Λ (SEQ ID NO:75) Name: Da3.1 Species: dalli Cloned: Yes DNA Sequence: CAAGAGGGATCGATAGCAGTTCATGATGTCTAAACTGGGAGCCTTGTTGACCATCT GTCTACTTCTGTTTTCCCTAACTGCTGTTCCGCTGGATGGAGATCAACATGCAGACC AACCTGCAGAGCGTCTGCAGGACCGCCTTCCAACTGAAAATCATCCCTTATATGATC CCGTCAAACGGTGTTGCGATGATTCGGAATGCGACTATTCTTGCTGGCCTTGCTGTA TTTTATCATAACCTTTGTTATCGCGGCCTCATCAAGTGTCAAATGAATAAGTAAAAT GATTGCAGT (SEQ ID NO:76) Translation: MMSKLGALLTICLLLFSLTAVPLDGDQHADQPAERLQDRLPTENHPLYDPVKRCCDDSE CDYSCWPCCILS (SEQ ID NO:77) Toxin Sequence: Cys-Cys-Asρ-Asρ-Ser-Xaal-Cys-Asp-Xaa5-Ser-Cys-Xaa4-Xaa3-Cys-Cys-Ile-Leu-Ser- Λ (SEQ ID NO:78) Name: Da3.2 Species: dalli Cloned: Yes DNA Sequence: CAAGAGGGATCGATAGCAGTTCATGATGTCTAAACTGGGAGTCTTGTTGACCATTTG TCTACTTCTGTTTCCCCTTACTGCTGTTCCACTGGATGGAGATCAGCCTGCAGACCG ACCTGCAGAGCGTATGCAGGACGGC ATTTC ATCTGAACATCATCCATTTTTTGATTC CGTCAAAAAGAAACAACAGTGTTGCCCGCCGGTGGCATGCAACATGGGATGCGAGC CTTGTTGTGGATGACCAGCTTTGTTATCGCGGCTCATGAAGTGTCCTAATGAATAAG TAAAACGATTGCAGT (SEQ ID NO:79) Translation: MMSK GVLLTICLLLFPLTAVPLDGDQPADRPAERMQDGISSEHHPFFDSVKKKQQCCP PVACNMGCEPCCG (SEQ ID NO:80) Toxin Sequence: Xaa2-Gln-Cys-Cys-Xaa3-Xaa3-Val-Ala-Cys-Asn-Met-Gly-Cys-Xaal-Xaa3-Cys-Cys-# (SEQ ID NO:81) Name: Da3.3 Species: dalli Cloned: Yes DNA Sequence: CAAGAAGGATCGATAGCAGTTCATGATGTCTAAACTGGGAGTCTTGTTGATCATATG TCTATTTCTGTTTCCCCTTACTGCTGTTCAGCTCAATGGAGATCAGCCTGCAGACCAA TCTGCAGAGCGTATGCAGGACAAAATTTCATCTGAACATCATCCCTTTTTTGATCCC GTCAAACGTTGTTGCAACGCGGGGTTTTGCCGCTTCGGATGCACGCCTTGTTGTTGG TGACCAGCTTTGTTATCGCGGCCTCATCAAGTGTCTAATGAATAAGTAAAATGATTG CAGT (SEQ TD NO:82) Translation: MMSKLGVLLIICLFLFPLTANQLNGDQPADQSAERMQDKISSEHHPFFDPNKRCCNAGF CRFGCTPCCW (SEQ ID NO:83) Toxin Sequence: Cys-Cys-Asn-Ala-Gly-Phe-Cys-Arg-Phe-Gly-Cys-Thr-Xaa3-Cys-Cys-Xaa4- A (SEQ ID NO:84) Name: Di3.1 Species: distans Cloned: Yes DNA Sequence: CAAGAGGGATCGATAGCAGTTCATGATGTCTAAACTGGGAGTCTTGCTGACCATCTT TCTGCTTCTGTTTCCCCTTACTGCTGTTCCGCTGGATGGAGATCAACCCGCAGACGG ACTTGCAGAGCGCATGCAGGACGACAGTTCAGCTGCACTGATTAGAGACTGGCTTC TTCAAACCCGACAGTGTTGTGTGCATCCATGCCCATGCACGCCTTGCTGTAGATGAC CAGCTTTGTCATCGCGGCTACGTCAAGTATCTAATGAATAAGTAAGTAAAACGATTG CAGT (SEQ ID NO:85) Translation: MMSKLGVLLTIFLLLFPLTAVPLDGDQPADGLAERMQDDSS AALIRDWLLQTRQCCVH PCPCTPCCR (SEQ ID NO:86) Toxin Sequence: Xaa2-Cys-Cys-Val-His-Xaa3-Cys-Xaa3-Cys-Thr-Xaa3-Cys-Cys-Arg- Λ (SEQ ID NO:87) Name: E3.1 Species: ermineus Cloned: Yes DNA Sequence: ACCTCAAGAGGGATCGATCGCAGTTCATGATGTCTAAACTGGGAGCCTTGTTGACC ATCTGTCTGCTTCTGTTTCCCATTACTGCTCTTCTGATGGATGGAGATCAGCCTGCAG ACCGACCTGCAGAGCGTACGGAGGATGACATTTCATCTGACTACATTCCCTGTTGCA GTTGGCCATGCCCCCGATACTCCAACGGTAAACTTGTTTGTTTTTGTTGCCTTGGATG ATAATGTGTTGATGACCAACTTTGTTATCACGGCTACGTCAAGTGTCTACTGAATAA GTAAAATGATTGCAGTA (SEQ ID NO:88) Translation: MMSKLGALLTICLLLFPITALLMDGDQPADRPAERTEDDISSDYIPCCSWPCPRYSNGKL VCFCCLG (SEQ ID NO:89) Toxin Sequence: Cys-Cys-Ser-Xaa4-Xaa3-Cys-Xaa3-Arg-Xaa5-Ser-Asn-Gly-Lys-Leu-Val-Cys-Phe-Cys-Cys- Leu-# (SEQ ID NO:90) Name: Ge3.2 Species: generalis Cloned: Yes DNA Sequence: GGATCCATGATGTCTAAACTGGGAGTCTTGTTGACCATCTGTCTGGTTCTGTTTCCCC TTACTGCTCTTCCACTGGATGGAGAACAACCTGTAGACCGACATGCCGAGCATATGC AGGATGACAATTCAGCTGCACAGAACCCCTGGGTTATTGCCATCAGACAGTGTTGC ACGTTCTGCAACTTTGGATGCCAACCTTGTTGCCTCACCTGATAACGTGTTGATGAC CAACTTTCTCGAG (SEQ TD NO:91) Translation: GSMMSKLGVLLTICLVLFPLTALPLDGEQPVDRHAEHMQDDNSAAQNPWVIAIRQCCT FCNFGCQPCCLT (SEQ ID NO:92) Toxin Sequence: Xaa2-Cys-Cys-Thr-Phe-Cys-Asn-Phe-Gly-Cys-Gln-Xaa3-Cys-Cys-Leu-Thr- Λ (SEQ ID NO:93) Name: Ge3.3 Species: generalis Cloned: Yes DNA Sequence: GGATCCATGATGTCTAAACTGGGAGTCTTGTTGACCATCTGTCTGGTTCTGTTTCCCC TTACTGCTCTTCCACTGGATGGAGAACAACCTGTAGACCGACATGCCGAGCATATGC AGGATGACAATTCAGCTGCACAGAACCCCTGGGTTATTGCCATCAGACAGTGTTGC ACGTTCTGCAACTTTGGATGCCAGCCTTGTTGCGTCCCCTGATAACGTGTTGATGAC CAACTTTCTCGAG (SEQ ID NO:94) Translation: GSMMSKLGVLLTICLVLFPLTALPLDGEQPVDRHAEHMQDDNSAAQNPWVIAIRQCCT FCNFGCQPCCVP (SEQ ID NO:95) Toxin Sequence: Xaa2-Cys-Cys-Thr-Phe-Cys-Asn-Phe-Gly-Cys-Gln-Xaa3-Cys-Cys-Val-Xaa3- Λ (SEQ ID NO:96) Name: μ-GIIIA Species: geographus Cloned: Yes DNA Sequence: GTCGACTCTAGAGGATCCGACAACAAAGAGTCAACCCCACTGCCACGTCAAGAGCG AAGCGCCACAGCTAAGACAAGAGGGATCGATAGCAGTTCATGATGTCTAAACTGGG AGTCTTGTTGACCATCTGTCTGCTTCTGTTTCCCCTTACTGCTCTTCCGATGGATGGA GATGAACCTGCAAACCGACCTGTCGAGCGTATGCAGGACAACATTTCATCTGAGCA GTATCCCTTGTTTGAGAAGAGACGAGATTGTTGCACTCCGCCGAAGAAATGCAAAG ACCGACAATGCAAACCCCAGAGATGTTGCGCTGGACGATAACGTGTTGATGACCAA CTTTATCACGGCTACGTCAAGTGTTTAGTGAATAAGTAAAATGATTGCAGTCTTGCT CAGATTTGCTTTTGTGTTTTGGTCTAAAGATCAATGACCAAACCGTTGTTTTGATGCG GATTGTCATATATTTCTCGATTCCAATCCAACACTAGATGATTTAATCACGATAGAT TAATTTTCTATCAATGCCTTGATTTTTCGTCTGTCATATCAGTTTTGTTTATATTTATT TTTTCGTCACTGTCTACACAAACGCATGCATGCACGCATGCACGCACACACGCACGC ACGCTCGCACAAACATGCGCGCGCACGCACACACACACACACACACACAAACACA CACAC AAGC AATCACAC AATTATTGACATTATTTATTTATTCATTGATGTATTTGTTA TTCGTTTGCTTGTTTTTAGAATAGTTTGAGGCCGTCTTTTTGGATTTATTTGAACTGC TTTATTGTATACGAGTACTTCGTGCTTTGAAACACTGCTGAAAATAAAACAAACACT GACGTAGC (SEQ ID NO:97) Translation: MMSKLGVLLTICLLLFPLTALPMDGDEPANRPVERMQDNISSEQYPLFEKRRDCCTPPK KCKDRQCKPQRCCAGR (SEQ ID NO:98) Toxin Sequence: Arg-Asp-Cys-Cys-Thr-Xaa3-Xaa3-Lys-Lys-Cys-Lys-Asp-Arg-Gln-Cys-Lys-Xaa3-Gln-Arg- Cys-Cys-Ala-# (SEQ ID NO:99) Name: μ-GIIIB Species: geographus Isolated: Yes Cloned: Yes DNA Sequence: GGCCAGACGACAACAAAGAGTCAACCCCACTGCCACGTCAAGAGCGAAGCGCCAC AGCTAAGACAAGAGGGATCGATAGCAGTTCATGATGTCTAAACTGGGAGTCTTGTT GACCATCTGTCTGCTTCTGTTTCCCCTTACTGCTCTTCCGATGGATGGAGATGAACCT GCAAACCGACCTGTCGAGCGTATGCAGGACAACATTTCATCTGAGCAGTATCCCTTG TTTGAGAAGAGACGAGATTGTTGCACTCCGCCGAGGAAATGCAAAGACCGACGATG CAAACCCATGAAATGTTGCGCTGGACGATAACGTGTTGATGACCAACTTTATCACG GCTAGCTCAGTGTTTAGTGAATAAGTAAAATGATTGCAGTCTTGCTCAGATTGCTTT TGTGTTTTGGTCTAAGATCAATGACCAAACCGTTGTTTTGATGCGGATTGTCATATA TTTCTCGATTCCAATCCAACACTAGATGATTTAATCACGATAGATTAATTTTCTATCA ATGCCTTGATTTTTCGTCTGTCATATCAGTTTTGTTTATATTTATTTTTTCGTCACTGT CTACACAAACGCATGCATGCACGCATGCACGCACACACGCACGCACGCTCGCACAA ACATGCGCGCGCACGCACACACACACACACACACAAACACACACACGAAGCAATC ACACAATTAGTTGACATTATTTATTTATTCATTGATGTATTTGTTATTCGTTTGCTTGT TTTTAGAATAGTTTGAGGCCGTCTTTTTGGATTTATTTGAACTGCTTTATTGTATACG AGTACTTCGTGCTTTGAAACACTGCTGAAAATAAAACAAACACTGACGTAGCAAAA AAAAAAA (SEQ ID NO:100) Translation: MMSKLGVLLTICLLLFPLTALPMDGDEPANRPVERMQDNISSEQYPLFEKRRDCCTPPR KCKDRRCKPMKCCAGR (SEQ ID NO: 101) Toxin Sequence: Arg-Asp-Cys-Cys-Thr-Xaa3-Xaa3-Arg-Lys-Cys-Lys-Asp-Arg-Arg-Cys-Lys-Xaa3-Met-Lys- Cys-Cys-Ala-# (SEQ ID NO:102) Name: μ-GIIIC Species: geographus Isolated: Yes Toxin Sequence: Arg-Asp-Cys-Cys-Thr-Xaa3-Xaa3-Lys-Lys-Cys-Lys-Asp-Arg-Arg-Cys-Lys-Xaa3-Leu-Lys- Cys-Cys-Ala-# (SEQ ID NO: 103) Name: Gm3.1 Species: gloriamaris Cloned: Yes DNA Sequence: CTCACTATAGGAATTCGAGCTCGGTACACGGGATCGATAGCAGTTCATGATGTCTAA ACTGGGAGCCTTGTTGACCATCTGTCTACTTCTGTTTTCCCTAACTGCTGTTCCGCTG GATGGAGATCAACATGCAGACCAACCTGCAGAGCGTCTGCATGACCGCCTTCCAAC TGAAAATCATCCCTTATATGATCCCGTCAAACGGTGTTGCGATGATTCGGAATGCGA CTATTCTTGCTGGCCTTGCTGTATGTTTGGATAACCTTTGTTATCGCGGCCTCGATAA GTGTCTAATGAATAAGTAAAACGATTGCAGTAGGC (SEQ ID NO: 104) Translation: MMSKLGALLTICLLLFSLTAVPLDGDQHADQPAERLHDRLPTENHPLYDPVKRCCDDSE CDYSCWPCCMFG (SEQ ID NO:105) Toxin Sequence: Cys-Cys-Asp-Asp-Ser-Xaal-Cys-Asp-Xaa5-Ser-Cys-Xaa4-Xaa3-Cys-Cys-Met-Phe-# (SEQ ID NO:106) Name: Gm3.2 Species: gloriamaris Cloned: Yes DNA Sequence: GTTCATGATGTCTAAACTGGGAGTCTTGTTGATCATCTGTCTACTTCTGTTTCCCCTT ACTGCTGTTCCGCTGGATGGAGATCAACCTGCAGACCGATATGCAGAGCGTATGCA GGACGACATTTCATCTGAACATCATCCCATGTTTGATGCCGTCAGAGGGTGTTGCCA TCTGTTGGCATGCCGCTTCGGATGCTCGCCTTGTTGTTGGTGATCAGCTTTGTTATCG CGGCCTCATCAAGTGACTCTAATGCAAA (SEQ TD NO: 107) Translation: MMSKLGVLLIICLLLFPLTAVPLDGDQPADRYAERMQDDISSEHHPMFDAVRGCCHLLA CRFGCSPCCW (SEQ ID NO: 108) Toxin Sequence: Gly-Cys-Cys-His-Leu-Leu-Ala-Cys-Arg-Phe-Gly-Cys-Ser-Xaa3-Cys-Cys-Xaa4- Λ (SEQ ID NO: 109) Name: Gm3.3 Species: gloriamaris Cloned: Yes DNA Sequence: GAGACGACAAGGAACAGTCAACCCCACAGCCACGCCAAGAGCAGACAGCCACAGC TACGTGAAGAAGGGTGGAGAGAGGTTCGTGATGTTGAAAATGGGAGTGGTGCTATT CATCTTCCTGGTACTGTTTCCCCTGGCAACGCTCCAGCTGGATGCAGATCAACCTGT AGAACGATATGCGGAGAACAAACAGCTCCTCAACCCAGATGAAAGGAGGGAAATC ATATTGCATGCTCTGGGGACGCGATGCTGTTCTTGGGATGTGTGCGACCACCCGAGT TGTACTTGCTGCGGCGGTTAGCGCCGAACATCCATGGCGCTGTGCTGGGCGGTTTTA TCCAACAACGACAGCGTTTGTTGATTTCATGTATCATTGCGCCCACGTCTCTTGTCTA AGAATGACGAACATGATTGCACTCTGGTTCAGATTTCGTGTTCTTTTCTGACAATAA ATGACAAAACTCCAAAAAA (SEQ ID NO: 110) Translation: MLKMGVVLFIFLVLFPLATLQLDADQPVERYAENKQLLNPDERREIILHALGTRCCSWD VCDHPSCTCCGG (SEQ ID NO:lll) Toxin Sequence: Cys-Cys-Ser-Xaa4-Asp-Val-Cys-Asp-His-Xaa3-Ser-Cys-Thr-Cys-Cys-Gly-# (SEQ ID NO:l 12) Name: La3.1 Species: laterculatus Cloned: Yes DNA Sequence: CGACCTCAAGAAGGATCGATAGCAGTTCATGATGTCTAAACTGGGAGTCTTGTTGA CCATCTGTCTGCTTCTGTTTCCCCTTACTGCTCTTCCGATGGATGGAGATCAACCTGC AGACCGACCTGCAGAGCGTATGCAGGACGTTTCATCTGAACAGCATCCCTTGTATG ATCCCGTCAAACGGTGTTGCGACTGGCCATGCAGCGGATGCATCCCTTGTTGCTAAT AGTAACAACGTGTTGATAACCAACTTTCTTACCACGACTACGTCAAGTGTCTAATGA ATAAGTAAAATGATTGCAGT (SEQ ID NO: 113) Translation: MMSKLGVLLTICLLLFPLTALPMDGDQPADRPAERMQDVSSEQHPLYDPVKRCCDWPC SGCIPCC (SEQ ID NO: 114) Toxin Sequence: Cys-Cys-Asp-Xaa4-Xaa3-Cys-Ser-Gly-Cys-Ile-Xaa3-Cys-Cys- Λ (SEQ ID NO: 115) Name: La3.2 Species: laterculatus Cloned: Yes DNA Sequence: CGACCTCAAGAAGGATCGATAGCAGTTCATGATGTCTAAACTGGGAGTCTTGTTGA CCATCTGTCTGCTTCTGTTTCCCCTTACTGCTCTGGATGGAGATCAACCTGCAGACC GACTTGCAGAGCGTATGCAGGACGACATTTCATCTGAGCAGCATCCCTTTGAAAAG AGACGAGACTGTTGCACACCTCCGAAGAAATGCAGAGACCGACAATGCAAACCTGC ACGTTGTTGCGGAGGATAACGTGTTGATGACCAACTTTGTTATCACGGCTACGTCAA GTGTCTAGTGAATAAGTAAAACGATTGCAGT (SEQ ID NO: 116) Translation: MMSIOLGVLLTICLLLFPLTALDGDQPADP AERMQDDISSEQHPFEKRRDCCTPPKKCR DRQCKPARCCGG (SEQ ID NO:l 17) Toxin Sequence: Arg-Asp-Cys-Cys-Thr-Xaa3-Xaa3-Lys-Lys-Cys-Arg-Asp-Arg-Gln-Cys-Lys-Xaa3-Ala-Arg- Cys-Cys-Gly-# (SEQ ID NO:l 18) Name: La3.3 Species: laterculatus Cloned: Yes DNA Sequence: GGGATCGATAGCAGTTCATGATGTCTAAACTGGGAGTCTTGTTGACCATCTGTCTGC TTCTGTTTCCCCTTACTGCTCTTCCGATGGATGGAGATCAACTTGCACGCCGATCTGC AGAGCGTATGCAGGACAACATTTCATCTGAGCAGCATCACCTCTTTGAAAAGAGAC GACCACCATGTTGCACCTATGACGGGAGTTGCCTAAAAGAATCATGCATGCGTAAA GCTTGTTGCGGATGATAACGTGTTGATGACCAACTTTGTTATCACGGCTACTCAAGT GTCTAATGAATAAGTAAAATGATTGCAGTA (SEQ ID NO: 119) Translation: MMSKLGVLLTICLLLFPLTALPMDGDQLARRSAERMQDNISSEQHHLFEKRRPPCCTYD GSCLKESCMRKACCG (SEQ ID NO: 120) Toxin Sequence: Arg-Xaa3-Xaa3-Cys-Cys-Thr-Xaa5-Asp-Gly-Ser-Cys-Leu-Lys-Xaal-Ser-Cys-Met-Arg-Lys- Ala-Cys-Cys-# (SEQ ID NO: 121) Name: La3.3A Species: laterculatus Cloned: Yes DNA Sequence: GGGATCGATAGCAGTTCATGATGTCTAAACTGGGAGTCTTGTTGACCACCTGTCTGC TTCTGTTTCCCCTTACTGCTCTTCCGATGGATGGAGATCAACTTGCACGCCGACCTG CAGAGCGTATGCAGGACAACATTTCATCTGAGCAGCATCCCTTCTTTGAAAGGAGA CGACCACCATGTTGCACCTATGACGGGAGTTGCCTAAAAGAATCATGCAAGCGTAA AGCTTGTTGCGGATAATAACGTGTTGATGACCAACTTTGTTATCACGGCTACTCAAG TGTCTAATGAATAAGTAAAATGATTGCAGTA (SEQ ID NO: 122) Translation: MMSKLGVLLTTCLLLFPLTALPMDGDQLARRPAERMQDNISSEQHPFFERRRPPCCTYD GSCLKESCKRKACCG (SEQ ID NO: 123) Toxin Sequence: Arg-Xaa3-Xaa3-Cys-Cys-Thr-Xaa5-Asp-Gly-Ser-Cys-Leu-Lys-Xaal-Ser-Cys-Lys-Arg-Lys- Ala-Cys-Cys-# (SEQ ID NO: 124) Name: Lp3.1 Species: leopardus Cloned: Yes DNA Sequence: GGATCCATGATGTCTAAACTGGGAGTCTTGTTGACCGTCTGTCTGCTTCTGTTTCCCC TTACTGCTCTTCGGCTGGTTGGAGATCAACCTGCAGAGCGACCTGCAAAGCGTACGC AGGACGACATTCCAGATGGACAGCATCCGTTAAATGATAGGCAGATAAACTGTTGC CCGTGGCCATGCCCTAGTACATGCCGCCATCAATGCTGCCATTAATGATAACGTGTT GATGACCAACTTTCTCGAG (SEQ ID NO: 125) Translation: GSMMSKLGVLLTVCLLLFPLTALRLVGDQPAERPAKRTQDDIPDGQHPLNDRQINCCP WPCPSTCRHQCCH (SEQ ID NO: 126) Toxin Sequence: Xaa2-Ile-Asn-Cys-Cys-Xaa3-Xaa4-Xaa3-Cys-Xaa3-Ser-Thr-Cys-Arg-His-Gln-Cys-Cys-His- A (SEQ ID NO: 127) Name: Lv3.1 Species: lividus Cloned: Yes DNA Sequence: GGATCCATGATGTCTAAACTGGGAGTCTTGTTGACCGTCTGTCTGCTTCTGTTTCCCC TTACTGCTCTTCGGCTGGTTAGAGATCAACCTGCAGAGCGACCTGCAAAGCGTACGC AGGACGACATTCCAAATGGACAGGATCCGTTAATTGATAGGCAGATAAATTGTTGC CCTTGGCCATGCCCTGATTCATGCCACTATCAATGCTGCCACTGATAACGTGTTGAT GACCAACTTTCTCGAG (SEQ ID NO: 128) Translation: GSMMSKLGVLLTVCLLLFPLTALRLVRDQPAERPAKRTQDDIPNGQDPLIDRQINCCPW PCPDSCHYQCCH (SEQ ID NO: 129) Toxin Sequence: Xaa2-Ile-Asn-Cys-Cys-Xaa3-Xaa4-Xaa3-Cys-Xaa3-Asp-Ser-Cys-His-Xaa5-Gln-Cys-Cys-His- Λ (SEQ ID NO:130) Name: L3.1 Species: lynceus Cloned: Yes DNA Sequence: AAGGATCGATAGCAGTTCATGATGTCTAAACTGGGAGTCTTGTTGACCATCTGTCTG CTTCTGTTTCCCCTTACTGCTCTTCCGATGGATGGAGATCAATCTGCAGACCGACTTG CAGAGCGTATGCAGGACAACATTTCATCTGAGCAGCATCCCTTCTTTGAAAAGAGA GGACGAGACTGTTGCACACCTCCGAGGAAATGCAGAGACCGAGCCTGCAAACCTCA ACGTTGTTGCGGAGGATAAGCTGTTGATGACCAACTTTGTTATACGGC (SEQ ID NO: 131) Translation: MMSKLGVLLTICLLLFPLTALPMDGDQSADRLAERMQDNISSEQHPFFEKRGRDCCTPP RKCRDRACKPQRCCGG (SEQ ID NO: 132) Toxin Sequence: Gly-Arg-Asp-Cys-Cys-Thr-Xaa3-Xaa3-Arg-Lys-Cys-Arg-Asp-Arg-Ala-Cys-Lys-Xaa3-Gln- Arg-Cys-Cys-Gly-# (SEQ ID NO: 133) Name: M3.1 Species: magus Cloned: Yes DNA Sequence: CAAGAGGGATCGATAGCAGTTCATGATGTCTAAACTGGGAGTCTTGTTGACCATCTG TCTGCTTCTGTTTCCCCTTACTGCTCTTCCGATGGATGGAGATGAACCTGCAAACCG ACCTGTCGAGCGTATGCAGGACAACATTTCATCTGAGCAGTATCCCTTGTTTGAGAA GAGACGAGATTGTTGCACTCCGCCGAAGAAATGCAAAGACCGACAATGCAAACCCC AGAGATGTTGCGCTGGACGATAACGTGTTGATGACCAACTTTATCACGGCTACGTCA AGTGTTTAGTGAATAAGTAAAATGATTGCAGTCTTGCTCAGATTTGCTTTTGTGTTTT GGTCTAAAGATCAATGACCAAACCGTTGTTTTGATGCGGATTGTCATATATTTCTCG ATTCCAATCCAACACTAGATGATTTAATCACGATAGATTAATTTTCTATCAATGCCT TGATTTTTCGTCTGTCATATCAGTTTTGTTTATATTTATTTTTTCGTCACTGTCTACAC AAACGCATGCATGCACGCATGCACGCACACACGCACGCACGCTCGCACAAACATGC GCGCGCACGCACACACACACACACACACACAAACACACACACGAAGCAATCACAC AATTAGTTGACATTATTTATTTATTCATTGATGTATTTGTTATTCGTTTGCTTGTTTTT AGAATAGTTTGAGGCCGTCTTTTTGGATTTATTTGAACTGCTTTATTGTATACGAGTA CTTCGTGCGGGGAAAC ACTGCTGAAAAT AAAACAAAC ACTGACGTAGCAAAAAAA AAAAA (SEQ ID NO: 134) Translation: MMSKLGNLLTICLLLFPLTALPMDGDEPANRPNERMQDNISSEQYPLFEKRRDCCTPPK KCKDRQCKPQRCCAGR (SEQ ID NO: 135) Toxin Sequence: Arg-Asp-Cys-Cys-Thr-Xaa3-Xaa3-Lys-Lys-Cys-Lys-Asp-Arg-Gln-Cys-Lys-Xaa3-Gln-Arg- Cys-Cys-Ala-# (SEQ ID NO:136) Name: M3.2 Species: magus Cloned: Yes DNA Sequence: CAAGAGGGATCGATAGCAGTTCATGATGTCTAAACTGGGAGTCTTGTTGACCATCTG TCTGCTTCTGTTTCCCCTTACTGCTCTTCCAATGGATGGAGATCAACCTGCAGACCA ACCTGCAGATCGTATGCAGGACGACATTTCATCTGAGCAGTATCCCTTGTTTGATAT GAGAAAAAGGTGTTGCGGCCCCGGCGGTTCATGCCCCGTATATTTCAGAGACAATT TTATTTGTGGTTGTTGTTAAATGACAACGTGTCGATGACCAACTTCATTATCACGAC TACGCCAAGTGTCTAATGAATAAATAAAATGATTGCAGTCTCGCTCAGATTTGCTTT TGTATTTTGGTCTAAAGATCAATGACCAAACCGTTGTTTTGGTGTGGATTTTCATATA TTTCTCGAGTCCTATCCAACACTAGATGATTTAATCACGATAGATCTGATTTTTTTAT CAAAGGCTTGGTTTTTCGTCTGTCACATCAGTTTTGTTTATATTTAATTTTTCGTCACT GATTACACACACGCATGAACGCACAGAGTACTAACACATACACACACACACACACA CACACACACACACACACACACACACACACACACACACACACGCGCGCGCGCGGCG CCATCTAGTAGCGCCGCGACGACACACAC (SEQ TD NO:137) Translation: MMSKLGVLLTICLLLFPLTALPMDGDQPADQPADRMQDDISSEQYPLFDMRKRCCGPG GSCPVYFRDNFICGCC (SEQ ID NO:138) Toxin Sequence: Cys-Cys-Gly-Xaa3-Gly-Gly-Ser-Cys-Xaa3-Val-Xaa5-Phe-Arg-Asp-Asn-Phe-Ile-Cys-Gly-Cys- Cys- Λ (SEQ ID NO:139) Name: M3.3 Species: magus Cloned: Yes DNA Sequence: CAAGAGGGATCGATAGCAGTTCATGATGTCTAAACTGGGAGTCTTGTTGACCATCTG TTTGCTTCTGTTTCCCCTTACTGCTCTTCCGAGGGATGGAGATCAATCTGTAGACCGA CCTGCAGAGCGTATGCAGGACGACATTTCATCTGAGCTGCATCCCTTGTCAATCAGA AAAAGAATGTGTTGCGGCGAGAGTGCGCCATGCCCCAGCTATTTCAGAAACAGTCA GATTTGTCATTGTTGTTAAATGACAACGTGTCGATGACCACCTTCGTTATCACGACT AATGATAAGTAAAATGATTGCAGTCTCGCTCAGATTTGCTTTTGTATTTTGGTCTAA AGATCAATGACCAAACCGTTGTTTTGATGTGGATTTTCATATATTTCTCGAGTCCTAT CCAACACTAGATGATTTAATCACGATAGATCTGATTTTTTTATCAAAGCCTTGGTTTT TCGTCTGTCACATCAGTTTTGTTTATATTTAATTTTTCGTCACTGATTACACACACGC ATGAACGCACAGACGTACTAACACATACACACACACACACACACACACACACACAC ACACACACACACACACACACAC (SEQ ID NO: 140) Translation: MMSKLGVLLTICLLLFPLTALPRDGDQSVDRPAERMQDDISSELHPLSIRKRMCCGESAP CPSYFRNSQICHCC (SEQ ID NO: 141) Toxin Sequence: Met-Cys-Cys-Gly-Xaal-Ser-Ala-Xaa3-Cys-Xaa3-Ser-Xaa5-Phe-Arg-Asn-Ser-Ghι-Ile-Cys-His- Cys-Cys- A (SEQ ID NO: 142) Name: M3.4 Species: magus Cloned: Yes DNA Sequence: CAAGAGGGATCGATAGCAGTTCATGATGTCTAAACTGGGAGTCTTGTTGACCATCTG TCTGCTTCTGTTTCCCCTTACTGCTCTTCCAATGGATGGAGATCAACCTGCAGACCA ACCTGCAGATCGTATGCAGGACGACATTTCATCTGAGCAGTATCCCTTGTTTGATAA GAGACAAAAGTGTTGCGGCCCCGGCGGTTCATGCCCCGTATATTTCACAGACAATTT TATTTGTGGTTGTTGTTAAATGACAACGTGTCGATGACCAACTTCATTATCACGACT ACGCCAAGTGTCTAATGAATAAATAAAATGATTGCAGTCTCGCTCAGATTTGCTTTT GTATTTGGTCTAAAGATCAATGACCAAACCGTTGTTTTGGTGCTGGATTTTCATATA TTTCTCGATTCCTATCCAACACTAGATGATTTAATCACGATAGATCTGATTTTTTTAT CAATGCCTTAATTTTTTGCTCTGTCATATCAGTTTTGTTTATAT (SEQ ID NO: 143) Translation: MMSKLGVLLTICLLLFPLTALPMDGDQPADQPADRMQDDISSEQYPLFDKRQKCCGPG GSCPVYFTDNFICGCC (SEQ ID NO: 144) Toxin Sequence: Xaa2-Lys-Cys-Cys-Gly-Xaa3-Gly-Gly-Ser-Cys-Xaa3-Val-Xaa5-Phe-Thr-Asp-Asn-Phe-Ile-Cys- Gly-Cys-Cys- Λ (SEQ ID NO: 145) Name: M3.5 Species: magus Cloned: Yes DNA Sequence: CAAGAGGGATCGATAGCAGTTCATGATGTCTAAACTGGGAGTCTTGTTGACCATCTG TCTGCTTCTGTTTCCCCTTACTGCTCTTCCAATGGATGGAGATCAACCTGCAGACCA ACCTGCAGATCGTATGCAGGACGACATTTCATCTGAGCAGTATCCCTTGTTTGATAA GAGACAAAAGTGTTGCGGCCCCGGCGGTTCATGCCCCGTATATTTCAGAGACAATTT TATTTGTGGTTGTTGTTAAATGACAACGTGTCGATGACCATCTTCATTATCACGACT ACGCCAAGTGTCTAATGAATAAATAAAATGATTGCAGTCTCGCTCAGATTTGCTTTT GTATTTTGGTCTAAAGATCAATGACCAAACCGTTGTTTTGGTGTGGATTTTCATATAT TTCTCGATTCCTATCCAACACTAGATGATTTAATCACGATAGATCTGATTTTTT (SEQ ID NO: 146) Translation: MMSKLGVLLTICLLLFPLTALPMDGDQPADQPADRMQDDISSEQYPLFDKRQKCCGPG GSCPVYFRDNFICGCC (SEQ ID NO: 147) Toxin Sequence: Xaa2-Lys-Cys-Cys-Gly-Xaa3-Gly-Gly-Ser-Cys-Xaa3-Val-Xaa5-Phe-Arg-Asp-Asn-Phe-Ile- Cys-Gly-Cys-Cys- Λ (SEQ ID NO: 148) Name: U001 Species: magus Isolated: No Toxin Sequence: Xaa2-Lys-Cys-Cys-Ser-Gly-Gly-Ser-Cys-Xaa3-Leu-Xaa5-Phe-Arg-Asp-Arg-Leu-Ile-Cys-Xaa3- Cys-Cys- A (SEQ ID NO: 149) Name: Comatose/Death Species: marmoreus Isolated: Yes Toxin Sequence: Ser-Lys-Gln-Cys-Cys-His-Leu-Ala-Ala-Cys-Arg-Phe-Gly-Cys-Thr-Xaa3-Cys-Cys-Asn- (SEQ ID NO:150) Name: Mr3.1 Species: marmoreus Cloned: Yes DNA Sequence: CAAGAAGGATCGATAGCAGTTCATGATGTCTAAACTGGGAGTCTTGTTGACCATCTG TCTGCTTCTGTTTCCCGTTACTGCTCTTCCGATGGATGGTGATCAACCTGCAGACCGA CTTGTAGAGCGTATGCAGGACAACATTTCATCTGAGCAGCATCCCTTCTTTGAAAAG AGAAGAGGAGGCTGTTGCACACCTCCGAGGAAATGCAAAGACCGAGCCTGCAAAC CTGCACGTTGCTGCGGCCCAGGATAACGTGTTGATGACCAACTTTGTTATCACGGCT ACGTCAAGTGTCTAGTGAATAAGTAAAACGATTGCAG (SEQ ID NO: 151) Translation: MMSKLGVLLTICLLLFPVTALPMDGDQPADRLVERMQDNISSEQHPFFEKRRGGCCTPP RKCKDRACKPARCCGPG (SEQ ID NO: 152) Toxin Sequence: Arg-Gly-Gly-Cys-Cys-Thr-Xaa3-Xaa3-Arg-Lys-Cys-Lys-Asρ-Arg-Ala-Cys-Lys-Xaa3-Ala-Arg- Cys-Cys-Gly-Xaa3-# (SEQ ID NO: 153) Name: Mr3.2 Species: marmoreus Cloned: Yes DNA Sequence: GAGCTCGGTACCCCGACCTCAAGAGGGATCGATAGCAGTTCATGATGTCTAAACTG GGAATCTTGTTGACCATCTGTCTACTTCTATTTCCCCTTACTGCTGTTCCGCTGGATG GAGATCAACCTGCAGACCGACCTGCAGAGCGTATGCAGGACGACATTTCATCTGAA CATCATCCCTTTTTTGATCCCGTCAAACGGTGTTGCAGGTTATCATGCGGCCTGGGA TGCCACCCTTGTTGTGGATGACCAGCTTTGTTATCGCGGCCTCATCAAGTGTCTAAT GAATAAGTAAAA (SEQ ID NO:154) Translation: MMS_KLGILLTICLLLFPLTAVPLDGDQPADRPAERMQDDISSEHHPFFDPVKRCCRLSCG LGCHPCCG (SEQ ID NO: 155) Toxin Sequence: Cys-Cys-Arg-Leu-Ser-Cys-Gly-Leu-Gly-Cys-His-Xaa3-Cys-Cys-# (SEQ ID NO: 156) Name: Mr3.3 Species: marmoreus Cloned: Yes DNA Sequence: GGCCTACACCAAGCTTGCATGCCTGCAGGTCGACTCTAGAGGATCCCCGATCGATA GCAGTTCATGATGTCTAGACTGGGAGTCTTGTTGACCATCTGTCTACTTCTGTTTCCC CTTACTGCTGTTCCGCTGGATGGAGATCAACCTGCGGACCGACCTGCAGAGCGCCTG CAGGACGACATTTCATCTGAACATCATCCCCATTTTGATTCCGGCAGAGAGTGTTGC GGTTCGTTCGCATGCCGCTTTGGATGCGTGCCTTGTTGTGTATGACCAGCTTTGTTAT CACGGCCTCATCGAGTGTCTAATGAATAAGTAAAACGATTGCAGTAGGCGGGTACC GAGCTCGAATTCC (SEQ ID NO: 157) Translation: MMSRLGVLLTICLLLFPLTAVPLDGDQPADRPAERLQDDISSEHHPHFDSGRECCGSFAC RFGCVPCCV (SEQ ID NO:158) Toxin Sequence: Xaal -Cys-Cys-Gly-Ser-Phe-Ala-Cys-Arg-Phe-Gly-Cys-Val-Xaa3-Cys-Cys-Val- A (SEQ ID NO: 159) Name: Mr3.4 Species: marmoreus Cloned: Yes DNA Sequence: CGACCTCAAGAGGGATCGATAGCAGTTCATGATGTCTAAACTGGGAGTCTTGTTGA CCATCTGTCTACTTCTATTTCCCCTTACTGCTGTTCCGCTGGATGGAGACCAACCTGC AGACCGACCTGCAGAGCGTATGCAGGACGACATTTCATCTGAACGTCATCCTTTTTT TGATCGCAGCAAACAGTGTTGCCATCTGCCGGCATGCCGCTTCGGATGTACGCCTTG TTGTTGGTGATCAGCTTTGTTATCGCGTCCTCATCAAGTGTCTAATGAATAAGTAAA ATGATTGCAG (SEQ ID NO:160) Translation: MMSKLGVLLTICLLLFPLTAVPLDGDQPADRPAERMQDDISSERHPFFDRSKQCCHLPA CRFGCTPCCW (SEQ ID NO: 161) Toxin Sequence: Ser-Lys-Gln-Cys-Cys-His-Leu-Xaa3-Ala-Cys-Arg-Phe-Gly-Cys-Thr-Xaa3-Cys-Cys-Xaa4- Λ (SEQ ID NO: 162) Name: Mr3.5 Species: marmoreus Cloned: Yes DNA Sequence: GGATCCATGATGTCTAAACTGGGAGTCTTGTTGACCATCTGTCTGCTTCTGTTTCCCC TTACTGCTCTTCCGCTGGATGGAGATCAACCTGCAGACCAACGTGCAGAGCGTACG CAGGCCGAGAAGCATTCCTTGCCTGATCCGAGAATGGGCTGTTGCCCGTTTCCATGC AAAACCAGTTGCACTACTTTGTGTTGCGGGTGATGATAACGTGTTGATGACCAACTT TCTCGAG (SEQ ID NO: 163) Translation: GSMMSKLGVLLTICLLLFPLTALPLDGDQPADQRAERTQAEKHSLPDPRMGCCPFPCKT SCTTLCCG (SEQ ID NO: 164) Toxin Sequence: Met-Gly-Cys-Cys-Xaa3-Phe-Xaa3-Cys-Lys-Thr-Ser-Cys-Thr-Tlιr-Leu-Cys-Cys-# (SEQ ID NO: 165) Name: U014 Species: marmoreus Isolated: Yes Toxin Sequence: Cys-Cys-His-Xaa4-Asn-Xaa4-Cys-Asp-His-Leu-Cys-Ser-Cys-Cys-Gly-Ser- Λ (SEQ ID NO: 166) Name: U017 Species: marmoreus Cloned: Yes DNA Sequence: GCCAAGCTTGCATGCCTGCAGGATGACTCTAGAGGATCCCCACCTCAAGAGGGATC GATAGCAGTTCATGATGTCTAAACTGGGAGTCTTGTTGACCATCTGTCTACTTCTGTT TGCCCTTACTGCTGTTCCGCTGGATGGAGATCAACCTGCAGACCGACCTGCAGAACG TATGCAGGACGACATTTCATCTGAACGTCATCCCATGTTTGATGCCGTCAGAGATTG TTGCCCGTTGCCGGCATGCCCCTTTGGATGCAACCCTTGTTGTGGATGACCAGCTTT GTTATCGGGACCTCATCAAGTGTCTAATGAATAAGTAAAAAACGATTCGAGTGGGT ACCGAGCTCGAATTCC (SEQ ID NO: 167) Translation: MMSKLGVLLTICLLLFALTAVPLDGDQPADRPAERMQDDISSERHPMFDAVRDCCPLP ACPFGCNPCCG (SEQ ID NO: 168) Toxin Sequence: Asρ-Cys-Cys-Xaa3-Leu-Xaa3-Ala-Cys-Xaa3-Phe-Gly-Cys-Asn-Xaa3-Cys-Cys-# (SEQ ID NO: 169) Name: U019 Species: marmoreus Isolated: Yes Toxin Sequence: Cys-Cys-Ala-Xaa3-Ser-Ala-Cys-Arg-Leu-Gly-Cys-Arg-Xaa3-Cys-Cys-Arg- Λ (SEQ ID NO: 170) Name: U020 Species: marmoreus Isolated: Yes Toxin Sequence: Cys-Cys-Ala-Xaa3-Ser-Ala-Cys-Arg-Leu-Gly-Cys-Arg-Xaa3-Cys-Cys-Arg- A (SEQ ID NO: 171) Name: U022 Species: marmoreus Isolated: Yes Toxin Sequence: Cys-Cys-Ala-Xaa3-Ser-Ala-Cys-Arg-Leu-Gly-Cys-Arg-Xaa3-Cys-Cys-Arg- Λ (SEQ ID NO: 172) Name: U024 Species: marmoreus Isolated: Yes Toxin Sequence: Gly-Cys-Cys-Gly-Ser-Phe-Ala-Cys-Arg-Phe-Gly-Cys-Val-Xaa3-Cys-Cys-Val- Λ (SEQ ID NO: 173) Name: Nb3.1 Species: nobilis Cloned: Yes DNA Sequence: GGATCCATGATGTCTAAACTGGGAGTCTTGTTGACCATCTGTCTACTTCTGTTTCCCC TTACTGCTCTTCCGCTGGATGAAGATCAACCGGTACACCGACCTGCAGAGCGTATGC AGGACATTTCATCTGATCAACATCTCTTCTTTGATCTCATCAAACGGTGCTGCGAGT TGCCATGCGGGCCAGGCTTTTGCGTCCCTTGTTGCTGACATCAATAACGTGTTGATG ACCAACTTTCTCGAG (SEQ ID NO: 174) Translation: GSMMSKLGVLLTICLLLFPLTALPLDEDQPVHRPAERMQDISSDQHLFFDLIKRCCELPC GPGFCVPCC (SEQ ID NO: 175) Toxin Sequence: Cys-Cys-Xaal-Leu-Xaa3-Cys-Gly-Xaa3-Gly-Phe-Cys-Val-Xaa3-Cys-Cys- Λ (SEQ ID NO: 176) Name: Nb3.2 Species: nobilis Cloned: Yes DNA Sequence: GGATCCATGATGTCTAAACTGGGAGTCTTGTTGACCATCTGTCTACTTCTGTTTCCCC TTACTGCTTTTCCGATGGATGGAGATCAACCTGCAGACCAACCTGCAGATCGTATGC AGGACGACATTTCATCTGAGCAGTATCCCTTGTTTGATAAGAGACAAAAGTGTTGCA CTGGGAAGAAGGGGTCATGCTCCGGCAAAGCATGCAAAAATCTCAAATGTTGCTCT GGACGATAACGTGTTGATGACCAACTTTCTCGAG (SEQ ID NO: 177) Translation: GSMMSKLGVLLTICLLLFPLTAFPMDGDQPADQPADRMQDDISSEQYPLFDKRQKCCT GKKGSCSGKACKNLKCCSGR (SEQ ID NO: 178) Toxin Sequence: Xaa2-Lys-Cys-Cys-Thr-Gly-Lys-Lys-Gly-Ser-Cys-Ser-Gly-Lys-Ala-Cys-Lys-Asn-Leu-Lys- Cys-Cys-Ser-# (SEQ ID NO:179) Name: Pu3.1 Species: pulicarius Cloned: Yes DNA Sequence: GGATCCATGATGTCTAAACTGGGAGTTTTGTTGACCATCTGTCTGCTTCTGTTTCCCC TTACTGCTGTTCCGCTGGATGGAGATCAACCTGCAGACCGACCTGCAGAGCGTATGC AGGACATTGCAACTGAACAGCATCCCTTCTTTGATCCCGTCAAACGGTGTTGCAACA GCTGTTACATGGGATGCATCCCTTGTTGCTTCTAGTAATAACGTGTTGATGACCAAC TTTCTCGAG (SEQ TD NO: 180) Translation: GSMMSKLGVLLTICLLLFPLTAVPLDGDQPADRPAERMQDIATEQHPFFDPVKRCCNSC YMGCIPCCF (SEQ ID NO: 181) Toxin Sequence: Cys-Cys-Asn-Ser-Cys-Xaa5-Met-Gly-Cys-Ile-Xaa3-Cys-Cys-Phe- Λ (SEQ ID NO: 182) Name: Qc3.1 Species: quercinus Cloned: Yes DNA Sequence: GGATCCATGATGTCTAAACTGGGAGTCTTGTTGACCATCTGTCTGCTTCTGTTTCCCC TTACAGCTCTTCAGCTGGATGGAGATCAACCTGCAGACCGACCTGCAGAGCGTACG CAGGACATTGCATCTGAACAGTATCGAAAGTTTGATCAGAGACAGAGGTGTTGCCA GTGGCCATGCCCCGGTAGTTGCAGATGCTGCCGTACTGGTTAACGTGTTGATGACCA ACTTTCTCGAG (SEQ ID NO: 183) Translation: GSMMSKLGVLLTICLLLFPLTALQLDGDQPADRPAERTQDIASEQYRKFDQRQRCCQW PCPGSCRCCRTG (SEQ ID NO: 184) Toxin Sequence: Xaa2-Arg-Cys-Cys-Gln-Xaa4-Xaa3-Cys-Xaa3-Gly-Ser-Cys-Arg-Cys-Cys-Arg-Thr-# (SEQ ID NO: 185) Name: QcIIIA Species: quercinus Isolated: Yes Toxin Sequence: Cys-Cys-Ser-Gln-Asp-Cys-Leu-Val-Cys-Ile-Xaa3-Cys-Cys-Xaa3-Asn-# (SEQ ID NO: 186) Name: QcIIIB Species: quercinus Isolated: Yes Toxin Sequence: Cys-Cys-Ser-Arg-His-Cys-Xaa4-Val-Cys-Ile-Xaa3-Cys-Cys-Xaa3-Asn-? (SEQ ID NO: 187) Name: R3.1 Species: radiatus Isolated: Yes Cloned: Yes DNA Sequence: TCAAGAAGGATCGATAGCAGTTCATGATGTCTAAACTGGGAGTCTTGTTGACCATCT GTCTGCTTCTGTTTCCCCTTACTGCTCTTCCGATGGATGGAGATCAACCTGTAGACCG ACTTGCAGAGCGTATGCAGGACAACATTTCATCTGAGCAGCATACCTTCTTTGAAAA GAGACTACCATCGTGTTGCTCCCTTAACTTGCGGCTTTGCCCAGTACCAGCATGCAA ACGTAACCCTTGTTGCACAGGATAACGTGTTGATGACCAACTTTGTTATCACGGCTA CGTCAAGTGTCTAGTGAATAAGTAAAACGATTGCAGT (SEQ ID NO: 188) Translation: MMSKLGVLLTICLLLFPLTALPMDGDQPVDRLAERMQDNISSEQHTFFEKRLPSCCSLN LRLCPVPACKRNPCCTG (SEQ ID NO: 189) Toxin Sequence: Leu-Xaa3-Ser-Cys-Cys-Ser-Leu-Asn-Leu-Arg-Leu-Cys-Xaa3-Val-Xaa3-Ala-Cys-Lys-Arg-Asn- Xaa3-Cys-Cys-Thr-# (SEQ ID NO: 190) Name: R3.2 Species: radiatus Cloned: Yes DNA Sequence: AGGTCGACTCTAGAGGATCCCCAAGGATCGATAGCAGTTCATGATGTCTAAACTGG GAGTCTTGTTGACCATCTGTCTGCTTCTGTTTCCCCTTACTGCTCTTCCGATGGATGG AGATCAACCTGCAGACCGACTTGCAGAGCGTATGCAGGACGACATTTCATCTGAGC AGCATCCCTTCTTTAAAAAGAGACAACAAAGATGTTGCACCGTTAAGAGGATTTGT CCAGTACCAGCATGCAGAAGTAAACCTTGTTGCAAATCATAACGTATTGATGACCA ACTTTGTTATCACGGCTACGTCAAGTGTCTAGTGAATAAGTAAAATGATTGCAG (SEQ ID NO: 191) Translation: MMSKLGVLLTICLLLFPLTALPMDGDQPADRLAERMQDDISSEQHPFFKKRQQRCCTV KRICPVPACRSKPCCKS (SEQ ID NO: 192) Toxin Sequence: Xaa2-Gln-Arg-Cys-Cys-Thr-Val-Lys-Arg-Ile-Cys-Xaa3-Val-Xaa3-Ala-Cys-Arg-Ser-Lys-Xaa3- Cys-Cys-Lys-Ser- Λ (SEQ ID NO: 193) Name: R3.3 Species: radiatus Cloned: Yes DNA Sequence: ACCTCAAGAAGGATCGATAGCAGTTCATGATGTCTAAACTGGGAGTCTTGTTGACC ATCTGTCTGCTTCTGTTTCCCGTTACTGCTCTTCCGATGGATGGTGATCAACCTGCAG ACCGACTTGTAGAGCGTATGCAGGACAACATTTCATCTGAGCAGCATCCCTTCTTTG AAAAGAGAAGAGGAGGCTGTTGCACACCTCCGAGGAAATGCAAAGACCGAGCCTG CAAACCTGCACGTTGCTGCGGCCCAGGATAACGTGTTGATGACCAACTTTGTTATCA CGGCTACGTCAAGTGTCTAGTGAATAAGTAAAACGATTGCAGT (SEQ ID NO: 194) Translation: MMSKLGVLLTICLLLFPVTALPMDGDQPADRLVERMQDNISSEQHPFFEKRRGGCCTPP RKCKDRACKPARCCGPG (SEQ ID NO: 195) Toxin Sequence: Arg-Gly-Gly-Cys-Cys-Thr-Xaa3-Xaa3-Arg-Lys-Cys-Lys-Asρ-Arg-Ala-Cys-Lys-Xaa3-Ala-Arg- Cys-Cys-Gly-Xaa3-# (SEQ ID NO: 196) Name: Ra3.1 Species: rattus Cloned: Yes DNA Sequence: GGATCCATGATGTCTAAACTGGGAGTCTTGGTGACCATCTGCCTGCTTCTGTTCCCT CTTGCTGCTTTTCCACTGGATGGAGATCAACCTGCAGACCACCCTGCAAAGCGTACG CAAGATGACAGTTCAGCTGCCCTGATCAATGCCTGGCTTGATGAATCCCAGACTTGC TGCAGTAACTGCGGTGAAGATTGTGATGGTTGTTGCCAGTAACGTGTTGATGACCAA CTTTCTCGAG (SEQ ID NO: 197) Translation: GSMMSKLGNLVTICLLLFPLAAFPLDGDQPADHPAKRTQDDSSAALINAWLDESQTCCS NCGEDCDGCCQ (SEQ ID NO:198) Toxin Sequence: Xaa2-Thr-Cys-Cys-Ser-Asn-Cys-Gly-Xaal -Asp-Cys-Asp-Gly-Cys-Cys-Gln- Λ (SEQ ID NO: 199) Name: Sm3.1 Species: stercusmuscarum Cloned: Yes DNA Sequence: GACCTCAAGAGGGATCGATAGCAGTTCGTGATGTCTAAACTGGGAGTCTTGTTGAC CATCTGTCTGCTTCTGTTTCCTCTTACTGCTCTTCCGATGGATGGAGATCAACCTGCA GACCAACCTGCAGATCGTATGCAGGACGACATTTCATCTGAGCAGTATCCCTTGTTT GATAAGAGACAAAAGTGTTGCACTGGGAAGAAGGGGTCATGCTCCGGCAAAGCAT GCAAAAATCTCAAATGTTGCTCTGGACGATAACGTGTTGATGACCAACTTTGTTATC ACGGCTACGTCAAGTGTCTAATGAATAAGTAAAACGATTGCAGT (SEQ ID NO:200) Translation: MSKLGVLLTICLLLFPLTALPMDGDQPADQPADRMQDDISSEQYPLFDKRQKCCTGKK GSCSGKACKNLKCCSGR (SEQ ID NO:201) Toxin Sequence: Xaa2-Lys-Cys-Cys-Thr-Gly-Lys-Lys-Gly-Ser-Cys-Ser-Gly-Lys-Ala-Cys-Lys-Asn-Leu-Lys- Cys-Cys-Ser-# (SEQ ID NO:202) Name: U034 Species: stercusmuscarum Isolated: Yes Cloned: Yes DNA Sequence: GATCGATAGCAGTTCGTGATGTCTAAACTGGGAGTCTTGTTGACCATCTGTCTGCTT CTGTTTCCCCTTACTGCTCTTCCGATGGATGGAGATCAACCTGCAGACCAACCTGCA GATCGTATGCAGAACGACATTTCATCTGAGCAGTATCCCTTGTTTGATAAGAGACAA AAGTGTTGCGGCCCCGGCGCGTCATGCCCCAGATATTTCAAAGACAATTTTATTTGT GGTTGTTGTTAAATGACAACGTGTCGATGACCAACTTCGTTATCACGACTTCGCCAA GTGTCTAATGAATAAGTAAAACGATTGCAGT (SEQ ID NO:203) Translation: MSKLGVLLTICLLLFPLTALPMDGDQPADQPADRMQNDISSEQYPLFDKRQKCCGPGAS CPRYFKDNFICGCC (SEQ ID NO:204) Toxin Sequence: Xaa2-Lys-Cys-Cys-Gly-Xaa3-Gly-Ala-Ser-Cys-Xaa3-Arg-Xaa5-Phe-Lys-Asρ-Asn-Phe-Ile- Cys-Gly-Cys-Cys- Λ (SEQ ID NO:205) Name: S3.1 Species: striatus Cloned: Yes DNA Sequence: CGACCTTTCAAGAGGGATCGATAGCAGTTCGCGATGTCTAAACTGGGGGTATTGTTG ACCATCTGTCTGCTTCTGTTTCCCCTTACTGCTCTTCCGATGGATGAAGATCAACCTG CAGACCAACTTGAAGATCGTATGCAGGACGACATTTCATCTGAGCAGTATCCCTCGT TTGTTAGGAGACAAAAGTGTTGCGGCGAAGGCTCGTCATGCCCCAAATATTTCAAA AACAATTTTATTTGTGGTTGTTGTTAAATGACAACGTGTCGATGACCAACTTCGTTA TCACGACTACGCCAAGTGTCTTGTCTAATGATAATAAAATGATTCC (SEQ ID NO:206) Translation: MSKLGVLLTICLLLFPLTALPMDEDQPADQLEDRMQDDISSEQYPSFVRRQKCCGEGSS CPKYFKNNFICGCC (SEQ ID NO:207) Toxin Sequence: Xaa2-Lys-Cys-Cys-Gly-Xaal-Gly-Ser-Ser-Cys-Xaa3-Lys-Xaa5-Phe-Lys-Asn-Asn-Phe-Ile-Cys- Gly-Cys-Cys- A (SEQ ID NO:208) Name: S3.2 Species: striatus Cloned: Yes DNA Sequence: GGATCCATGATGTCTAAACTGGGAGTCTTGTTGACCGTCTGTCTGCTTCTGTTTCCCC TTACTGCTCTTCCGCTGGATGGAGATCAACCTGCAGACCGACCTGCAGAGCGTATGC AGGACGACATTTCATCTGACGAGCATCCCTTGTTTGATAAGAGACAAAACTGTTGCA ATGGGGGATGCTCCAGCAAATGGTGCAGAGATCACGCACGTTGTTGCGGTCGATGA TAACGTGTTGATGACCAACTTTCTCGAG (SEQ ID NO:209) Translation: GSMMSKLGVLLTVCLLLFPLTALPLDGDQPADRPAERMQDDISSDEHPLFDKRQNCCN GGCSSKWCRDHARCCGR (SEQ ID NO:210) Toxin Sequence: Xaa2-Asn-Cys-Cys-Asn-Gly-Gly-Cys-Ser-Ser-Lys-Xaa4-Cys-Arg-Asp-His-Ala-Arg-Cys-Cys-# (SEQ ID NO.211) Name: Ts3.1 Species: tessulatus Cloned: Yes DNA Sequence: GGATCCATGATGTCTAAACTGGGAGTCTTGTTGACCATGTGTCTGCTTCTGTTTCCCC TTACTGCTGTTCCGCTGGATGGAGATCAACCTGCAGACCGACCTGCAGAGCGTAGG CAGGACATTGCAACTGACGATCATCCTTTGTTTGATCCCGTCAAACGGTGCTGCCAC AAATGCTATATGGGATGCATCCCTTGTTGCATTTAGTAACGTGTTGATGACCAACTT TCTCGAG (SEQ ID NO:212) Translation: GSMMSKLGVLLTMCLLLFPLTAVPLDGDQPADRPAERRQDIATDDHPLFDPVKRCCHK CYMGCIPCCI (SEQ ID NO:213) Toxin Sequence: Cys-Cys-His-Lys-Cys-Xaa5-Met-Gly-Cys-Ile-Xaa3-Cys-Cys-Ile- A (SEQ ID NO:214) Name: Ts3.2 Species: tessulatus Cloned: Yes DNA Sequence: GGATCCATGATGTCTAAACTGGGAGTCTTGTTGACCATCTGTGTGCTTCTGTTTCCCC TTACTGCTGTTCCGCTGGATGGAGATCAACCTGCAGACCAACCTGCAGAGCGTACG CAGAACGAGCAGCATCCCTTGTATGATCAGAAAAGAAAGTGTTGCCGGCCGCCATG CGCCATGAGCTGCGGCATGGCTAGGTGTTGCTATTAATGATAACGTGTTGATGACCA ACTTTCTCGAG (SEQ ID NO:215) Translation: GSMMSKLGVLLTICVLLFPLTAVPLDGDQPADQPAERTQNEQHPLYDQKRKCCRPPCA MSCGMARCCY (SEQ ID NO:216) Toxin Sequence: Lys-Cys-Cys-Arg-Xaa3-Xaa3-Cys-Ala-Met-Ser-Cys-Gly-Met-Ala-Arg-Cys-Cys-Xaa5- Λ (SEQ ID NO:217) Name: Circling Species: textile Isolated: Yes Cloned: Yes DNA Sequence: GAGTCAACCCACTGTCACGCCAAGAGCGGACGCCACAGCTAAGGCAAGAAGGATC GATAGCAGTTCATGATGTCTAAACTGGGAGCCTTGTTGACCATCTGTCTACTTCTGT TTTCCCTTACTGCTGTTCCGCTGGATGGAGATCAACATGCAGACCAACCTGCACAGC GTCTGCAGGACCGCATTCCAACTGAAGATCATCCCTTATTTGATCCCAACAAACGGT GTTGCCCGCCGGTGGCATGCAACATGGGATGCAAGCCTTGTTGTGGATGACCAGCTT TGTTATCGCGGTCTCATGAAGTGTCTAATGAATAAGTAAAACGATTGCAGTTTCGTT CAGATTTGCTGTTGTATTTTGGTCTAAAGATTAATGACCAAACTGTTCTTTTGATCCG GATTTTCACGTATTTCTCGATTCCTATTCAACACTAGATAAGTTAATCACGACAGAT CTGATTTTCCATCAATGCCTTGCTTTTTGGTCTGTCATATAAATCTTGTTTATATTTAA TTTCTCGTCACTTTCAACACGCACACACACACACACACACACGCGCGCGC (SEQ ID NO.-218) Translation: MMSKLGALLTICLLLFSLTANPLDGDQHADQPAQRLQDRIPTEDHPLFDPNKRCCPPVA CNMGCKPCCG (SEQ ID NO:219) Toxin Sequence: Cys-Cys-Xaa3-Xaa3-Val-Ala-Cys-Asn-Met-Gly-Cys-Lys-Xaa3-Cys-Cys-Gly- Λ (SEQ ID NO:220) Name: Scratcher I Species: textile Cloned: Yes DNA Sequence: GGATCCAGACGACAAAGAAGAGTCAACCCACTGCCACGTCAAGAGCAGAGCCCAC AGCTAAGACAAGAAGGATCGATAGCAGTTCATGATGTTTAAACTGGGAGTCTTGTT GACCATCTGTCTCCTTCTGTTTTCCCTTAATGCTGTTCCGTTGGATGGAGATCAACCT GCAGACCAACCTGCAGAGCGTCTGCTGGACGACATTTCATTTGAAAATAATCCCTTT TATGATCCCGCCAAACGGTGTTGCAGGACTTGCTTCGGTTGCACACCTTGTTGTGGA TGACCAGCCTCATCAAGTGTCTAACGAATAAGTAAAGCGATTGCAGTCTCGTTCAG ATTTACTTTTGTATTCTGGTCTAAAGATTAATGACCAAACTCTTCTTTTGATCCGGAT GTACATATATTTCTCGATTCCTATCCAACGCTAGATAAGCTAATCACGACAGATCTG ATTTTCTGTCAATGCCTTGCTTTTTGGTCTCTCATATCACTCTTGTTTATATTTAATTT CTCGTCACTATATATATATATACACACACACACACACGGAATTCCGATTGTCCAGTA CCGTTCTTGGGATCGAGGTATTGCTGCGATGGCTTATTCTGTACTCTTTTCTTCTGCG CTTGATAGTGATGTCTTCTACTCCCATCTGTGCTACCCCTGGCTTGATCTTTGATAGG CGTGTGCCCTTCACTGGTTATAAACCCCTCTGATCCTACTCTCTGGACGCCTCGGGG GCCCAACCTCCAAATAAAGCGACATCCAATGAAAAAA (SEQ ID NO:221) Translation: MMFKLGVLLTICLLLFSLNAVPLDGDQPADQPAERLLDDISFENNPFYDPAKRCCRTCF GCTPCCG (SEQ ID NO:222) Toxin Sequence: Cys-Cys-Arg-Thr-Cys-Phe-Gly-Cys-Thr-Xaa3-Cys-Cys-# (SEQ ID NO:223) Name: Tx3.1 Species: textile Cloned: Yes DNA Sequence: GGAACAGTCAACCCCACAGCCACGCCAAGAGCAGACAGCCACAGCTACGTGAAGA AGGGTGGAGAGAGGTTCATGATGTTGAAAATGGGAGTGGTGCTATTCATCTTTCTGG TACTGTTTCCCCTGGCAACGCTCCAGCTGGATGCAGATCAACCTGTAGAACGATATG CGGAGAACAAACAGCTCCTCAACCCAGATGAAAGGAGGGAAATCCTATTGCCTGCT CTGAGGAAGTTCTGCTGTGATTCGAATTGGTGCCACATTTCGGATTGTGAGTGCTGC TACGGTTAGCGCCGAACATCCATGGCACTGTGCTGGGCGGTTTCATCCCAACAACG ACAGCGTTTGTTGATTTCATGTATCATTGCGCCCACGTCTCTTGTCTAAGAATGACG AACATGATTGCACTCTGGTTCAGATTTCGTGTTCTTTTCTGACAATAAATGACAAAcC TCC (SEQ ID NO:224) Translation: MMLKMGWLFIFLVLFPLATLQLDADQPVERYAENKQLLNPDERREILLPALRKFCCDS NWCHISDCECCYG (SEQ ID NO:225) Toxin Sequence: Phe-Cys-Cys-Asρ-Ser-Asn-Xaa4-Cys-His-Ile-Ser-Asp-Cys-Xaal-Cys-Cys-Xaa5-# (SEQ ID NO:226) Name: U031 Species: textile Isolated: Yes Cloned: Yes DNA Sequence: CAAGGAACAGTCAACCCCACAGCCACGCCAAGAGCAGACAGCCACAGCTACGTGA AGAAGGGTGGAGAGAGGTTCGTGATGTTGAAAATGGGAGTGGTGCTATTCATCTTC CTGGTACTGTTTCCCCTGGCAACGCTCCAGCTGGATGCAGATCAACCTGTAGAACGA TATGCGGAGAACAAACAGCTCCTCAGCCCAGATGAAAGGAGGGAAATCATATTGCA TGCTCTGGGGACGCGATGCTGTTCTTGGGATGTGTGCGACCACCCGAGTTGTACTTG CTGCGGTTAGCGCCGAACATCCATGGCGCTGTGCTGGGCGGTTTTATCCCAACAACG ACAGCGTTTGTTGATTTCATGTATCATTGCGCCCACGTCTCTTGTCTAAGAATGACG AACATGATTGCACTCTGGTTCAGATTTCGTGTTCTTTTCTGACAATAAATGACAAAA CNCC (SEQ ID NO:227) Translation: MLKMGWLFIFLVLFPLATLQLDADQPVERYAENKQLLSPDERREIILHALGTRCCSWD VCDHPSCTCCG (SEQ ID NO:228) Toxin Sequence: Cys-Cys-Ser-Xaa4-Asp-Val-Cys-Asp-His-Xaa3-Ser-Cys-Thr-Cys-Cys-# (SEQ ID NO:229) Name: U032 Species: textile Isolated: Yes Cloned: Yes DNA Sequence: GGATCCATGATGTCTAAACTGGGAGTCTTGTTGACCATCTGTCTGCTTCTGTTTCCCC TTACTGCTCTTCCGCTGGATGGAGATCAACCCGCAGACCAAGCTGCAGAGCGTATG CAGGCCGAGCAGCATCCCTTGTTTGATCAGAAAAGACGGTGCTGCAAGTTTCCATG CCCCGATAGTTGCAGATATTTGTGTTGCGGGTGATGATAACGTGTTGATGACCAACT TTCTCGAG (SEQ ID NO:230) Translation: GSMMSKLGVLLTICLLLFPLTALPLDGDQPADQAAERMQAEQHPLFDQKRRCCKFPCP DSCRYLCCG (SEQ ID NO:231) Toxin Sequence: Arg-Cys-Cys-Lys-Phe-Xaa3-Cys-Xaa3-Asp-Ser-Cys-Arg-Xaa5-Leu-Cys-Cys-# (SEQ ID NO:232) Name: T3.1 Species: tulipa Cloned: Yes DNA Sequence: CGACCTCAAGAGGGATCGATAGCAGTTCATGTCTAAACTGGGAGTCTTGTTGACAA TCTGTCTGCTTCTGTTTCCCCTTACTGCTCTGCCGATGGATGGAGATGAACCTGCAG ACCGACCTGCAGAGCGTATGCAGGACAACATTTCATCTGAGCAGCATCCCTTGTTTG AGGAGAGACACGGATGTTGCAAGGGGCCCGAAGGATGCTCCTCCAGAGAATGCAG ACCCCAACATTGTTGCGGTCGACGATAACGTGTTGAGGGCCAACTTTGTTATCACGG CTACGTCAAGTGTTTAGTGAATAAGTAAAATGATTGCAG (SEQ ID NO:233) Translation: MSKLGNLLTICLLLFPLTALPMDGDEPADRPAERMQDNISSEQHPLFEERHGCCKGPEG CSSRECRPQHCCGRR (SEQ ID NO:234) Toxin Sequence: His-Gly-Cys-Cys-Lys-Gly-Xaa3-Xaal-Gly-Cys-Ser-Ser-Arg-Xaal-Cys-Arg-Xaa3-Gln-His- Cys-Cys-# (SEQ ID NO:235) Name: Fi3.1 Species: figulinus Cloned: Yes DNA Sequence: CAAGAAGGATCGATAGCAGTTCATGATGTCTAAACTGGGAGTCTTGCTGACCATCT GTCTGCTTCTGATTCCCCTTACTGCTCTTTCGCTGGATGGAGATCAACCTGCAGACC GACCTGCAGAGCGTATGCAGGATGGAATTTCATCTGAACAGCATCCCATGTTTGATC CCGTCAGACGGTGTTGCCCGTGGCCATGCAACATAGGATGCGTACCTTGTTGTTGAT GACCAGTTTTGTTATCGCGGCCTCATCAAATGTCTAATGAATAAGTAAAACGATTGC AGT (SEQ ID NO:236) Translation: MMSKLGVLLTICLLLIPLTALSLDGDQPADRPAERMQDGISSEQHPMFDPVRRCCPWPC NIGCVPCC (SEQ ID NO:237) Toxin Sequence: Cys-Cys-Xaa3-Xaa4-Xaa3-Cys-Asn-Ile-Gly-Cys-Val-Xaa3-Cys-Cys- Λ (SEQ ID NO:238) Name: Fi3.2 Species: figulinus Cloned: Yes DNA Sequence: CAAGAGGGATCGATAGCAGTTCATGATGTTTAAACTGGGAGTCCTGTTGACCATCTG TATGCTTCTGTTTCCCTTTACTGCTCTTCCGCTGGATGGAGAGCAACCTGCAGACCA ACCTGCAGAGCGCATGCAGTATGACATGTTACGTGCAATGAATCCCTGGTTTGATCC CGTCAAAAGGTGCTGCTCGAAGAACTGCGCAGTATGCATCCCTTGTTGCCCGTAACT GACCAGCTTGATTATCGCGGCCAAGGCTCTAATGAATAAGTAAAACGATTGCAGT (SEQ ID NO:239) Translation: MMFKLGVLLTICMLLFPFTALPLDGEQPADQPAERMQYDMLRAMNPWFDPVKRCCSK NCAVCIPCCP (SEQ ID NO:240) Toxin Sequence: Cys-Cys-Ser-Lys-Asn-Cys-Ala-Val-Cys-Ile-Xaa3-Cys-Cys-Xaa3- A (SEQ ID NO:241) Name: Fi3.3 Species: figulinus Cloned: Yes DNA Sequence: CAAGAGGGATCGATAGCAGTTCATGATGTCTAAACTGAGAGTCTTGTTGACCTTATG TCTGCTTCTGTTTCCCCTTACTGCTCTTCCGCTGAATGAAGATCAACCTGCAGAGCGT ATGCAGGACGACAATTCATCTGAGCAGCACCCCTTGTATGACCACAAACGAAAGTG TTGCCGGTGGCCATGCCCCGCAAGATGCGGCTCTTGTTGCCTGTAATAACGTGTTGG CCAACTTTGTTATCACGGCCACGTCAAATGTTTAATGAATAAGTAAAACGATTGCAG T (SEQ ID NO:242) Translation: MMSKLRVLLTLCLLLFPLTALPLNEDQPAERMQDDNSSEQHPLYDHKRKCCRWPCPAR CGSCCL (SEQ ID NO:243) Toxin Sequence: Cys-Cys-Arg-Xaa4-Xaa3-Cys-Xaa3-Ala-Arg-Cys-Gly-Ser-Cys-Cys-Leu- Λ (SEQ ID NO:244) Name: Fi3.4 Species: figulinus Cloned: Yes DNA Sequence: CAAGAGGGATCGATAGCAGTTCATGATGTCTAAACTGGGAGTCTTGTTGACCTTATG TCTGCTTCTGTTTCCCCTGACTGCTCTTCCGCTGGATGAAGATCAAGCTGCAGACCG ACCTGCAGAGCGTATGCAGGGCATGTCATCTGAACAGCATCCCTTCTTTGATCCCGT CAAACGGTGTTGCGAGTTGTCACGCTGCCTTGGATGCGTCCCTTGTTGCACATCTTA ATAACGTGTGGATGACCAACTGTGTTATCACGGCCACGTCAAGTGTCTAATGAATA AGTAAAATGATTGCAGT (SEQ ID NO:245) Translation: MMSKLGVLLTLCLLLFPLTALPLDEDQAADRPAERMQGMSSEQHPFFDPVKRCCELSR CLGCVPCCTS (SEQ ID NO:246) Toxin Sequence: Cys-Cys-Xaal-Leu-Ser-Arg-Cys-Leu-Gly-Cys-Val-Xaa3-Cys-Cys-Thr-Ser- A (SEQ ID NO:247) Name: Fi3.5 Species: figulinus Cloned: Yes DNA Sequence: CAAGAGGGATCGATAGCAGTTCATGATGTCTAAACTGGGAGTCTTGTTGACCTTATG TCTGCTTCTGTTTCCCCTGACTGCTCTTCCGCTGGATGAAGATCAACCTGCAGACCG ACCTGCAGAGCGTATGCAGGGCATGTCATCTGAACAGCATCCCTTCTTTGATCCCGT CAAACGGTGTTGCGAGTTGTCAAAATGCCATGGATGCGTCCCTTGTTGCATACCTTA ATAACGTGCGGATGACCAACTGTGTTATCACGGCCACGTCAAGTGTCTAATGAATA AGTAAAATGATTGCAGT (SEQ ID NO:248) Translation: MMSKLGVLLTLCLLLFPLTALPLDEDQPADRPAERMQGMSSEQHPFFDPVKRCCELSK CHGCVPCCIP (SEQ ID NO:249) Toxin Sequence: Cys-Cys-Xaal-Leu-Ser-Lys-Cys-His-Gly-Cys-Val-Xaa3-Cys-Cys-Ile-Xaa3- Λ (SEQ ID NO:250) Name: Qc3.2 Species: quercinus Cloned: Yes DNA Sequence: CAAGAGGGATCGATAGCAGTTCATGATGTCTAAACTCGGAGTCTTGTTGACCATCTG TCTGGTTCTGTTTCCCCTTACAGCTCTTCAGCTGGATGGAGATCAACCTGCAGACCG ACCTGCAGAGCGTACGCAGGACATTTCATCTGAACAGTATCGAAAGTTTGATCAGA GACAGAGGTGTTGCCGGTGGCCATGCCCCGGTAGTTGCAGATGCTGCCGTTATCGTT AACGTGTTGGTGACCAGCTTTGTTATCACGACCACGCCAAGTGTCTAACGAATAAGT AAAATGATTGCAGT (SEQ ID NO:251) Translation: MMSKLGVLLTICLVLFPLTALQLDGDQPADRPAERTQDISSEQYRKFDQRQRCCRWPCP GSCRCCRYR (SEQ ID NO:252) Toxin Sequence: Xaa2-Arg-Cys-Cys-Arg-Xaa4-Xaa3-Cys-Xaa3-Gly-Ser-Cys-Arg-Cys-Cys-Arg-Xaa5-Arg- A (SEQ ID NO:253) Name: Qc3.3 Species: quercinus Cloned: Yes DNA Sequence: CAAGAGGGATCGATAGCAGTTCATGATGTCTAAACTGGGAGTCTTGTTGACCATCTG TCTGCTTCTGTTTCCCCTTACTGCTCTTCCACTGGATGGAGATCAACCTGCAGATCAA TCTGCAGAGCGACCTGCAGAGCGTACGCAGGACGACATTCAGCAGCATCCGTTATA TGATCCGAAAAGAAGGTGTTGCCGTTATCCATGCCCCGACAGCTGCCACGGATCTTG CTGCTATAAGTGATAACATGTTGATGGCCAGCTTTGTTATCACGGCCACGTCAAGTG TCTAATGAATAAGTAAAACGATTGCAGT (SEQ ID NO:254) Translation: MMSKLGVLLTICLLLFPLTALPLDGDQPADQSAERPAERTQDDIQQHPLYDPKRRCCRY PCPDSCHGSCCYK (SEQ ID NO:255) Toxin Sequence: Arg-Cys-Cys-Arg-Xaa5-Xaa3-Cys-Xaa3-Asp-Ser-Cys-His-Gly-Ser-Cys-Cys-Xaa5-Lys- A (SEQ ID NO:256) Name: Wi3.1 Species: wittigi Cloned: Yes DNA Sequence: GGATCCATGATGTCTAAACTGGGAGTCTTGTTGACCATCTGTCTGCTTCTGTTTCCCA TTACTGCTCTTCCGGTGGGTGGAGATCAGCCTGCAGACCGACTTGCAGAGCGTATGC AGGACGACACTTCATCTGAGCAGCATCCCTTTGAAAAGAGACTACCATCATGTTGC GACTTTGAGAGGCTTTGCGTAGTACCAGCATGCATACGTCATCAGTGTTGCACAGGA TAACGTGTTGATGACCAACTTTCTCGAG (SEQ ID NO:257) Translation: MMSKLGVLLTICLLLFPITALPVGGDQPADRLAERMQDDTSSEQHPFEKRLPSCCDFERL CVVPACIRHQCCTG (SEQ ID NO:258) Toxin Sequence: Leu-Xaa3-Ser-Cys-Cys-Asp-Phe-Xaal-Arg-Leu-Cys-Val-Val-Xaa3-Ala-Cys-Ile-Arg-His-Gln- Cys-Cys-Thr-# (SEQ ID NO:259) Name: bt3a Species: betulinus Isolated: Yes Toxin Sequence: Cys-Cys-Lys-Gln-Ser-Cys-Thr-Thr-Cys-Met-Xaa3-Cys-Cys-Xaa4- A (SEQ ID NO:260) Name: T3.2 Species: tulipa « Cloned: Yes DNA Sequence: GGATCCATGATGTCTAAACTGGGAGTCTTGTTGACAATCTGTCTGCTTCTGTTTCCCC TTACTGCTCTGCCGATGGATGGAGATGAACCTGCAGACCGACCTGCAGAGCGTATG CAGGACAACATTTCATCTGAGCAGCATCCCTTGTTTGAGGAGAGACACGGATGTTG CGAGGGGCCGAAGGGATGCTCCTCCAGAGAATGCAGACCCCAACATTGTTGCGGTC GACGATAACGTGTTGATGACCAACTNTCTCGAG (SEQ ID NO:261) Translation: MMSKLGVLLTICLLLFPLTALPMDGDEPADRPAERMQDNISSEQHPLFEERHGCCEGPK GCSSRECRPQHCCGRR (SEQ ID NO:262) Toxin Sequence: His-Gly-Cys-Cys-Xaal-Gly-Xaa3-Lys-Gly-Cys-Ser-Ser-Arg-Xaal-Cys-Arg-Xaa3-Gln-His- Cys-Cys-# (SEQ ID NO:263) Name: A3.5 Species: aurisiacus Cloned: Yes DNA Sequence: GGATCCATGATGTCTAAACTGGGAGTCTTGTTGACCATCTGTCTACTTCTGTTTCCCC TTACTGCTTTTCCGATGGATGGAGATCAACCTGCAGACCAACCTGCAGATCGTATGC AGGACGACATTTCATCTGAGCAGTATCCCTTGTTTGATAAGAGACAAAAGTGTTGCA CTGGGAGGAAGGGGTCATGCTCCGGCAAAGCATGCAAAAATCTCAAATGTTGCTCT GGACGATAACGTGTTGATGACCAACTTTCTCGAN (SEQ ID NO:264) Translation: MMSKLGVLLTICLLLFPLTAFPMDGDQPADQPADRMQDDISSEQYPLFDKRQKCCTGR KGSCSGKACKNLKCCSGR (SEQ ID NO:265) Toxin Sequence: Xaa2-Lys-Cys-Cys-Thr-Gly-Arg-Lys-Gly-Ser-Cys-Ser-Gly-Lys-Ala-Cys-Lys-Asn-Leu-Lys- Cys-Cys-Ser-# (SEQ ID NO:266) Name: Bt3.5 Species: betulinus Cloned: Yes DNA Sequence: GGATCCATGATGTCTAAACTGGGAGTCTTGTTGACCATCTGTCTGCTTCTGTTTCCCC TTACTGCTGTTCCGTTGGATGGAGATCAACCTGCAGACCAACCTGCAGAGCGTATGC AGAACGAGCAGCATCCCTCGTTTGATCAGAAAAGAAGGTGCTGCCGGTGGCCATGC CCCAGTATATGCGGCATGGCTAGGTGTTGCTTCGTCATGATAACGTGTTGATGACCA ACTTTCTCGAG (SEQ TD NO:267) Translation: MMSKLGVLLTICLLLFPLTAVPLDGDQPADQPAERMQNEQHPSFDQKRRCCRWPCPSIC GMARCCFVMITC (SEQ ID NO:268) Toxin Sequence: Arg-Cys-Cys-Arg-Xaa4-Xaa3-Cys-Xaa3-Ser-Ile-Cys-Gly-Met-Ala-Arg-Cys-Cys-Phe-Nal-Met- Ile-Thr-Cys- A (SEQ ID ΝO:269) Name: Bt3.6 Species: betulinus Cloned: Yes DNA Sequence: GGATCCATGATGTCTAAACTGGGAGTCTTGTTGATCATCTGTCTGCTTCTGTTTCCCC TTACTGCTGTTCCGCTGGATGGAGATCAGCCTGCAGAGCGTACGCAGATCGAGCAG CATCCCTTGTTTGACCAGAAAAGAAGGTGTTGCCGGTGGCCATGCCCCAGTAGATG CGGCATGGCTAGGTGTTGCTTCGTCATGATAACGTGTTGATGANCGACCTCTCNAG (SEQ ID NO:270) Translation: MMSKLGVLLIICLLLFPLTAVPLDGDQPAERTQIEQHPLFDQKRRCCRWPCPSRCGMAR CCFVMITC (SEQ ID NO:271) Toxin Sequence: Arg-Cys-Cys-Arg-Xaa4-Xaa3-Cys-Xaa3-Ser-Arg-Cys-Gly-Met-Ala-Arg-Cys-Cys-Phe-Val- Met-Ile-Thr-Cys- A (SEQ ID NO:272) Name: Pr3.1 Species: parius Cloned: Yes DNA Sequence: GGATCCATGATGTCTAAACTGGGAGTCTTGTTGACCATCTGTCTGCTTCTGTTTCCCC TTACTGCTCTTCCGATGGATGGTGATCAACCTGCAGACCGACTTGTAGAGCGTATGC AGGACAACATTTCATCTGAGCAGCATCCCTTCTTTGAAAAGAGAAGAGGAGGCTGT TGCACACCTCCGAAGAAATGCAAAGACCGAGCCTGCAAACCTGCACGTTGCTGCGG CCCAGGATAACGTGTTGATGACCAACTTTCTCGCC (SEQ ID NO:273) Translation: MMSKLGVLLTICLLLFPLTALPMDGDQPADRLVERMQDNISSEQHPFFEKRRGGCCTPP KKCKDRACKPARCCGPG (SEQ ID NO:274) Toxin Sequence: Arg-Gly-Gly-Cys-Cys-Thr-Xaa3-Xaa3-Lys-Lys-Cys-Lys-Asp-Arg-Ala-Cys-Lys-Xaa3-Ala-Arg- Cys-Cys-Gly-Xaa3-# (SEQ ID NO:275) Name: Pr3.2 Species: parius Cloned: Yes DNA Sequence: GGATCCATGATGTCTAAACTGGGAGTCTTGTTGACCATCTGTCTGCTTCTGTTTCCCC TTACTGCTCTTCCGATGGATGGTGATCAACCTGCAGACCGACTTGTAGAGCGTATGC AGGACAACATTTCATCTGAGCAGCATCCCTTCTTTGAAAAGAGAAGAGGCTGTTGC ACACCTCCGAGGAAATGCAAAGACCGAGCCTGCAAACCTGCACGTTGTTGCGGCCC AGGATAACGTGTTGATGACCAACTTTCTCGAG (SEQ TD NO:276) Translation: MMSKXGVLLTICLLLFPLTALPMDGDQPADRLVERMQDNISSEQHPFFEKRRGCCTPPR KCKDRACKPARCCGPG (SEQ ID NO:277) Toxin Sequence: Arg-Gly-Cys-Cy s-Thr-Xaa3 -Xaa3 -Arg-Ly s-Cys-Lys- Asp- Arg- Ala-Cy s-Lys-Xaa3 - Ala-Arg- Cys-Cys-Gly-Xaa3-# (SEQ ID NO:278) Name: Ct3.1 Species: coronatus Cloned: Yes DNA Sequence: GGATCCATGATGTCTAAACTGGGAGTCTTGTTGACCATCTGTCTGCTTCTGTTTCCAA TTACTGCCCTTCCGCTGGATGAAGATCAACCTGCAGACCGACCTGCAGAGCGTATGC AGGACATTGCAACTGAACAGCATCCCTTGTTTGATCCCGTCAAACGGTGCTGCGATT GGCCATGCATCCCAGGATGCACCCCTTGTTGCTTGCCTTGATAACGTGTTGATGACC AACTTTCTCGAG (SEQ ID NO:279) Translation: MMSKLGVLLTICLLLFPITALPLDEDQPADRPAERMQDIATEQHPLFDPVKRCCDWPCIP GCTPCCLP (SEQ ID NO:280) Toxin Sequence: Cys-Cys-Asp-Xaa4-Xaa3-Cys-Ile-Xaa3-Gly-Cys-Thr-Xaa3-Cys-Cys-Leu-Xaa3- A (SEQ ID NO:281) Name: Ms3.1 Species: musicus Cloned: Yes DNA Sequence: GGATCCATGATGTCTAAACTGGGAGTCCTGTTGACCATCTGTCTGCTTCTGTTTCCTC TTTCTGCTCTTCCGATGGATGAAGATCAACTTGCAGACCTACCTGCAGAGCGTATGC GGGACACTGCAACTGTAGATCATCCCTCCTATGATCCTGACAAAGCGTGCTGCGAG CAGAGCTGTACAACATGCTTTCCGTGCTGCTAGCCTTGAACACAGTAACGTGTTGAT GACCAACTTTCTCGAG (SEQ ID NO:282) Translation: MMSKLGNLLTICLLLFPLSALPMDEDQLADLPAERMRDTATVDHPSYDPDKACCEQSC TTCFPCC (SEQ ID ΝO:283) Toxin Sequence: Ala-Cys-Cys-Xaal -Gln-Ser-Cys-Thr-Thr-Cys-Phe-Xaa3-Cys-Cys- A (SEQ ID NO:284) Name: bt3b Species: betulinus Isolated: Yes Toxin Sequence: Ala-Cys-Cys-Xaal-Gln-Ser-Cys-Thr-Thr-Cys-Met-Xaa3-Cys-Cys- A (SEQ ID NO:285) Name: bt3c Species: betulinus Isolated: Yes Toxin Sequence: Cys-Cys-Xaal-Gln-Ser-Cys-Thr-Thr-Cys-Met-Xaa3-Cys-Cys-Xaa4-? (SEQ ID NO:286) Name: Pn3.2 Species: pennaceus Cloned: Yes DNA Sequence: GGATCCATGATGTCTAAACTGGGAGTCTTGTTGACCATCTGTCTGCTTCTGTTTCCCC TTACTGCTCTTCCGCTGGATGGAGATCAACCTGCATACCAAGCTGCAGAGCGTATGC AGGCCGAGCATCATCCCTTGTTTGATCAGAAAAGACGGTGCTGCAAGTTTCCATGCC CCGATAGTTGCAAATATTTGTGTTGCGGGTGATGATAACATGTTGATGACCAACTTT CTTGAG (SEQ ID NO:287) Translation: MMS-O.GVLLTICLLLFPLTALPLDGDQPAYQAAERMQAEHHPLFDQKRRCCKFPCPDS CKYLCCG (SEQ ID NO:288) Toxin Sequence: Arg-Cys-Cys-Lys-Phe-Xaa3-Cys-Xaa3-Asp-Ser-Cys-Lys-Xaa5-Leu-Cys-Cys-# (SEQ ID NO:289) Name: Pu3.2 Species: pulicarius Cloned: Yes DNA Sequence: GGATCCATGATGTCTAAACTGGGAGTCTTGTTGACCATCTGTCTGCTTCTGTTTCCCC TTACTGCTCTTCCGATGGATGGTGATCAACTTGCAGACCGACTTGTAGAGCGTATGC AGGACAACATTTCATCTGAGCAGCATCCCTTCTTTGATCCCGTCAAACGGTGTTGCG TCAGCTGTTACATGGGATGCATCCCTTGTTGCTTCTAGTAATAACGTGTTGATGACC AACTTTCTCGAG (SEQ ID NO:290) Translation: MMSKLGVLLTICLLLFPLTALPMDGDQLADRLVERMQDNISSEQHPFFDPVKRCCVSCY MGCIPCCF (SEQ ID NO:291) Toxin Sequence: Cys-Cys-Val-Ser-Cys-Xaa5-Met-Gly-Cys-Ile-Xaa3-Cys-Cys-Phe- Λ (SEQ ID NO:292) Name: Pu3.3 Species: pulicarius Cloned: Yes DNA Sequence: GGATCCATGATGTCTAAACTGGGAGTCTTGTTGACCGTCTGTCTGCTTCTGTGTCCCC TTACTGCTCTTCCACTGGATGAAGATCAACTTGCAGACCGACCTGCAGAGCGTATGC AGGATGACACTTCAGCTGCACAGATTTTCGGGTTTGATCCCGTCAAACGGTGCTGCA AATTGCTATGCTACTCGGGATGCACTCCTTGTTGCCATATTTGATAACGTGTTGATG ACCAACTTTCTCGAG (SEQ ID NO:293) Translation: MMSKLGVLLTVCLLLCPLTALPLDEDQLADRPAERMQDDTSAAQIFGFDPVKRCCKLL CYSGCTPCCHI (SEQ ID NO:294) Toxin Sequence: Cys-Cys-Lys-Leu-Leu-Cys-Xaa5-Ser-Gly-Cys-Thr-Xaa3-Cys-Cys-His-Ile- A (SEQ ID NO:295) Name: Ra3.2 Species: rattus Cloned: Yes DNA Sequence: GGATCCATGATGTCTAAACTGGGAGTCTTGTTGACCATCTGTCTGCTTGTGTTTCCGC TTACTGCTCTTCCGATGGATGGTGATCAACCTGCAGACCGACTTGTAGAGCGTATAC AGGACAACATTTCATCTGAGCAGCATCCCTTCTTTGAAAAGAGAAGAGGCTGTTGC GCACCTCCGAGGAAATGCAAAGACCGAGCCTGCAAACCTGCACGTTGCTGCGGCCC AGGATAACGTGTTGATGACCAACTTTCTCGAG (SEQ ID NO:296) Translation: MMSKLGVLLTICLLVFPLTALPMDGDQPADRLVERIQDNTSSEQHPFFEKRRGCCAPPRK CKDRACKPARCCGPG (SEQ ID NO.297) Toxin Sequence: Arg-Gly-Cys-Cys-Ala-Xaa3-Xaa3-Arg-Lys-Cys-Lys-Asp-Arg-Ala-Cys-Lys-Xaa3-Ala-Arg- Cys-Cys-Gly-Xaa3-# (SEQ ID NO:298) Name: Sm3.3 Species: stercusmuscarum Cloned: Yes DNA Sequence: GGATCCATGATGTCTAAACTGGGAGTCTTGTTGACAATCTGTCTGCTTCTGTTTCCCC TTATTGCTCTTCCGCTGGATGGAGATCAACCTGCAGACCGACCTGCAGAGCGTATGC AGGACGACATTTCATCTGAGAAGCATCCCTTGTTTGATAAGAGACAACGGTGTTGC AATGGGCGGAGGGGATGCTCCAGCAGATGGTGCAGAGATCACTCACGTTGTTGCGG TCGACGATAACGTGTTGATGACCAACTTTCTCGAG (SEQ ID NO:299) Translation: MMSKX.GVLLTICLLLFPLIALPLDGDQPADRPAERMQDDISSEKHPLFDKRQRCCNGRR GCSSRWCRDHSRCCGRR (SEQ ID NO:300) Toxin Sequence: Xaa2-Arg-Cys-Cys-Asn-Gly-Arg-Arg-Gly-Cys-Ser-Ser-Arg-Xaa4-Cys-Arg-Asp-His-Ser-Arg- Cys-Cys-# (SEQ ID NO:301) Name: Eb3.1 Species: ebraeus Cloned: Yes DNA Sequence: GGATCCATGATGTCTAAACTGGGAGTCTTGTTGACCATCTGTCTGCTTCTGTTTCCCC TTACTGCTCTTCCACTGGATGAAGGTCAACCTGCAGACCTACCTGCAGAGCGTATGC AGGACATTGCAACTGAACAGCATCCCTTGTTTGATCCTGTCAAACGGTGTTGCGAGC AGCCATGCTACATGGGATGCATCCCTTGTTGCTTCTAATAATAACGTGTTGATGACC AACTTTCTCGAG (SEQ TD NO:302) Translation: MMSKLGVLLTICLLLFPLTALPLDEGQPADLPAERMQDIATEQHPLFDPVKRCCEQPCY MGCIPCCF (SEQ ID NO:303) Toxin Sequence: Cys-Cys-Xaal-Gln-Xaa3-Cys-Xaa5-Met-Gly-Cys-Ile-Xaa3-Cys-Cys-Phe- A (SEQ ID NO:304) Name: Eb3.2 Species: ebraeus Cloned: Yes DNA Sequence: GGATCCATGATGTCTAAACTGGGAGTCTTGTTGACCATCTGTCTGCTTCTGTTTCCCC TTACTGCTCTTCCACTGGATGAAGATCAACCTGCAGACCTACCTGCAGAGCGTATGC AGGACATTGCAACTGAACAGCATCCCTTGTTTGATCCTGTCAAACGGTGCTGCGCGC AGCCATGCTACATGGGATGCATCCCTTGTTGCTTCTAATAATAACGTGTTGATGACC AACTTTCTCGAG (SEQ ID NO:305) Translation: MMSKLGVLLTICLLLFPLTALPLDEDQPADLPAERMQDIATEQHPLFDPNKRCCAQPCY MGCIPCCF (SEQ ID ΝO:306) Toxin Sequence: Cys-Cys-Ala-Gln-Xaa3-Cys-Xaa5-Met-Gly-Cys-Ile-Xaa3-Cys-Cys-Phe- A (SEQ ID NO:307) Name: Fd3.2 Species: flavidus Cloned: Yes DNA Sequence: GGATCCATGATGTCTAAACTGGGAGTCTTGTTGACCATCTGTCTGCTTCTGTTTCCCC TTACTGCTGTTCCGTTGGATGGAGATCAACCTGCAGACCAGCCTGCAGAGCGTATGC AGAACGAGCAGCATCCCTTGTTTGATCAGAAAAGAAGGTGCTGCCGGTGGCCATGC CCCAGTATATGCGGCATGGCTAGGTGTTGCTCGTCATGATAACGTGTTGATGACCAA CTTTCTCGAG (SEQ ID NO:308) Translation: MMSKLGVLLTICLLLFPLTAVPLDGDQPADQPAERMQNEQHPLFDQKRRCCRWPCPSIC GMARCCSS (SEQ ID NO:309) Toxin Sequence: Arg-Cys-Cys-Arg-Xaa4-Xaa3-Cys-Xaa3-Ser-Ile-Cys-Gly-Met-Ala-Arg-Cys-Cys-Ser-Ser- A (SEQ ID NO:310) Name: MG.l Species: miliaris Cloned: Yes DNA Sequence: GGATCCATGATGTCTAAACTGGGAGTCTTGTTGACCATCTGTCTGCTTCTGTTTCCAA TTACTGCCCTTCCACTGGATGAAGATCAACCTGCAGACCGACCTGCAGAGCGTATGC AGGACATTGCAACTGAACAGCATCCCTTGTTTGATCCCGTCAAACGGTGTTGCGATT GGCCATGCAGCGCAGGATGCTACCCTTGTTGCTTCCCTTAATAACGTGTTGATGACC AACTNANGNAAAAAAA (SEQ ID NO:311) Translation: MMSKLGVLLTICLLLFPITALPLDEDQPADRPAERMQDIATEQHPLFDPNKRCCDWPCS AGCYPCCFP (SEQ ID ΝO:312) Toxin Sequence: Cys-Cys-Asp-Xaa4-Xaa3-Cys-Ser-Ala-Gly-Cys-Xaa5-Xaa3-Cys-Cys-Phe-Xaa3- A (SEQ ID NO:313) Name: Mf3.2 Species: miliaris Cloned: Yes Notes: DNA Sequence: GGATCCATGATGTCTAAACTGGGAGTGGTGCCATTCGTCTTTCTGGTCCTGTTTCCCC TGGCAACACTCCAACTGGATGCAGATCAACCTGCAGACCGACCTGCGCGTAAAAAG GGCATTGCAACTAAACGGCATCCCTTGTCTGATCCTGTCAGAGGGTGTTGCCCTCCA ATGTGCACACCATGCTTCCCTTGCTGTTTTCGTTAATAACGTGTTGATGNATGATGN AN (SEQ ID NO:314) Translation: MMSKLGV F Lλ^FPLATLQLDADQPADRPARKKGIAT_faiHPLSDPVRGCCPPMCTPCFPCC FR (SEQ ID NO:315) Toxin Sequence: Gly-Cys-Cys-Xaa3-Xaa3-Met-Cys-Thr-Xaa3-Cys-Phe-Xaa3-Cys-Cys-Phe-Arg- A (SEQ ID NO:316) Name: Af3.1 Species: ammiralis Cloned: Yes DNA Sequence: CAAGAGGGATCGATAGCAGTTCATGATGTCTAAACTGGGAGTCTTGTTGACCATCTG TCTGCTTCTGTTTCCCCTTACTGCTCTTCCGCTGGATGGAGATCAACCTGCAGACCA AGCTGCAGAGCGTATGCAGGCCGAGCAGCATCCCTTGTTTGATCAGAAAAGACGGT GTTGCAGGTTTCCATGCCCCGATACTTGCAGACATTTGTGTTGCGGGTGATGATAAC GTGCTGATGACCCACTTTGTCATCACGGCTACGTCAAGTGTCTAATGAATAAGTAAA ATGATTGCAGT (SEQ ID NO:317) Translation: MMSKLGVLLTICLLLFPLTALPLDGDQPADQAAERMQAEQHPLFDQKRRCCRFPCPDT CRHLCCG (SEQ ID NO:318) Toxin Sequence: Arg-Cys-Cys-Arg-Phe-Xaa3-Cys-Xaa3-Asp-Thr-Cys-Arg-His-Leu-Cys-Cys-# (SEQ ID NO:319) Name: Af3.2 Species: ammiralis Cloned: Yes DNA Sequence: CAAGAGGGATCGATAGCAGTTCATGATGTTTAAACTGGGAGTCTTGCTGACCATCTG TCTACTTCTGTTTTCCCTTAATGCTGTTCCGCTGGATGGAGATCAACCTGCAGACCA ACCTGCAGAGCGTCTGCTGGACGACATTTCATCTGAAAATAATCCCTTTTATGATCC CGCCAAACGGTGTTGCATGACTTGCTTCGGTTGCACACCTTGTTGTGGATGACCAGC CTCATCAAGTGTCTAACGAATAAGTAAAACGATTGCAGT (SEQ ID NO:320) Translation: MMFKLGVLLTICLLLFSLNAVPLDGDQPADQPAERLLDDISSENNPFYDPAKRCCMTCF GCTPCCG (SEQ ID NO:321) Toxin Sequence: Cys-Cys-Met-Thr-Cys-Phe-Gly-Cys-Thr-Xaa3-Cys-Cys-# (SEQ ID NO:322) Name: Af3.3 Species: ammiralis Cloned: Yes DNA Sequence: CAAGAAGGATCGATAGCAGTTCATGATGTCTAAACTGGGAGCCTTGTTGACCATCT GTCTACTTCTGTTTTCCCTTACTGCTGTTCCGCTGGATGGAGATCAACATGCAGACC AACCTGCAGAGCGTCTGCAGGACCGCCTTCCAACTGAAAATCATCCCTTATATGATC CCGTCAAACGGTGTTGCGATGATTCGGAATGCGACTATTCTTGCTGGCCTTGCTGTA TTTTTTCATAACCTTTGTTATCGCGGCCTCATCCTAGTGTCAAATGAATAAGTAAAA CGATTGCAGT (SEQ ID NO:323) Translation: 1VIMS_KLGALLTICLLLFSLTAVPLDGDQHADQPAEPAQDI^PTENHPLYDPVKRCCDDSE CDYSCWPCCIFS (SEQ ID NO:324) Toxin Sequence: Cys-Cys-Asp-Asp-Ser-Xaal-Cys-Asρ-Xaa5-Ser-Cys-Xaa4-Xaa3-Cys-Cys-Ile-Phe-Ser- A (SEQ ID O:325) Name: Aβ.4 Species: ammiralis Cloned: Yes DNA Sequence: CAAGAGGGATCGATAGCAGTTCATGATGTTTAAACTCGGAGTCTTGCTGACCATCTG TCTACTTCTGTTTTCCCTAATtGCTGTTCCGCTGGATGGAGATCAACATGCAGACCAA CCTGCAGAGCGTCTGCAGGACCGCCTTCCAACTGAAAATCATCCCTTATATGATCCC GTCAAACGGTGTTGCAGGTTGTTATGCCTCAGTTGCAACCCTTGTTGTGGATGACCA GCTTTGTTATCACGGCCTCATCAAGTGTCTAATGAATAAGTAAAACGATTGCAGT (SEQ ID NO:326) Translation: MMF_Ω J GVLLTICLLLFSLLVVPLDGDQHADQPAERLQDRLPTENHPLYDPVKRCCRLLC LSCNPCCG (SEQ ID NO:327) Toxin Sequence: Cys-Cys-Arg-Leu-Leu-Cys-Leu-Ser-Cys-Asn-Xaa3-Cys-Cys-# (SEQ ID NO:328) Name: Af3.6 Species: ammiralis Cloned: Yes DNA Sequence: CAAGAAGGATCGATAGCAGTTCATGATGTCTAAACTGGGAGCCTTGTTGACCATCT GTCTACTTCTGTTTTCCCTTACTGCTGTTCCGCTGGATGGAGATCAACATGCAGACC AACCTGCAGAGCGTCTGCAGGACCGCATTCCAACTGAAGATCATCCCTTATTTGATC CCAACAAACGGTGTTGCGATGATTCGGAATGCGGCTATTCATGCTGGCCTTGCTGTT ATGGATAAGCTTTGTTATCGCGGCCTCATCCAGTGTCAACGAATAAGTAAAACGATT GCAGT (SEQ ID NO:329) Translation: MMSKLGALLTICLLLFSLTAVPLDGDQHADQPAERLQDRIPTEDHPLFDPNKRCCDDSE CGYSCWPCCYG (SEQ ID NO:330) Toxin Sequence: Cys-Cys-Asp-Asp-Ser-Xaal -Cys-Gly-Xaa5-Ser-Cys-Xaa4-Xaa3-Cys-Cys-Xaa5-# (SEQ ID NO.331) Name: SS.l Species: spurius Cloned: Yes DNA Sequence: CAAGAAGGATCGATAGCAGTTCATGATGTCTAAACTGGGAGTCTTGCTGACCATCT GTCTGCTTCTGTTTCCACGTACTTCTCTTCCGCTGGATGGAGATCAACCTGCAGTCCG ATCTGCAAAGCGTATGCATTCATCTATACAGCGTCGTTTCTTTGATCCCGTCAAACG GTGTTGCCCTAGATGCAGCGAGTGCAACCCTTGTTGTGGATGACCAGCTTTGTCATC GCGGCCTCATTAAGTGTCTAATGAATAAGTAAAATGATTGCAGT (SEQ ID NO:332) Translation: MMSKLGNLLTICLLLFPRTSLPLDGDQPANRSAKRMHSSIQRRFFDPVKRCCPRCSECNP CCG (SEQ ID NO:333) Toxin Sequence: Cys-Cys-Xaa3-Arg-Cys-Ser-Xaal-Cys-Asn-Xaa3-Cys-Cys-# (SEQ ID NO:334) Name: Om3.1 Species: omaria Cloned: Yes DNA Sequence: CAAGAGGGATCGATAGCAGTTCATGATGTCTAAACTGGGAGTCTCGTTGACCATCT GTCTACTTCTATTTTCCCTTACTGCTGTTCCGCTTGATGGAGATCAACATGCAGACCA ACCTGCAGAGCGTCTGCAGGGCGACATTTTATCTGAAAAGCATCCCTTATTTAATCC CGTCAAACGGTGTTGCGATGAGGAAGAATGCAGCAGTGCATGCTGGCCTTGTTGTT GGGGGTGATCAGCTTTGTTATCGCGGCCTCATCAAGTGTCTAATGAATAAGTAAAAT GATTGCAGT (SEQ ID NO:335) Translation: MMSKLGVSLTICLLLFSLTAVPLDGDQHADQPAERLQGDILSEKHPLFNPVKRCCDEEE CSSACWPCCWG (SEQ ID NO:336) Toxin Sequence: Cys-Cys-Asp-Xaal -Xaal -Xaal -Cys-Ser-Ser-Ala-Cys-Xaa4-Xaa3-Cys-Cys-Xaa4-# (SEQ ID NO:337) Name: Om3.2 Species: omaria Cloned: Yes DNA Sequence: CAAGAAGGATCGATAGCAGTTCATGATGTCTAAACTGGGAGTCTTGTTGATCATCTG TCTACTTCTGTGTCCCCTTACTGCTGTTCTGGAGGATGGAGATCAACCTGCAGACCG ACCTGCAGAGCGTATGCAGGACGACATTTCAACTGAGCATCATCCCTTTTATGATCC CGTCAAACGGTGTTGCAAGTACGGGTGGACATGCTTGCTAGGATGCACTCCTTGTGA TTGTTGACCAGTTTTGTTATCGCGGCCTCGTCAAGTGTCTAATGAATAAGTAAAACG ATTGCAGT (SEQ ID NO:338) Translation: MMSKLGVLLIICLLLCPLTAVLEDGDQPADRPAERMQDDISTEHHPFYDPVKRCCKYG WTCLLGCTPCDC (SEQ ID NO:339) Toxin Sequence: Cys-Cys-Lys-Xaa5-Gly-Xaa4-Thr-Cys-Leu-Leu-Gly-Cys-Thr-Xaa3-Cys-Asp-Cys- A (SEQ ID NO:340) Name: Om3.3 Species: omaria Cloned: Yes DNA Sequence: CAAGAGGGATCGATAGCAGTTCATGATGTCTATACTGGGAGTCTTGTTGATCATCTG TCTACTTCTGTGTCCCCTTACTGCTGTTCTGGAGGATGGAGATCAACCTGCAGACCG ACCTGCAGAGCGTATGCAGGACGGCATTTCATCTGAACATCATCCCTTTTTGGATCC CGTCAAACGGTGTTGCCATCTATTGGCATGCCGCTTTGGATGCTCGCCTTGTTGTTG GTGACCAGCTTTGTTATCGCGGCCTCATCAAGTGTCTAATGAATAAGTAAAACGATT GCAGT (SEQ ID NO:341) Translation: MMSILGVLLIICLLLCPLTAVLEDGDQPADRPAERMQDGISSEHHPFLDPVKRCCHLLAC RFGCSPCCW (SEQ ID NO:342) Toxin Sequence: Cys-Cys-His-Leu-Leu-Ala-Cys-Arg-Phe-Gly-Cys-Ser-Xaa3-Cys-Cys-Xaa4- A (SEQ ID NO:343) Name: Om3.4 Species: omaria Cloned: Yes DNA Sequence: CAAGAAGGATCGATAGCAGTTCATGATGTCTAAACTGGGAGTCTTGTTGATCATCTG TCTACTTCTTTGTCCCCTTACTGCTGTTCCGCAGGATGGAGATCAACCTGCAGACCG ACCTGCAGAGCGTATGCAGGGCGGCATTTCATCTGAACATCATCCCTTTTTTGATCC CGTCAAACGGTGTTGCAGGTACGGGTGGACATGCTGGCTAGGATGCACTCCCTGTG GTTGTTGACCAGCTTTGTTATCGCGGCCTCATCAAGTGTCTAATGAATAAGTAAAAC GATTGCAGT (SEQ TD NO:344) Translation: MMSKLGVLLIICLLLCPLTAVPQDGDQPADRPAERMQGGISSEHHPFFDPVKRCCRYGW TCWLGCTPCGC (SEQ TD NO:345) Toxin Sequence: Cys-Cys-Arg-Xaa5-Gly-Xaa4-Thr-Cys-Xaa4-Leu-Gly-Cys-Thr-Xaa3-Cys-Gly-Cys- A (SEQ ID NO:346) Name: Ep3.1 Species: episcopatus Cloned: Yes DNA Sequence: CAAGAAGGATCGATAGCAGTTCATGATGTCTAAACTGGGAGTCTTGTTGACCATCTG TCTACTTCTGTTTTCCCTTATTGCTGTTCCGCTTGATGGAGATCAACATGC AGACC AA CCTGCAGAGCGTCTGCAGGGCGACATTTTATCTGAAAAGCATCCCTTATTTATGCCT GTCAAACGGTGTTGCGATGAGGACGAATGCAACAGTTCATGCTGGCCTTGTTGTTGG GGGTGATCAGCTTTGTTATCGCGGCCTGATCAAGTGTATAATGAATAAGTAAAACG ATTGCAGT (SEQ ID NO:347) Translation: MMSKLGVLLTICLLLFSLIAVPLDGDQHADQPAERLQGDILSEKHPLFMPVKRCCDEDE CNSSCWPCCWG (SEQ ID NO:348) Toxin Sequence: Cys-Cys-Asp-Xaal -Asp-Xaal -Cys-Asn-Ser-Ser-Cys-Xaa4-Xaa3-Cys-Cys-Xaa4-# (SEQ TD NO:349) Name: Eρ3.2 Species: episcopatus Cloned: Yes DNA Sequence: CAAGAGGGATCGATAGCAGTTCATGATGTCTAAACTGGGAGTCTTGTTGACCATCTG TCTACTTCTGTTTTCCCTTATTGCTGTTCCGCTTGATGGAGATCAACATGCAGACCAA CCTGCAGAGCGTCTGCAGGGCGACATTTTATCTGAAAAGCATCCCTTATTTATGCCT GTCAAACGGTGTTGCGATGAGGACGAATGCAGCAGTTCATGCTGGCCTTGTTGTTGG GGATGAGCAGCTTTGTTATCGCGGCCTCATCAAGTGTCTAATGAATAAGTAAAACG ATTGCAGT (SEQ ID NO:350) Translation: MMS_KLGVLLTICLLLFSLIAWLDGDQHADQPAERLQGDILSEKHPLFMPVKRCCDEDE CSSSCWPCCWG (SEQ ID NO:351) Toxin Sequence: Cys-Cys-Asp-Xaal -Asp-Xaal -Cys-Ser-Ser-Ser-Cys-Xaa4-Xaa3-Cys-Cys-Xaa4-# (SEQ TD NO:352) Name: Ep3.3 Species: episcopatus Cloned: Yes DNA Sequence: CAAGAGGGATCGATAGCAGTTCATGATGTCTAAACTGGGAGTCTTGTTGACCATCTG TCTACTTCTGTTTTCCCTTACTGCTGTTCCGCTTGATGGAGATCAACATGCAGACCAA CCTGCAGAGCGTCTGCAGGGCGACATTTTATCTGAAAAGCATCCCTTATTTAATCCC GTCAAACGGTGTTGCCCGGCGGCGGCATGTGCCATGGGATGCAAGCCTTGTTGTGG ATGAGCAGCTTTGTTATCGTGGCCTCATCAAGTGTCTAATGAATAAGTAAAACGATT GCAGT (SEQ ID NO:353) Translation: MMSKLGVLLTICLLLFSLTAVPLDGDQHADQPAERLQGDILSEKHPLFNPVKRCCPAAA CAMGCKPCCG (SEQ ID NO:354) Toxin Sequence: Cys-Cys-Xaa3-Ala-Ala-Ala-Cys-Ala-Met-Gly-Cys-Lys-Xaa3-Cys-Cys-# (SEQ ID NO:355) Name: Au3.2 Species: aulicus Cloned: Yes DNA Sequence: CAAGAGGGATCGATAGCAGTTCATGATGTCTAAACTGGGAGTCTTGTTGACCATCTG TCTGCTTCTGTTTTCCGTTACTGCTCTTCCGCCGGATGGAGATCAACCTGCAGACCG AGCTGCAGAGCGTAGGCAGGTCGAGCAGCATCCCGTGTTTGATCATGAAAGAGGGT GTTGCTCGCCACCATGCCACAGTATTTGCGCTGCTTTCTGTTGCGGGTGATGATAAC GTGTTGATGACCCACTTTGTCATCACGGCTGCGTCAAGTGTCTAATGAATAAGTAAA ATGATTGCAGT (SEQ ID NO:356) Translation: MMSKLGVLLTICLLLFSVTALPPDGDQPADRAAERRQVEQHPVFDHERGCCSPPCHSIC AAFCCG (SEQ ID NO:357) Toxin Sequence: Gly-Cys-Cys-Ser-Xaa3-Xaa3-Cys-His-Ser-Ile-Cys-Ala-Ala-Phe-Cys-Cys-# (SEQ ID NO:358) Name: Au3.3 Species: aulicus Cloned: Yes DNA Sequence: CAAGAGGGATCGATAGCAGTTCATGATGTCTAAACTGGGAGTCTTGTTGACCATCTG TCTACTTCTGTTTTCCCTTACTGCTGTTCCGCTTGATGGAGATCAACATGCAGACCAA CCTGCAGAGCGTCTGCAGGGCGACATTTTATCTGAAAAGCATCCCTTATTTAATCCC GTCAAACGGTGTTGCCGACCGGTGGCATGTGCCATGGGATGCAAGCCTTGTTGTGG ATGAGCAGCTTTGTTATCGTGGCCTCATCAAGTGTCTAATGAATAAGTAAAATGATT GCAGT (SEQ ID NO:359) Translation: MMSKLGNLLTICLLLFSLTANPLDGDQHADQPAERLQGDILSEKHPLFNPVKRCCRPVA CAMGCKPCCG (SEQ ID NO:360) Toxin Sequence: Cys-Cys-Arg-Xaa3-Val-Ala-Cys-Ala-Met-Gly-Cys-Lys-Xaa3-Cys-Cys-# (SEQ TD NO:361) Name: Au3.4 Species: aulicus Cloned: Yes DNA Sequence: CAAGAGGGATCGATAGCAGTTCaTGATGTCTAAACTGGGAGTCTTGTTGATCATCTG TCTACTTCTGTCTCCCCTTACTGCTGTTCCGCTGGATGGAGATCAACCTGCAGACCG ACCTGCAGAGCGTATGCAGGACGACATTTCATCTGAACATCAACCCATGTTTGATGC CATCAGACAGTGTTGCCCGGCGGTGGCATGCGCCATGGGATGCGAGCCTTGTTGTG GATGACCAGCTTTGTTATCGCGGCCTCATCAAGTGTCTAATGAATAAGTAAAATGAT TGCAGT (SEQ ID NO:362) Translation: MMSKLGVLLIICLLLSPLTAVPLDGDQPADRPAERMQDDISSEHQPMFDAIRQCCPAVA CAMGCEPCCG (SEQ ID NO:363) Toxin Sequence: Xaa2-Cys-Cys-Xaa3-Ala-Val-Ala-Cys-Ala-Met-Gly-Cys-Xaal-Xaa3-Cys-Cys-# (SEQ TD NO:364) Name: Ae3.1 Species: aureus Cloned: Yes DNA Sequence: CAAGAAGGATCGATAGCAGTTCATGATGTCTAAACTGGGAGCCTTGTTGACCATCT GTCTACTTCTGTTTTCCCTTACTGCTGTTCCGCTGGATGGAGATCAACATGCAGACC AACATGCAGAGCGTCTGCATGACCGCCTTCCAACTGAAAATCATCCCTTATATGATC CCGTCAAACGGTGTTGCGATGATTCGGAATGCGACTATTCTTGCTGGCCTTGCTGTA TTTTTGGATAACCTTTGTTATCGCGGCCTCATCAAGTGTCAAATGAATAAGTAAAAC GATTGCAGT (SEQ ID NO:365) Translation: MMSKLGALLTICLLLFSLTAVPLDGDQHADQHAERLHDRLPTENHPLYDPVKRCCDDS ECDYSCWPCCIFG (SEQ ID NO:366) Toxin Sequence: Cys-Cys-Asρ-Asρ-Ser-Xaal-Cys-Asp-Xaa5-Ser-Cys-Xaa4-Xaa3-Cys-Cys-Ile-Phe-# (SEQ ID NO:367) Name: Ae3.2 Species: aureus Cloned: Yes DNA Sequence: CAAGAGGGATCGATAGCAGTTCATGATGTCTAAACTGGGAGCCTTGTTGACCATCT GTCTACTTCTGTTTTCCCTAACTGCTGTTCCGCTGGATGGAGATCAACATGCAGACC AACCTGCAGAGCGTCTGCAGGACCGCATTCCAACTGAAAATCATCCCTTATTTGATC CGAACAAACGGTGTTGCAATGATTGGGAATGCGACGATTCATGCTGGCCTTGCTGTT ATGGATAACCTTTGTTATCGCGGCCTCATCAAGTGTCAAATGAATAAGTAAAACGAT TGCAGT (SEQ TD NO:368) Translation: MMSKLGALLTICLLLFSLTAVPLDGDQHADQPAERLQDRIPTENHPLFDPNKRCCNDWE CDDSCWPCCYG (SEQ ID NO:369) Toxin Sequence: Cys-Cys-Asn-Asρ-Xaa4-Xaal-Cys-Asp-Asp-Ser-Cys-Xaa4-Xaa3-Cys-Cys-Xaa5-# (SEQ ID NO:370) Name: Cn3.1 Species: consors Cloned: Yes DNA Sequence: CAAGAGGGATCGATAGCAGTTCATGATGTCTAAACTGGGAGTCTTGTTGACCATCTG TTTGCTTCTGTTTCCCCTTACTGCTCTTCCAATGGATGGAGATCAATCTGTAGACCGA CCTGCAGAGCGTATGCAGGACGACATTTCATCTGAGCTGCATCCCTTGTTCAATCAG AAAAGAATGTGTTGCGGCGAAGGTGCGCCATGCCCCAGCTATTTCAGAAACAGTCA GATTTGTCATTGTTGTTAAATGACAACGTGTCGATGACCAACTTCGTTATCACGACT AATGAATAAGTAAAATGATTGCAGT (SEQ ID NO:371) Translation: MMSKLGVLLTICLLLFPLTALPMDGDQSVDRPAERMQDDISSELHPLFNQKRMCCGEG APCPSYFRNSQICHCC (SEQ ID NO:372) Toxin Sequence: Met-Cys-Cys-Gly-Xaal-Gly-Ala-Xaa3-Cys-Xaa3-Ser-Xaa5-Phe-Arg-Asn-Ser-Gln-Ile-Cys-His- Cys-Cys- A (SEQ ID NO:373) Name: Cn3.3 Species: consors Cloned: Yes DNA Sequence: TAAGAGGGATCGATAGCAGTTCATGATGTCTAAACTGGGAGTCTTGTTGACCATCTG TCTGCTTCTGTTTCCCCTTATTGCTCTTCCAATGGATGGAGATCAACCTGCAGACCGA CCTGCAGAGCGTATGCAgGACGACATTTCATCTCAGCAGCATCCCTTGTTTGATAAG AGAGGCCGCTGTTGCGATGTGCCGAACGCATGCTCCGGCAGATGGTGCAGAGATCA CGCACAATGTTGCGGATGACGATAACGTGTTGATGACCAACTTTGTGATCACGGCTA CATCAAGTGAATAAGTAAAACGATTGCAGT (SEQ ID NO:374) Translation: MMSKLGVLLTICLLLFPLIALPMDGDQPADRPAERMQDDISSQQHPLFDKRGRCCDVPN ACSGRWCRDHAQCCG (SEQ ID NO:375) Toxin Sequence: Gly-Arg-Cys-Cys-Asp-Val-Xaa3-Asn-Ala-Cys-Ser-Gly-Arg-Xaa4-Cys-Arg-Asp-His-Ala-Gln- Cys-Cys-# (SEQ ID NO:376) Name: Cn3.4 Species: consors Cloned: Yes DNA Sequence: CAAGAGGGATCGATAGCAGTTCATGATGTCTAAACTGGGAGTCTTGTTGACTGTCTG TTTGCTTCTGTTTCCCCTTACTGCTCTTCCGATGGATGGAGATCAACCTGCAGACCAA CCTGCAGAGCGTATGCAGGACGACATTTCATCTGAGCAGCATCCCTTGTTTGATAAG AGACAAAGGTGTTGCACTGGGAAGAAGGGGTCATGCTCCGGTAAAGCATGCAAAA GTCTCAAATGTTGCTCTGGACGATAACGTGTTGATGACCAACTTTGTTATCACGGCT ACGTCAAGTGTCTAGTGAATAAGTAAAACGATTGCAGT (SEQ ID NO:377) Translation: MMSKLGVLLTVCLLLFPLTALPMDGDQPADQPAERMQDDISSEQHPLFDKRQRCCTGK KGSCSGKACKSLKCCSGR (SEQ ID NO:378) Toxin Sequence: Xaa2-Arg-Cys-Cys-Thr-Gly-Lys-Lys-Gly-Ser-Cys-Ser-Gly-Lys-Ala-Cys-Lys-Ser-Leu-Lys-Cys- Cys-Ser-# (SEQ ID NO:379) Name: Em3.1 Species: emaciatus Cloned: Yes DNA Sequence: CAAGAGGGATCGATAGCAGTTCATGATGTCTAAACTGGGAGTCTTGCTGACCATCTGTCTGCTTCTGTT TCCCCT ACTGTTCTTCCGATGGATGGAGATCAACCTGCAGACCTACCTGCATTGCGTGCGCAGTTCTT TGCACCTGAACATAGTCCCCGGTTTGACCCCGTCAAACGGTGCTGCTCGCGGGATTGCAGTGTTTGCAT CCCT GTTGCCCGTATGGATCACCTTGATTATTGCGGCCACGTCAAGTGTCTAATGAATAAGTAAAATG ATTGCAGT (SEQ ID NO:380) Translation: MMSKLGVLLTICLLLFPLTVLPMDGDQPADLPALRAQFFAPEHSPRFDPVKRCCSRDCSVCIPCCPYGSP (SEQ ID NO:381) Toxin Sequence: Cys-Cys-Ser-Arg-Asp-Cys-Ser-Val-Cys-Ile-Xaa3-Cys-Cys-Xaa3-Xaa5-Gly-Ser-Xaa3- A (SEQ ID NO:382) Where: Xaal is Glu or γ-carboxy-Glu Xaa2 is Gin or pyro-Glu Xaa3 is Pro or hydroxy-Pro Xaa4 is Trp or bromo-Trp Xaa5 is Tyr, 125 I-Tyr, mono-iodo-Tyr, di-iodo-Tyr, O-sulpho-Tyr or O-phospho-Tyr A is free carboxyl or amidated C-terminus, preferably free carboxyl # is free carboxyl or amidated C-terminus, preferably amidated ? = Status of C-term not known. TABLE2 Alignment of μ-Conopeptides (SEQ ID NO:) TYPE 1 A3 . 4 (F283 ) CCKVQ-CES- -C TPC T (383 ) Ak3.1 (F585) CCELP-CGPGFC VPCCT (384) Ar3.1 CCERP-CNIG-C VPCCT (385) Bn.3.1 (F586) CCNWP-CSMG-C IPCCYY~ (386) Bt3.1 CCELP-CH-G-C VPCCWP~ (387) Bt3.2 CCGLP-CN-G-C VPCCWPS Λ (388) Bt3.3 CCSRN-CAV--C IPCCPNWPA Λ (389) bt3a CCKQS-CTT--C MPCC " (390) φ Φ LΠ o o LΠ o LΠ o cπ ι-3 W del ι-3 rt rt m w ω ω ω w μ oi w M μ N rsi~ J if Φ Φ LO σι VD VO Φ M3 si Ul Ul W <! TJ CQ CQ TJ TJ LO to — U014 CCHWN CDHL-C SCCGS" (439) U017 --DCCOLPACPFG-C NOCC# (440) U019 CCAPSACR G-C ROCCR" (441) U020 CCAOSACRLG-C ROCCR Λ (442) U022 CCAPSACRLG-C RPCCR Λ (443) U024 --GCCGSFACRFG-C VOCCV Λ (444) U031 CCS DVCDHPSC TCC# (445) U032 (F353) R--CCKFP-CPDS-C--RYLCC# (446) Ae3.1 CCDDSECDYS-C WPCCIF# (447) Ae3 .2 CCNDWECDDS-C WPCCY# (448) Af3 .1 R--CCR-FPCPDT-C RHLCC# (449) Af3 .2 CC--MTC-FG-C TPCC# (450) A£3 .3 CCDDSECDYS-C WPCCIFS~ (451) Af3 .4 ---CCR-LLC-LS-C---NPCC# (452) Af3 .6 CCDDSECGYS-C WPCCY# (453) Au3 .2 G--CCS-PPCHSI-C--AAFCC# (454) Au3 .3 CCRPVACAMG-C KPCC# (455) Au3.4 Z--CCPAVACAMG-C EPCC# (456) Em3 1 CCS-RDC-SV-C IPCCPYGSP" (457) E 3 1 CCDEDECNSS-C WPCCW# (458) Ep3 2 CCDEDECSSS-C WPCCW# (459) Ep3 3 CCPAAACAMG-C KPCC# (460) Om3 1 CCDEEECSSA-C WPCCW# (461) Om3 3 CCHLLACRFG-C SPCCVT (462) Sf3 1 CC--PRC-SE-C NPCC# (463) TYPE 2 Pn3. .2 (AA049) -RCC--KFP-CPDS-C--KYLCC# (464) Fd3. .2 (Z831) -RCC--RWP-CPSI-C-GMARCCSS Λ (465) Pu3. .3 (AA405) --CC--KLL-CYSG-C TPCCHA (466) Eb3. .1 (Z821) --CC--EQP-CYMG-C IPCCF Λ (467) Eb3. .2 (Z822) --CC--AQP-CYMG-C IPCCF~ (468) Pu3, .2 (AA403) --CC--V-S-CYMG-C IPCCF'- (469) Mf3, .1 (Z882) --CC--DWP-CSAG-C YPCCFP Λ (470) Mf3 .2 (Z885) -GCC--PPM-C-TP-C FPCCFR (471) Ra3 .2 (AA414) RGCCAPPR -C DRACK-PARCCGP# (472) Sm3 .3 (AA419) ZRCCNGRRG-CSSR CRDHSRCC# (473) Cn3 .3 GRCCDVPNA-CSGRWCRDHAQCC# (474) Cn3 .4 ZRCCTGKKGSCSGKACKSL-KCCS# (475) TYPE : I A3.1 -MCCGEGRKCPSYFRNSQICHCC" (476) A3.2 (F84) --CCR-- PCPRQIDGEY-CGCCL# (477) Bu3.5 -RCCGEGLTCPRYWKNSQICACC" (478) Ca3.1 --CCGPGGSCPVYFRDNFICGCC" (479) Cr3.1 RKCCGKDGPCPKYFKDNFICGCC" (480) E3 --CCS--WPCPRYSNGKLVCFCCL# (481) M3 --CCGPGGSCPVYFRDNFICGCC" (482) M3 -MCCGESAPCPSYFRNSQICHCC" (483) M3 ZKCCGPGGSCPVYFTDNFICGCC" (484) M3 ZKCCGPGGSCPVYFRDNFICGCC" (485) S3 ZKCCGEGSSCPKYFKNNFICGCC" (486) U001 ZKCCS-GGSCPLYFRDRLICPCC" (487) U034 ZKCCGPGASCPRYFKDNFICGCC" (488) Cn3.1 -MCCGEGAPCPSYFRNSQICHCC Λ (489) TYPE 4 A3.3 (F83) ZK--CCTGK- --KGSCSGKACKNL-KCCS# (490) A3.5 (Z488) ZK--CCTGR- --KGSCSGKACKNL-KCCS# (491) Bu3.1 VTDRCCK- - - -GKREC-GRWCRDHSRCC# (492) Bu3.1A VGDRCCK- - - -GKRGC-GRWCRDHSRCC# (493) Bu3.2 VGERCCK NGKRGC-GR CRDHSRCC# (494) Bu3.3 IλDRCCN-KGNGKRGC-SRWCRDHSRCC# (495) Bu3.4 VGLYCCRPKPNGQMMC-DRWCEKNSRCCtt (496) Ca3.2 -RD-CCTPP KK-CKDRQCKPQ-RCCA# (497) L3.1 GRD-CCTPP RK-CRDRACKPQ-RCCG# (498) L3.2 ZRL-CCGFP KS-CRSRQCKPH-RCC# (499) La3.2 -RD-CCTPP KK-CRDRQCKPA-RCCG# (500) La3.3 RPP-CCTYD GS-CLKESCMRK-ACC# (501) La3.3A RPP-CCTYD GS-CLKESCKRK-ACCtt (502) μ-GIIIA -RD-CCTOO KK-CKDRQCKOQ-RCCA# (503) μ-GIIIB -RD-CCTOO RK-CKDRRCKOM-KCCA# (504) μ-GIIIC -RD-CCTOO KK-CKDRRCKOL-KCCA# (505) μ-PIIIA ZRL-CCGFO KS-CRSRQCKOH-RCC# (506) M3.1 -RD-CCTPP KK-CKDRQCKPQ-RCCA# (507) Mr3.1 RGG-CCTPP RK-CKDRACKPA-RCCGP# (508) Nb3-.2 (F582) ZK--CCTGK KGSCSGKACKNL-KCCStt (509) Pr3.1 (Z500) RGG-CCTPP KK-CKDRACKPA-RCCGP# (510) Pr3.2 (Z501) -RG-CCTPP RK-CKDRACKPA-RCCGP# (511) R3.1 LOS-CCSLN LRLCOVOACKRN-OCCTtt (512) R3.2 ZQR-CCTVK RICOVOACRSK-OCCKS" (513 ) R3.3 RGG-CCTPP RK-CKDRACKPA-RCCGP# (514) Sm3.1 ZK--CCTGK KGSCSGKACKNL-KCCStt (515) T3.1 H-G-CCKGO EG-CSSRECROQ-HCC# (516) T3.2 (Y088) H-G-CCEGP KG-CSSRECRPQ-HCC# (517) Wi3.1 (M548) LPS - CCDFE RLCWPACIRH-QCCTtt ( 518 ) Type 5 Om3 . 2 CCKYGWTCLLGCTPCDC Λ ( 519 ) Om3.4 CCRYGWTCWLGCTPCGC" (520) Type 6 S3.2 (F352) Z-NCCNGG-CSSKWCRDHARCC# (432) EXAMPLE 3 Effect of Intrathecal Administration of μ-Conopeptides [0087] Male C57 black mice (20-25g) are obtained from Charles River Laboratories. These mice and the animals are housed in a temperature controlled (23° ± 3° C) room with a 12 hour light-dark cycle with free access to food and water. All animals are euthanized in accordance with Public Health Service policies on the humane care of laboratory animals. [0088] Intrathecal (it) drug injections are performed as described (Hylden and Wilcox, 1980). A μ-conopeptide or vehicle is administered in a volume of 5 μl. Duration of hind-limb paralysis is assessed. This experiment reveals that injection of μ-conopeptides into the intrathecal space of C57 black mice produced a paralysis of the animal. The animals in this experiment recovered fully. EXAMPLE 4 Effect of μ-Conopeptides as a Local Anesthetic [0089] Male Hartley guinea pigs (retired breeders) are obtained form Charles River Laboratories. The local anesthetic test is performed essentially as described (Bulbring and Wajda, 1945). On the day prior to test day, a patch on the back of the guinea pig is denuded of hair, first by shaving with electric clippers and subsequently with depilatory cream (Nair®). Depilatory cream is applied for five minutes and removed with a warm washcloth. The guinea pigs are dried and returned to their cages. On the following day, intradermal injections (0.1 ml vols) of lidocaine, bupivacaine, a μ-conopeptide or vehicle (0.5% cyclodextran) are made into the denuded patch. The injection produced a raised wheal on the surface of the skin which is circled with a felt-tipped pen. Typically, four injections are made on the back of each guinea pig. In some cases, guinea pigs are reused following at least one week of recovery and injecting into an unused portion ofthe skin. The stimulus consists of mild pin pricks (not hard enough to break the skin) with a 26G needle. The response is a localized skin twitch caused by contraction of cutaneous muscles. A unit test consisted of six uniform pin pricks, 3-5 seconds apart, within the injected area. Unit scores range from 0 (complete anesthesia) to 6 (no anesthesia). For potency experiments, the unit test is repeated at each site at five minute intervals for 30 minutes, and unit test scores summed (with 36 representing no anesthesia to 0 representing complete anesthesia. For duration experiments, unit tests are performed as described over the course of several hours to days. [0090] μ-Conopeptides of the present invention produce a potent and long lasting local anesthetic effect in the intracutaneous wheal test in the guinea pig. As expected, bupivacaine has a slightly longer duration thatn lidocaine, consistent with clinical observations. EXAMPLE 5 Muscle Relaxant Effect of μ-Conopeptides in Anesthetized Monkeys [0091] μ-Conopeptides are dissolved 0.9 percent saline at a concentration of 2 mg/ml. Rhesus monkeys are anesthetized with halothane, nitrous oxide and oxygen. The maintenance concentration of halothane is 1.0%. Arterial and venous catheters are placed in the femoral vessels for drug administration and recording of the arterial pressure. Controlled ventilation is accomplished via an endotrachael tube. Twitch and tetanic contractions of the tibialis arterior muscle are elicited indirectly via the sciatic nerve. Recordings of arterial pressure electrocardiogram (lead I), heart rate, and muscle function are made simultaneously. Four to six animals received each listed compound. Four additional animals received succinylcholine chloride or d-tubocurarine chloride as controls. It is seen that the tested μ-conopeptides generally provide similar or better results than those seen for succinylcholine chloride or d- tubocurarine chloride. EXAMPLE 6 In vivo Activity of μ-Conopeptides in Pain Models [0092] The anti-pain activity of μ-conopeptides is shown in several animal models. These models include the nerve injury model (Chaplan, et al., 1997), the nocioceptive response to s.c. formalin injection in rats (Codene, 1993) and an NMDA-induced persistent pain model (Liu, et al, 1997). In each of these models it is seen that the μ-conopeptides and μ-conopeptides derivatives have analgesic properties. [0093] More specifically, this study evaluates the effect of intrathecal administration of μ-conopeptides in mice models of nocioceptive and neuropathic pain. For nocioceptive pain, the effect of the μ-conopeptides is studied in two different tests of inflammatory pain. The first is the formalin test, ideal because it produces a relatively short-lived, but reliable pain behavior that is readily quantified. There are two phases of pain behavior, the second of which is presumed to result largely from formalin-evoked inflammation of the hind paw. A μ-conopeptide is administered 10 minutes prior to injection of formalin. The number of flinches and/or the duration of licking produced by the injection is monitored. Since the first phase is presumed to be due to direct activation of primary afferents, and thus less dependent on long term changes in the spinal cord, μ-conopeptides are presumed to have greatest effect on the magnitude of pain behavior in the second phase. [0094] The mechanical and thermal thresholds in animals that received an injection of complete Freund's adjuvant into the hind paw are also studied. This produces a localized inflammation including swelling of the hind paw and a profound decrease in mechanical and thermal thresholds, that are detected within 24 hours after injection. The changes in thresholds in rats that receive μ-conopeptides are compared with those of rats that receive vehicle intrathecal injections. [0095] An important issue is whether the drugs are effective when administered after the pain model has been established, or whether they are effective only if used as a pretreatment. Clearly, the clinical need is for drugs that are effective after the pain has developed. To address this issue, animals are studied in which μ-conopeptides are administered repeatedly, after the inflammation (CFA) or nerve injury has been established. In these experiments, a μ-conopeptide is injected daily by the intrathecal (i.t.) route. The mechanical and thermal thresholds (measured, respectively, with von Frey hairs in freely moving animals and with the Hargreave's test, also in freely moving animals) are repeated for a 2 to 4 week period after the injury is induced and the changes in pain measured monitored over time. EXAMPLE 7 Effect of u-Conotoxins in a Pain Model [0096] Analgesic activity of μ-conotoxins is also tested in pain models as follows. [0097] Persistent pain (formalin test). Intrathecal (it) drug injections are performed as described by Hylden and Wilcox (1980). An μ-conopeptide or vehicle is administered in a volume of 5 μl. Fifteen minutes after the i.t. injection, the right hindpaw is injected with 20 μl of 5% formalin. Animals are placed in clear plexiglass cylinders backed by mirrors to facilitate observation. Animals are closely observed for 2 minutes per 5 minute period, and the amount of time the animal spent licking the injected paw is recorded in this manner for a total of 45-50 minutes. Results are expressed as licking time in seconds per five minutes. At the end of the experiment, all animals are placed on an accelerating rotorod and the latency to first fall was recorded. μ-Conopeptides are found to be active in this model which is predictive of efficacy for treating neuropathic pain. [0098] Acute pain (tail-flick). A μ-conopeptide or saline is administered intrathecally (i.t.) according to the method of Hylden and Wilcox (1980) in a constant volume of 5 μl. Mice are gently wrapped in a towel with the tail exposed. At various time-points following the i.t. injection, the tail is dipped in a water bath maintained at 54° C. and the time to a vigorous tail withdrawal is recorded. If there is no withdrawal by 8 seconds, the tail is removed to avoid tissue damage. [0099] Neuropathic pain. The partial sciatic nerve ligation model is used to assess the efficacy of μ-conopeptides in neuropathic pain. Nerve injury is produced according to the methods of Malmberg and Basbaum (1998). Animals are anesthetized with a ketamine/xylazine solution, the sciatic nerve is exposed and tightly ligated with 8-0 silk suture around 1/3 to Vz of the nerve. In sham-operated mice the nerve is exposed, but not ligated. Animals are allowed to recover for at least 1 week before testing is performed. On the testing day, mice are placed in plexiglass cylinders on a wire mesh frame and allowed to habituate for at least 60 minutes. Mechanical allodynia is assessed with calibrated von Frey filaments using the up-down method as described by Chaplan et al. (1994), and the 50% withdrawal threshold is calculated. Animals that did not respond to any of the filaments in the series are assigned a maximal value of 3.6 grams, which is the filament that typically lifted the hindlimb without bending, and corresponds to approximately 1/10 the animal's body weight. [0100] The data obtained demonstrate that μ-conopeptides have potent analgesic properties in three commonly used models of pain: acute, persistent/inflammatory and neuropathic pain models. EXAMPLE 8 Activity of μ-Conopeptide S3.2 onNeuronal Sodium Channels [0101] μ-Conopeptide S3.2 was tested for activity on sodium channels as follows. S3.2 was administered to mice by intracerbroventricular (ICV) injection. Administration of S3.2 in this manner caused mice to show a spectrum of activity that is charcteristic of all sodium channel blockers, including rapdi loss of righting reflex, coma-like inactivity and spastic uncontrolled limb movement. Following intrathecal (it) administration to mice, S3.2 causes rapid hindlimb paralysis that spreads to include the entire body over a course of 10-20 minutes followed by death, presumably due to respiratory paralysis. However, unlike classic μ- conopeptides, S3.2 has no significant activity following intravenous administration (iv) to mice. Classic μ-conopeptides, such as GIIIA and PIIIA, cause rapid paralysis and death following iv administration, indicating their activity at skeletal muscle sodium channels. To confirm the selectivity of S3.2, 80 nmol was administered iv to rats. The effect of S3.2 was measured on skeletal muscle contraction, blood pressure and heart rate. S3.2 was found to have no effect on any of these parameters. Controls were performed using classical μ-conopeptides, including Sm3.1, Sm.3.3 and Bu3.1 described herein, also administered iv at 80 nmol. These control peptides caused a dramatic decrease in skeletal muscle contractility, as well as a significant drop in systemic blood pressure. Thus, μ-conopeptide S3.2 suprisingly is selective for neuronal sodium channels. The most obvious difference between the S3.2 sequence and the sequences of these other peptides is a shortened first loop (the first loop between cysteine residues) which lacks a charged amino acid. [0102] It will be appreciated that the methods and compositions of the instant invention can be incorporated in the form of a variety of embodiments, only a few of which are disclosed herein. It will be apparent to the artisan that other embodiments exist and do not depart from the spirit of the invention. Thus, the described embodiments are illustrative and should not be construed as restrictive. BIBLIOGRAPHY Abiko, H. et al. (1986). Brain Res. 38:328-335. Aldrete, J.A. et al. (1979). Crit. Care Med. 7:466-470. Barnay, G. et al. (2000). J. Med. Chem. Bitan, G. et al. (1997). J Peptide Res. 49:421-426. Bodansky et al. (1966). Chem. Ind. 38:1597-98. Bulbring, W. and Wajda, j. (1945). J. Pharmacol. Exp. Ther. 85:78-84. Cartier, G.E. et al. (1996). J. Biol. Chem. 271:7522-7528. Chandler, P. et al. (1993). J. Biol. Chem. 268:17173-17178. Chaplan S.R. (1994). J Neuroscience Methods 53:55-63. Chaplan S.R. (1997). J Pharmacol. Exp. Ther. 280:829-838. Clark, C. et al. (1981). Toxicon 19:691-699. Codere, TJ. (1993). Eur. J. Neurosci. 5:390-393. Craik, D.j. et al. (1991). Toxicon 39:43-60. Cmz, LJ. at al. (1976). Verliger 18:302-308. Ettinger, LJ. et al. (1978). Cancer 41:1270-1273. Goodman and Gilman 's The Pharmacological Basis of Therapeutics, Seventh Ed., Gilman, A.G. et al., eds., Macmillan Publishing Co., New York (1985). Hammerland et al. (1992). Eur. J. Pharmacol. 226:239-244. Heading, C. (1999). Curr. Opin. CPNS Invest. Drugs 1:153-166 Horiki, K. et al. (1978). Chemistry Letters 165-68. Hubry, V. et al. (1994). Reactive Polymers 22:231-241. Hylden, J.L.K.and Wilcox, G. (1980). Eur. J. Pharmacol. 67:313-316. Kaiser et al. (1970). Anal. Biochem. 34:595. Kapoor (1970). J. Pharm. Sci. 59:1-27. Kornreich, W.D. et al. (1986). U.S. Patent No. 4,569,967. Luer, M.S. & Hatton, j. (1993). Annals Pharmcotherapy 27:912-921. Liu, H. et al. (1997). Nature 386:721-724. Malmberg, A.B. and Basbaum, A.I. (1998). Pain 76:215-222. Martinez, J.S. et al. (1995). Biochem. 34:14519-14526. Mclntosh, J. M. et al. (1998). Methods Enzymol. 294:605-624. The Merck Manual of Diagnosis and Therapy, 16 Ed., Berkow, R. et al., eds., Merck Research Laboratories, Rahway, NX, pp. 1436-1445 (1992). Methoden der Organischen Chemie (Houben-Weyl): Synthese von Peptiden, E. Wunsch (Ed.), Georg Thieme Verlag, Stuttgart, Ger. (1974). Nehlig, A. et al. (1990). Effects of phenobarbital in the developing rat brain. In Neonatal Seizures, Wasterlain, CG. and Vertt, P. (eds.), Raven Press, New York, pp. 285-194. Nishiuchi, Y. et al. (1993). Int. J. Pept. Protein Res. 42:533-538. Olivera, B.M. et al. (1984). U.S. Patent 4,447,356. Olivera, B.M. et al. (1985). Science 230:1338-1343. Olivera, B.M. et al. (1990). Science 249:257-263. Olivera, B.M. et al. (1996). U.S. Patent 5,514,774. Omstein, et al. (1993). Biorganic Medicinal Chemistry Letters 3:43-48. Remington's Pharmaceutical Sciences, 18th Ed. (1990, Mack Publishing Co., Easton, PA). Rivier, J.R. et al. (1978). Biopolymers 17:1927-38. Rivier, J.R. et al. (1987). Biochem. 26:8508-8512. Sambrook, J. et al. (1989). Molecular Cloning: A Laboratory Manual, 2nd Ed., Cold Spring Harbor Laboratory, Cold Spring Harbor, NY. Shon, K.-J. et al. (1994). Biochemistry 33:11420-11425. Stewart and Young, Solid-Phase Peptide Synthesis, Freeman & Co., San Francisco, CA (1969). Vale et al. (1978). U.S. Patent 4,105,603. Troupin, A.S. et al. (1986). MK-801. In New Anticonvulsant Drugs, Current Problems in Epilepsy 4, Meldrum, B.S. and Porter, R.J. (eds.), John Libbey, London, pp. 191-202. Van de Steen, P. et al. (1998). Critical Rev. in Biochem. and Mol. Biol. 33:151-208. White, H.S., et al. (1992). Epilepsy Res. 12:217-226. White, H.S., et al. (1995). Experimental Selection, Quantification, and Evaluation of Antiepilep- tic Drugs. In Antiepileptic Drugs, 4th Ed., Levy, R.H., eds., Raven Press, N.Y., pp. 99- 110. Wong, E.H.P. et al. (1986). Proc. Natl. Acad. Sci. USA 83:7104-7108. Zhou L.M., et al. (1996). J. Neurochem. 66:620-628. Zimm, S. et al. (1984). Cancer Res. 44:1698-1701. U.S. Patent No. 3,842,067. U.S. Patent No. 3,862,925. U.S. Patent No. 3,972,859. U.S. Patent No. 5,514,774. U.S. Patent No. 5,550,050. U.S. Patent No. 5,670,622. U.S. Patent No. 5,719,264. U.S. Patent No. 5,844,077 (1998). Published PCT Application WO 92/19195. Published PCT Application WO 94/25503. Published PCT Application WO 95/01203. Published PCT Application WO 95/05452. Published PCT Application WO 96/02286. Published PCT Application WO 96/02646. Published PCT Application WO 96/40871. Published PCT Application WO 96/40959. Published PCT Application WO 97/12635. Published PCT Application WO 98/03189. Published PCT Application WO 00/23092.

Claims: WHAT IS CLAIMED IS: 1. An isolated peptide selected from the group consisting of: (a) a peptide set forth in Table 1 or Table 2 and (b) a derivative ofthe peptide in (a). 2. The isolated peptide of claim 1, wherein Xaa t is Glu, Xa^ is pyro-Glu, Xaa 4 is Trp and Xaa 5 is Tyr. 3. The derivative of the peptide of claim 1 , in which the Arg residues may be substituted by Lys, ornithine, homoargine, nor-Lys, N-methyl-Lys, N,N-dimethyl-Lys, N,N,N- trimethyl-Lys or any synthetic basic amino acid; the Lys residues may be substituted by Arg, ornithine, homoargine, nor-Lys, or any synthetic basic amino acid; the Tyr residues may be substituted with meta-Tyr, ortho-Tyr, nor-Tyr, mono-halo-Tyr, di-halo-Tyr, O- sulpho-Tyr, O-phospho-Tyr, nitro-Tyr or any synthetic hydroxy containing amino acid; the Ser residues may be substituted with Thr or any synthetic hydroxylated amino acid; the Thr residues may be substituted with Ser or any synthetic hydroxylated amino acid; the Phe residues may be substituted with any synthetic aromatic amino acid; the Trp residues may be substituted with Trp (D), neo-Trp, halo-Trp (D or L) or any aromatic synthetic amino acid; the Asn, Ser, Thr or Hyp residues may be glycosylated;. the Tyr residues may also be substituted with the 3-hydroxyl or 2-hydroxyl isomers (meta-Tyr or ortho-Tyr, respectively) and corresponding O-sulpho- and O-phospho-derivatives; the acidic amino acid residues may be substituted with any synthetic acidic amino acid, e.g., tetrazolyl derivatives of Gly and Ala; the aliphatic amino acids may be substituted by synthetic derivatives bearing non-natural aliphatic branched or linear side chains C n H 2n+2 up to and including n=8; the Met residues may be subsituted by Nle; the Cys residues may be in D or L configuration and may optionally be substituted with homocysteine (D or L); pairs of Cys residues may be replaced pairwise with isoteric lactam or ester- thioether replacements, such as Ser/(Glu or Asp), Lys/(Glu or Asp), Cys/Glu (or Asp) or Cys/Ala combinations; and the peptide may be radioiodinated or radiotriated. 4. A substantially pure μ-conotoxin peptide derivative comprising a permutant of the peptide of claim 1,2 or 3. 5. A substantially pure μ-conotoxin peptide derivative comprising the peptide or peptide derivative of claim 1, 2 or 3 modified to contain an O-glycan, an S-glycan or an N- glycan. 6. A substantially pure μ-conotoxin peptide derivative comprising the peptide derivative of claim 4 modified to contain an O-glycan, an S-glycan or an N-glycan. 7. An isolated nucleic acid encoding a μ-conopeptide propeptide having an amino acid sequence set forth in Table 1. 8. The isolated nucleic acid of claim 7, wherein the nucleic acid comprises a nucleotide sequence set forth in Table 1. 9. An isolated μ-conopeptide propeptide having an amino acid sequence set forth in Table 1. 10. A method for treating or preventing disorders associated with voltage gated ion channel disorders in which comprises administering to a patient in need thereof a therapeutically effective amount of a peptide of claim 1 or a pharmaceutically acceptible salt thereof. 11. The method of claim 10, wherein said disorder is a neurologic disorder. 12. The method of claim 11, wherein said neurologic disorder is Amytrophic Lateral Sclerosis. 13. The method of claim 11 , wherein said neurologic disorder is head trauma. 14. The method of claim 11, wherein said neurologic disorder is epilepsy. 15. The method of claim 11, wherein said neurologic disorder is a neurotoxic injury associated with conditions of hypoxia, anoxia or ischemia. 16. The method of claim 15, wherein said neurotoxic injury is associated with stroke, cerebrovascular accident, brain or spinal cord trauma, myocardial infarct, physical trauma, drownings, suffocation, perinatal asphyxia, or hypoglycemic events. 17. The method of claim 10, wherein said disorder is pain. 18. The method of claim 17, wherein said pain is migraine, acute pain, persistent pain, chronic pain, neuropathic pain or nociceptive pain. 19. The method of claim 18, wherein the pain is trigeminal neuralgia, diabetic neuropathy, post-herpetic neuralgia, neuroma pain, phantom limb pain. 20. The method of claim 17, wherein said pain is burn pain. 21. The method of claim 10, wherein said disorder is a neuromuscular disorder. 22. The method of claim 21, wherein said neuromuscular disorder is myofacial pain syndrome, chronic muscle spasm, dystonias or spasticity. 23. A method for providing musculoskeletal relaxation in a patient undergoing a surgical procedure requiring anesthesia which comprises administering to a patient in need thereof a therapeutically effective amount of a peptide of claim 1 or a pharmaceutically acceptible salt thereof. 24. A method of alleviating pain which comprises administering to a mammal that is either exhibiting pain or is about to be subjected to a pain-causing event a pain-alleviating amount of a peptide of claim 1 or a pharmaceutically acceptible salt thereof. 25. The method of claim 24, wherein the peptide is administered as a local anesthetic. 26. The method of claim 24, wherein the peptide is administered as an occular anesthetic. 27. A method for characterizing a pore occlusion site on a sodium channel subtype comprising determining the affinity of said site for a peptide of claim 1. 28. The method of claim 27, wherein said sodium channel subtype is a neuronal sodium channel subtype and said peptide is μ-conopeptide S3.2 comprising an amino acid sequence as set forth in SEQ ID NO:211 or SEQ ID NO:432. 29. A method for screening a small molecule library to identify a small molecule which is a selective blocking agent of a sodium channel subtype comprising (a) measuring the blocking activity of a small molecule on said sodium channel subtype, (b) measuring the blocking activity of a peptide of claim 1 on said sodium channel subtype and (c) comparing the blocking activity of said small molecule with the blocking activity of said peptide. 30. The method of claim 29, wherein said sodium channel subtype is a neuronal sodium channel subtype and said peptide is μ-conopeptide S3.2 comprising an amino acid sequence as set forth in SEQ ID NO:211 or SEQ ID NO:432. 31. A method for screening a small molecule library to identify a small molecule which is a selective blocking agent of a sodium channel subtype comprising (a) measuring the binding affinity of a small molecule on said sodium channel subtype, (b) measuring the binding affinity of a peptide of claim 1 on said sodium channel subtype and (c) comparing the binding affinity of said small molecule with the binding affinity of said peptide. 32. The method of claim 31 , wherein said peptide is radiolabeled. 33. The method of claim 31, wherein said sodium channel subtype is a neuronal sodium channel subtype and said peptide is μ-conopeptide S3.2 comprising an amino acid sequence as set forth in SEQ ID NO:211 or SEQ TD NO:432. 34. The method of claim 33, wherein said peptide is radiolabeled. 35. A method for screening a small molecule library to identify a small molecule which is a selective blocking agent of a sodium channel subtype comprising (a) allowing a peptide of claim 1 to bind to a sodium channel subtype, (b) adding a small molecule and (c) measuring the amount of displacement of said peptide on said sodium channel subtype by said small molecule. 36. The method of claim 35, wherein said peptide is radiolabeled. 37. The method of claim 35, wherein said sodium channel subtype is a neuronal sodium channel subtype and said peptide is μ-conopeptide S3.2 comprising an amino acid sequence as set forth in SEQ ID NO:211 or SEQ TD NO:432. 38. The method of claim 37, wherein said peptide is radiolabeled. 39. A method for screening a small molecule library to identify a small molecule which is a selective blocking agent of a sodium channel subtype comprising (a) allowing a small molecule to bind to a sodium channel subtype, (b) adding a peptide of claim 1 and (c) measuring the amount of displacement of said small molecule on said sodium channel subtype by said small peptide. 40. The method of claim 39, wherein said sodium channel subtype is a neuronal sodium channel subtype and said peptide is μ-conopeptide S3.2 comprising an amino acid sequence as set forth in SEQ TD NO:211 or SEQ ID NO:432. 41. A method of identifying compounds that mimic the therapeutic activity of a μ-conotoxin, comprising the steps of: (a) conducting a biological assay on a test compound to determine the therapeutic activity; and (b) comparing the results obtained from the biological assay ofthe test compound to the results obtained from the biological assay of a μ-conotoxin, wherein said μ-conotoxin is a peptide of claim 1. 42. The method of claim 41, wherein said μ-conotoxin is S3.2 comprising an amino acid set forth in SEQ TD NO:211 or SEQ IN NO:432.

Inventors: CARTIER G EDWARD, CRUZ LOURDES J, GARRETT JAMES E, JACOBSEN RICHARD, JONES ROBERT M, MCINTOSH J MICHAEL, OLIVERA BALDOMERO M, SHEN GREGORY S, SHON KI-JOON, WATKINS MAREN, CARTIER, G., EDWARD, CRUZ, LOURDES, J., GARRETT, JAMES, E., JACOBSEN, RICHARD, JONES, ROBERT, M., MCINTOSH, J., MICHAEL, OLIVERA, BALDOMERO, M., SHEN, GREGORY, S., SHON, KI-JOON, WATKINS, MAREN
Applicants: COGNETIX INC, UNIV UTAH RES FOUND, COGNETIX, INC., UNIVERSITY OF UTAH RESEARCH FOUNDATION
Application year: 2001
Main classification: A61K
IPC codes: A61K35, A61K38, A61P3, A61P9, A61P15, A61P17, A61P21, A61P23, A61P25, A61P27, A61P29, A61P35, A61P39, A61P43, C07K14, C12N15, G01N33